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Tissue engineering is an interdisciplinary field that aims to restore, maintain, or 
improve diseased or damaged tissues. Electrospinning has become one of the most 
popular means to fabricate a scaffold for various tissue engineering applications as the 
process is extremely versatile and inexpensive. The ability for electrospinning to 
consistently create nanofibrous structures capable of mimicking the native extracellular 
matrix (ECM) is the basis behind why this technique is so successful in tissue 
engineering. Cardiovascular disease has been the leading cause of death in the United 
States for over 100 years, and because of this, the need for coronary artery replacements 
 xiv 
 
is in serious demand. More specifically, small diameter vessels (<6 mm I.D.) are most 
needed, due to the fact that they are most often affected and the current clinical 
replacements provide less than optimal long-term patency and regenerative ability. Tissue 
engineering of vascular grafts has been investigated for over 50 years, however, synthetic 
replacements made of Dacron
®
 and expanded-poly(tetrafluoroethylene) (e-PTFE) still 
remain the clinical standard. This study examines a variety of different ways to alter 
different characteristics of electrospun constructs, to create scaffolds that would be 
favorable for use as a blood vessel replacement; the end goal being the creation of an 
acellular bioresorbable vascular graft that would provide sufficient mechanical support to 
withstand physiological forces, as well as ample biocompatibility to allow host cells to 
infiltrate and regenerate the graft as the structure degrades. As a way of tailoring the 
mechanical and thermal properties of a scaffold to be more conducive to that of a native 
artery, a novel co-polymer was created from the random copolymerization of two 
monomers; 1,4-Dioxan-2-one (DX) and DL-3-methyl-1,4-dioxan-2-one (DL-3-MeDX) 
were mixed at different ratios and electrospun, forming nanofibrous scaffolds that 
exhibited different mechanical and thermal properties. Next, scaffolds were electrospun 
from natural and synthetic polymers, and the potential for these materials to elicit the 
formation of an acute thrombotic occlusion was investigated by quantifying tissue factor 
expression from monocytes using a novel technique. Tissue factor expression by 
monocytes on the electrospun natural and synthetic polymer scaffolds was compared to 
that of e-PTFE to determine their potential for use as vascular graft materials. Platelet-
rich plasma (PRP), a naturally occurring blood component which is comprised of 
supraphysiologic concentrations of autologous growth factors, was activated and 
 xv 
 
lyophilized to form a preparation rich in growth factors (PRGF). PRGF was electrospun 
for the first time, to create a scaffold that would mimic the role of the native ECM in the 
wound healing cascade. Characterization of these scaffolds proved their bioactivity was 
enhanced, with cell infiltration occurring throughout the structures in as little as 3 days. 
Lastly, PRP/PRGF and/or heparin were incorporated into electrospun PCL scaffolds as a 
means of enhancing the regenerative potential and reducing the thrombogenic potential of 
the scaffolds, while supplying the constructs with mechanical stability. The release of 
several pro-regenerative growth factors and chemokines from the PRP incorporated 
scaffolds was analyzed and the effect of PRP and heparin on scaffold degradation 
characteristics was determined. Additionally, cell proliferation, migration, sprout 
formation, and chemokine release were evaluated, and results from these experiments 
proved the addition of PRP could enhance the regenerative potential of the electrospun 
scaffolds. The results from this study reveal the variety of ways in which a number of 
characteristics of an electrospun scaffold can be altered to create a more ideal 
bioresorbable vascular graft that has the potential to be regenerated within the body, 
while providing enough mechanical support for this to occur over time. 
 
 
 
 
 
 
 
 
 
 
  
 
 
Chapter 1:  TISSUE ENGINEERING BACKGROUND 
 
 
Preface: The following chapter is an excerpt from a book chapter which appeared in 
Tissue Engineering: From Lab to Clinic, edited by N. Pallua and C. Suschek and 
published by Springer Science and Business Media, Pg. 41-67, 2011. The work included 
is a broad overview on tissue engineering as a whole, and provides insight into the aim of 
the discipline, as well as clinical applications that have emerged from the field thus far.  
 
 
Natural and Synthetic Scaffolds 
 
 
Patricia S. Wolfe, Scott A. Sell, Gary L. Bowlin 
 
Department of Biomedical Engineering 
Virginia Commonwealth University 
Richmond, VA 23284 
 
Introduction 
Tissue engineering is an interdisciplinary field aimed at the application of the 
principles and methods of engineering and the life sciences toward the fundamental 
understanding of structure-function relationships in normal and pathological mammalian 
tissues and the development of biological substitutes to restore, maintain, or improve 
tissue functions [1-6]. Typically this involves collaborative efforts between materials 
scientists, cell and molecular biologists, immunologists, surgeons, and engineers to create 
replacement tissues that will be accepted by the body and promote native extracellular 
matrix (ECM) production. This requires the use of materials that do not activate catabolic 
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pathways in the body, ultimately leading to fibrous encapsulation or destruction of the 
material [4, 6-8].       
Natural and synthetic ECM analogues have played a vital role in the field of tissue 
engineering since the early 1980s [5, 9, 10]. Improvements in the fabrication process as 
well as scaffold structure continue to occur in hopes of finding an ideal scaffold for each 
specific tissue engineering application. The overall function of the biodegradable scaffold 
is to create a 3D microenvironment that will provide the necessary support for 
transplanted or host cells to induce normal physiologic regeneration and function.  
Ideally, the scaffold should mimic the native ECM it is going to replace. In order for this 
to happen, several design considerations should be taken into account including 
fabrication, structure, biocompatibility, and biodegradability [10]. Many different 
materials have been used to create scaffolds for different tissue engineering applications, 
each one offering different features and characteristics. 
Although tissue engineering scaffolds have come a long way since they were first 
introduced, there are currently very few products on the market to show for their success. 
As for the products that are available, even though they have made a remarkable impact 
in the medical industry and have improved the quality of life for many, there are still 
several limitations and drawbacks, which will be discussed in a later section. 
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Aim of the Discipline 
Tissue Engineering ECM  
   The use of isolated cells or cell substitutes is the most direct tissue engineering 
approach, typically using autologous or allogenic cells as therapeutic agents. This allows 
for the replacement of cells in areas of damaged tissue, ultimately using the cell‟s ability 
for replication to promote tissue repair and resumed function [3, 4]. These cells can be 
differentiated and tissue specific (i.e. injecting chondrocytes into cartilage [11]) or can be 
undifferentiated, generic stem cells that could be injected into areas of damaged tissue 
and allowed to differentiate as needed [8, 12]. The upside of such an approach is the 
avoidance of surgery, as well as the ability to manipulate cells as needed in vitro prior to 
their implantation into the body. However, the major drawback of this approach is the 
time required to culture a usable number of cells. Without the presence of a large 
universal cell bank, cells must be taken from a donor and cultured to a usable number 
prior to implantation in their eventual recipient [3, 8]. 
 Another approach to tissue engineering is the use of either pre-cellularized or 
acellular ECM analogues. The use of matrix analogues may be the most challenging, 
albeit potentially the most beneficial, approach to tissue engineering. The ultimate goal of 
this approach to tissue engineering is to enhance the body‟s ability to heal and repair 
itself by introducing a scaffold that the body recognizes and incorporates directly into the 
reparative process of the tissue. These systems are meant to mimic the native ECM and 
can serve as a structural framework for both cells and signaling molecules using the body 
as a bioreactor, exerting normal physiologic biomechanical and biochemical signals upon 
the scaffold. The idea being that the ECM analogue will induce cells to more accurately 
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reproduce their normal physiological behavior, thereby improving tissue regeneration and 
repair [5, 13, 14]. A number of tissue-inducing signaling molecules have been 
incorporated into ECM analogue scaffolds to aid this process. These signaling molecules 
can include a wide number of cytokines and chemokines to promote cell growth, instruct 
differentiation, and promote cellular migration [4]. Since they are open to immunological 
attack, much research has been done on the material composition of these matrix 
analogue systems in order to produce matrices that elicit little to no immune response and 
most closely mimic both the structure and function of native ECM.   
 
Native ECM 
Mammalian tissue is composed of two major components: cells (both 
parenchymal and mesenchymal) and ECM. A large majority of tissue volume is 
composed of the ECM component, which also provides much of a tissue‟s geometric 
shape. From a structural standpoint, the ECM is a complex arrangement of proteins and 
polysaccharides such as collagen, hyaluronic acid, proteoglycans, glycosaminoglycans, 
and elastin (Table 1.1). These ECM components are constantly being synthesized, 
secreted, oriented, modified, and degraded by the cellular components that they support. 
Historically, the function of native ECM was only believed to be as a structural 
framework for tissues. However, it is now understood that the ECM, through interaction 
with receptors on the surfaces of cells, directly takes part in promoting cell adhesion, 
migration, growth, differentiation, and apoptosis. The ECM also plays a role in cytokine 
activity and intracellular signaling. Growth factors and signaling molecules can be stored 
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within ECM to preserve against their degradation, or they can attach to the surface of the 
ECM to present themselves more efficiently to cell receptors [4, 7, 15].   
Table 1.1. Some major ECM components, their function, and location. Adapted from [4]. 
Component Function Location 
Collagen 
Tissue architecture, tensile strength, cell-
matrix interaction, matrix-matrix interaction 
Widely distributed 
Elastin Tissue architecture, elasticity 
Tissues requiring 
elasticity (lung, blood 
vessel, skin) 
Proteoglycans 
Cell-matrix interaction, matrix-matrix 
interaction, cell proliferation, cell migration 
Widely distributed 
Hyaluronan 
Cell-matrix interaction, matrix-matrix 
interaction, cell proliferation, cell migration 
Widely distributed 
Laminin 
Basement membrane component, cell 
migration 
Basement membranes 
Fibronectin 
Tissue architecture, cell-matrix interaction, 
matrix-matrix interaction, cell proliferation, 
cell migration 
Widely distributed 
Fibrinogen Cell proliferation, cell migration, hemostasis Blood, wound healing 
 
Interactions between cells and the ECM are complex and dynamic, and play 
critical roles during development, wound healing, and environmental maintenance 
(Figure 1.1). During development, cell-ECM interaction is responsible for pattern 
formation, morphogenesis, and phenotype acquisition and maintenance. During the 
wound healing process, clot formation, inflammation, formation of granulation tissue, 
and remodeling are all mediated by cell-ECM interaction. Initial attraction and adhesion 
of cells to the ECM is induced by multiple, low affinity charge and hydrophobic 
interactions. During the spreading phase of adhesion, heterodimeric transmembrane 
proteins known as integrins, as well as other receptors, on the cell surface bind to specific 
small peptide fragment sequences on the ECM molecules. This allows for cells to bind to 
the ECM, through focal adhesions, and promote direct communication between the two. 
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Integrin binding is both specific and reversible and allows cells to differentiate, secrete 
and absorb matrix, and transmit signals [7]. Signals are sent from the ECM across the cell 
membrane to soluble molecules in the cytoplasm and through direct connections with the 
cytoskeleton and into the cell nucleus, evoking a cellular response, termed “outside-in” 
signalling. This direct contact allows for stronger, more specific signaling than through 
the release of diffusible signaling molecules. Cell-ECM interactions can also be of an 
“inside-out” nature, when changes within the cell feed back to alter the activity of surface 
receptors, ultimately creating changes in the integrin and non-integrin receptors in focal 
adhesions [7]. In what is known as dynamic reciprocity, the cellular response to the ECM 
signaling can often alter the state of the ECM. For example cells may release matrix 
metalloproteases to break down an overly dense ECM to allow for their migration or 
proliferation [4, 15]. 
 
Figure 1.1. ECM-cell interaction depicting integrin receptors. Reprinted from [4]. 
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ECM Analogue Scaffolds 
 As complex a structure as the native ECM has been revealed to be, it should be no 
surprise that the creation of a successful engineered ECM analogue has proven to be 
extremely challenging. Ideally, one would like to mimic both the fibrillar form and the 
complex function of the native ECM [16-18]. To attain a successful ECM analogue 
scaffold, there are several design and material criteria that must be met.  First and 
foremost, the scaffolding material should be subjected to the same standards as any other 
biomaterial implanted in the body, namely, the scaffold should not initiate any adverse 
tissue or immune reactions. For many applications, scaffolding materials should be 
biodegradable or bioabsorbable at a rate that will allow for their gradual incorporation 
into the surrounding tissue without any fibrous encapsulation or residual evidence of their 
presence [6, 9, 16, 17]. ECM analogue scaffolds have been fabricated from an extensive 
array of materials through a number of different fabrication techniques. A wide number 
of different polymers, both synthetic and natural in origin, have been used as ECM 
analogues. The most common matrix materials in use today are polymers such as 
poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and their copolymer, polylactide-co-
glycolide (PLGA). However there has also been extensive work done with 
polycaprolactone (PCL) and polydioxanone (PDO), as well as some polyanhydrides, 
polyorthoesters, polycarbonates, and polyfumarates [6, 17]. As for ECM analogues 
engineered from natural materials, collagens [19], elastin [20], fibrinogen [21], and silk 
[22] have been used. ECM substitutes of this variety have the potential for a greater 
upside than their synthetic counterparts due to the fact that they are constructed from 
native ECM materials and may be expected to retain some of their biologic behavior [6, 
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23]. Inorganic materials such as hydroxyapatite, tricalciumphosphate, ceramics, and glass 
have also been used [6, 12]. 
 The architecture of the scaffold is every bit as important as the material from 
which it is fabricated. As previously stated, an ECM analogue should mimic the form of 
the native ECM. To be ideal, this ECM analogue would need to mimic the topographical 
features and geometry on the macro-scale, micro-scale, and even nano-scale levels, as 
each influences cell response to the scaffold [24]. Native ECM is composed of nanoscale 
fibers that can provide structural integrity to tissues. Recent advances in fabrication 
techniques (self-assembly, phase separation, and electrospinning) have made the creation 
of consistently nanofibrous scaffolds possible. The use of nanofibrous scaffolds creates 
structures with a very high surface area to volume ratio to support cell growth and 
infiltration [9, 25, 26]. In addition, the morphological similarities between the 
nanofibrous structures and the native ECM are believed to improve cellular response and 
overall biocompatibility [25].   
Success as a tissue-engineering scaffold in many applications is ultimately 
dependant upon the ability for cells to infiltrate the ECM analogue, migrate throughout its 
thickness, proliferate, and restore normal physiologic function [27, 28]. The scaffold‟s 
porous structure, a combination of microporous (pore diameters < 2 µm), mesoporous 
(pores with diameter 2 µm – 50 µm), or macroporous (pore diameters > 50 µm) void 
spaces, plays a major role in cellular penetration [23, 29]. As yet there has been no 
concrete claim to an ideal pore diameter, but it has been documented that pores with a 
small diameter, yet larger than the diameter of a cell, are favorable [9]. Not only do the 
pores of an ECM analogue scaffold need to be of a sufficient size for tissue growth to 
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occur, but they also need to be open and interconnected. Interconnectivity refers to the 
extent of which pores are connected with their neighboring pores, and has a large effect 
on nutrient and waste diffusion, cell migration, and overall scaffold permeability [6, 30, 
31]. The terms porosity and permeability are often incorrectly used interchangeably in the 
realm of tissue engineering and in the consideration of ECM analogue scaffolds. By 
definition, porosity is the amount of void space contained within a structure, while 
permeability is a measure of the ease of which a fluid can move through the structure. 
Matrix permeability ultimately depends on the combination of scaffold porosity, pore size 
and distribution, pore interconnectivity, and pore orientation and scaffold porosity to 
determine the hydraulic permeability of an ECM analogue scaffold [30, 31]. 
 Although not commonly reported for tissue engineered scaffolds, permeability 
and porosity are extremely important to the success of an ECM analogue. Healthy, living 
tissue in vivo relies on the microvasculature to distribute blood and exchange metabolites 
through a combination of diffusion over short distances and flow-limited exchange. There 
are currently no tissue engineered products that contain their own pre-vascularised 
capillary bed to provide nutrients to the structure, chaining their initial effectiveness to 
the limits of passive diffusion [32]. The limitations of diffusion-based nutrient transport 
restrict the maximum thickness of avascular tissue engineered constructs to less than 2 
mm [33]. Scaffolds with increased porosity and permeability help to promote the 
diffusion of nutrients to cellular constituents, while promoting the diffusion of metabolic 
waste away from the cells. An increase in nutrient penetration distance will promote cell 
migration away from the scaffold periphery, and the presence of interconnected 
macropores will augment their ability to migrate [30, 31]. The degradation behavior of 
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synthetic polymer-based scaffolds is also controlled in part by the permeability of the 
ECM analogue. Low porosity and permeability scaffolds made of poly( -hydroxy acids) 
have exhibited increased rates of degradation due to an increase in autocatalytic activity. 
Essentially, as the polymers breakdown via hydrolysis, the acidic byproducts become 
trapped within the scaffold and lower the local pH. This reduced pH then accelerates the 
degradation of the polymer from the inside out resulting in a rapid loss of mechanical 
stability [30, 34].   
 
Clinical application 
The use of ECM as a commercially available product has grown dramatically in 
recent years, with the majority of products consisting of decelullarized xenogenic ECM 
materials. SIS based products such as Restore™, CuffPatch™, Surgisis®, Oasis®, and 
Durasis
®
 are packaged as sheets and used for tissue reinforcement and wound repair. TEI 
Biosciences produces a number of products for specialized applications derived of fetal 
bovine skin. These include TissueMend® for rotator cuff repair, Durepair® for repair of 
cranial or spinal dura, Xenoform™ for gastrointestinal and urologic repair, SurgiMend™ 
for soft tissue membranes, and PriMatrix™ for general wound management. Horse and 
bovine pericardium-based products have been created and used for a number of different 
repair and reinforcement applications by Pegassus Biologicals (OrthADAPT™, and 
DurADAPT™) and Synovis Surgical (Veritas®, Dura-Guard®, Vascu-Guard®, and 
Peri-Guard®), respectively. 
Allogenic decellularized ECM-based products have also made it to market for a 
number of different applications. Alloderm is a human skin product that has been used in 
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the abdominal wall, breast, and grafting applications. Graft Jacket® is a skin-based 
product used for foot ulcers, while Axis™ Dermis has been used for pelvic organ 
prolapse. Another allogenic product on the market is Suspend™, composed of 
decellularized human fascia lata and used as a urethral sling. 
Current with the writing of this chapter, there are four cellular based ECM 
products on the market. Smith & Nephew produces both Dermagraft™ and Transcyte™.  
Dermagraft™ is a full thickness diabetic ulcer graft composed of fibroblasts on a 
bioabsorbable ECM scaffold, while Transcyte™ is a graft for mid to intermediate partial 
thickness burns made from the ECM produced by human fibroblasts. Organogenesis, Inc. 
markets Apligraf®, composed of human fibroblasts on a matrix of collagen and secreted 
ECM, used to treat venous and diabetic foot ulcers. Finally, a product made from bovine 
collagen seeded with human fibroblasts, OrCel™ is manufactured by Ortec International 
to treat burn wounds [35]. 
To date, there are no engineered ECM analogue products in clinical use. While 
there has been a large amount of funding and research committed to the development of 
such a product, engineered ECM products are currently limited strictly to the laboratory 
setting. 
 
Conclusions 
Tissue Engineering has made a profound impact on the quality of life for many, 
and with the field growing at a rapid rate, that number will continue to increase as more 
exciting and path breaking discoveries are made. Polymeric scaffolds, both synthetic and 
natural, used as ECM analogues have the potential to replace, and further regenerate new 
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tissue by providing a suitable environment for cells to be able to communicate through 
signals and function properly through attachment, differentiation, migration and 
proliferation. ECM analogues created by different techniques design the structural 
characteristics needed to mimic the native ECM, which will open the doors to many new 
clinical options for applications including bone, cartilage, cardiovascular, nerve, skin, 
ligament, tendon, breast, and liver. Although there are limitations that still stand in the 
way of having an ideal scaffold, the challenge of designing a successful ECM analogue is 
slowly being conquered as professionals in the field continue to make significant 
improvements on a daily basis. 
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Abstract 
 Arteriosclerosis has accounted for three quarters of the deaths related to 
cardiovascular disease (CVD). Arteriosclerosis is a vascular disease that is characterized 
 14 
 
by a thickening of the arterial wall and subsequent decrease in the arterial lumen, 
eventually causing loss of circulation distal to the site of disease. Small diameter arteries 
(< 6 mm) are affected the most by CVD due to their already decreased blood flow. The 
increasing populations of people who are obese, diabetic, or aging supplement a strong 
need for the production of a commercially available small diameter vascular graft. Tissue 
engineering has become a promising approach for generating a biocompatible vessel with 
the potential to regenerate new tissue. Multiple factors have to be accounted for when 
designing a vascular graft that has the ability to self-repair and self-remodel such as the 
choice of polymer, choice of cell type, and choice of growth conditions. To date, 
historical landmarks such as the initial research of Weinberg and Bell have led 
researchers closer and closer to a functional end product [36]. 
 
Introduction 
Cardiovascular disease, specifically coronary heart disease (CHD) resulting from 
arteriosclerosis, remains the leading cause of death in the United States and has been so 
virtually every year since 1900 [37]. Once blood flow in the coronary artery is 
compromised, vascular bypass is an option to restore blood flow to tissues distal to the 
restriction or blockage [38]. In 2005 there were 469,000 bypass procedures performed 
due to CHD [37], which typically involve the replacement of a coronary artery with a 
patients own saphenous vein or internal mammary artery. Biological grafts are a 
formidable option since they already retain the natural architecture that arteries require. 
When these grafts are used as replacements, they begin to adapt to their new 
environment, altering their structure to match the mechanical requirements of the tissue.   
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While these autologous replacements have an acceptable patency rate, they are 
not always a viable option as the patient may also suffer from peripheral vascular disease, 
affecting upwards of 8 million Americans and up to 20% of those 65 years of age or older 
[37]. Further complicating the use of autologous vessels is the fact that they are limited in 
number and a previous bypass operation may have already required the vessel‟s use [39]. 
Currently available commercial alternatives to the autologous vessel gold standard are 
limited to synthetic vessels made of e-PTFE and woven or knitted Dacron . These 
materials have been used with moderate success as medium and large diameter 
prosthetics, but their efficacy is severely limited when used as small diameter vessels. 
Larger diameter vessels experience higher flows and less resistance than small diameter 
vessels, such as the popliteal or coronary arteries, where low blood flow and high shear 
makes the synthetic graft more prone to thrombus formation and intimal hyperplasia [38-
49]. Dacron  and e-PTFE grafts are non-degradable and lack the ability to promote 
native tissue regeneration, making them a permanent fixture in the body. As a permanent 
fixture, the graft is constantly threatened with attack from the patient‟s own foreign body 
response as well as bacterial graft infection [46, 48, 50]. To this extent, a vascular 
replacement that matches the body‟s mechanical and cellular requirements is highly 
necessary in the field of vascular tissue engineering, requiring “ideal” characteristics. A 
tissue engineered vascular graft needs to meet several criteria to be considered ideal:   
1.  Easy for surgeons to handle with excellent suture retention and resistance to kinking 
while remaining flexible.  
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2.  Grafts need to be biocompatible and retain non-toxic, non-thrombogenic, and 
infection resistant characteristics, all of which are associated with a confluent, quiescent, 
nonactivated endothelium. 
3.  They must induce an appropriate healing response that does not result in 
inflammation, hyperplasia, or fibrous capsule formation. 
4.  It is necessary for the grafts to be leak resistant yet have sufficient porosity to allow 
for the ingrowth of autologous tissue, leading to tissue that is indistinguishable from the 
native vessel. 
5.  Mechanical strength is a paramount concern where grafts must retain a compliance, 
the ability to withstand long-term hemodynamic stress without failure, similar to that of 
native artery to prevent intimal hyperplasia while; 
6.  Resisting creep and permanent deformation leading to aneurysm formation. 
7.  Grafts should express physiological properties such as vasoconstriction and relaxation. 
8.  Finally, they should be easy to manufacture, produce, sterilize, and store, as well as be 
economical and available off-the-shelf in a variety of sizes [46, 51]. 
Vascular tissue, more specifically arterial tissue, is subdivided into two separate 
categories: elastic (> 6 mm inner diameter (ID)) and muscular (< 6 mm ID). The 
architecture of both elastic and muscular arteries is composed of three separate layers: 
intima, media, and adventitia, which vary in thickness and composition as a function of 
anatomic location (Figure 2.1). The intima is the innermost layer of all blood vessels and 
is composed of a single layer of endothelial cells (EC) lining the vascular wall, a thin 
basal lamina, and a subendothelial layer containing collagenous bundles, elastic fibrils, 
smooth muscle cells (SMC), and some fibroblasts (FB). The media, the thickest of the 
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three layers, is made up of SMC, a various number of laminae depending on location, 
bundles of collagenous fibrils, and a network of elastin fibrils. The adventitia is the 
outermost layer of the vessel wall and like the media, its thickness varies as a function of 
anatomic location, consisting of dense fibroelastic connective tissue containing FB [52, 
53]. Incorporated with these three layers, is the vasa vasorum, a network of blood vessels 
which innervate both the media and adventitial layers to supply oxygen and nutrients to 
the cells in those regions.   
 
Figure 2.1. Drawing of arterial wall depicting the native tissue‟s three primary layers: 
intima, media, adventitia. Reprinted with permission from [44]. 
 
As arteries move away from the heart and towards the periphery, their diameter 
decreases. This decrease in diameter coincides with changes in the architectural makeup. 
Structurally, the intima is similar in both elastic and muscular arteries and therefore does 
not affect the overall properties when comparing the two. Instead, both the medial and 
adventitial layers change in thickness and composition as arteries move away from the 
heart and toward the periphery. Those arteries with larger diameters, such as the aorta or 
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carotid, contain a medial layer with SMC and numerous elastic laminae. Muscular 
arteries, such as the femoral, retain the three layered structure yet their medial layer 
contains a higher density of SMC and a lower number of elastic laminae. As for the 
adventitia, elastic arteries contain a relatively thin outer layer that constitutes only 10% of 
the vascular wall whereas in muscular arteries the adventitia often occupies 50% of the 
vascular wall. Functionally, for the media, this design change is due to a smaller 
circumferential stress in the wall of the muscular artery, decreasing the overall demand 
for elastic recoil and energy dissipation [54], while increases in nerve innervations 
account for the increased adventitial thickness [52]. 
Blood vessels are continuously subjected to stress and strain in the circumferential 
and longitudinal directions. Each layer in the wall plays a significant mechanical role to 
its proper functionality. In vivo studies and clinical observations have shown that 
decreased values of tensile and shear stress in surgically injured vessels are correlated 
with activation of cell proliferation and ECM production, leading to vessel occlusion 
[55]. A decrease in tensile properties is not just a change in the circumferential direction, 
but a multi-directional change. As a consequence, compliance, hoop stress, and overall 
hysteretic properties can be affected. These changes can affect cell and fiber orientation.   
 In addition to circumferential and longitudinal stress, one of the most important 
stresses exerted on the inner lumen of arterial tissue is shear stress. Arteriosclerosis tends 
to develop in regions of the circulation where flow is either low or turbulent, such as 
regions where arteries bifurcate [56-58]. EC respond to increased blood flow by causing 
the relaxation of the surrounding smooth muscle through nitric oxide. Conversely, 
decreased flow induces vessel narrowing that is also mediated by signals from the 
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endothelium, and in severe cases low flow leads to vessel regression and apoptosis of EC 
[59]. 
 Besides the ultimate importance of shear stress, circumferential stress due to 
cyclic loading also mediates proper functionality of the arterial wall, preventing 
arteriosclerosis. Vascular EC sense and respond to cyclic strain both morphologically and 
phenotypically. However, if hypertension occurs in a blood vessel, EC, in addition to 
SMC, are highly affected. Accumulating evidence demonstrates that high cyclic strain 
affects EC, whereby in one study Reape et al. found that monocyte chemotactic protein-1 
is synthesized when EC are subjected to high mechanical deformation [60], while other 
studies have found that mechanical strain in hypertensive models influences 
atherosclerotic plaque development through increased expression of adhesion molecules 
[61-63]. SMC are mostly affected by increases or decreases in blood pressure. Normal 
blood pressure and flow allows both SMC and EC to cross-talk and maintain the integrity 
of the vascular wall over time. If blood pressure rises over a long period of time, signal 
transduction pathways begin to break down the ECM and remodel the arterial wall, 
resulting in vascular hypertrophy [64]. If the pathophysiology involved in vascular 
disease was better understood, then this knowledge may produce vascular graft designs 
that approach what would be considered ideal. 
 
Historical Vascular Replacements 
Vascular grafts have been in the process of development since the late 19
th
 
century when Eck attempted the first delineation of a basic technique for vascular suture, 
performing a lateral anastomosis of the portal vein to the inferior vena cava [65]. 
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However, it was not until the early 20
th
 century when Alexis Carrel explored the basic 
patterns of healing of arteries and veins, the reactions to different types of sutures, and 
the possibility of organ transplantation, winning him the Nobel Prize for Physiology or 
Medicine in 1912 [66].   
There were many ventures into bridging the gap of a particular blood vessel. In 
World War I, German surgeons treated aneurysms by bridging the defect with pieces of 
the patient‟s vein [66]. A femoro-popliteal bypass with a reversed saphenous vein graft 
was first performed by Kunlin in 1948. During the same period, fresh arterial allografts 
were beginning to be used in human vascular reconstructive surgery. In 1952, Blakemore 
and Voorhees developed one of the first synthetic vascular prostheses, Vinyon-N cloth, 
which was used to bridge arterial defects in dogs [67]. Although early clinical results 
were promising, Vinyon-N did not display sufficient long-term stability, nor did it 
provide an appropriate scaffold for tissue in-growth. These historical experimentations 
paved the way towards tissue engineered vascular grafts, and set into motion the quest for 
the ideal vascular replacement. 
 
Endothelial Cell Seeding 
This quest began by modifying materials that were already approved for vascular 
replacement surgeries, e-PTFE and Dacron. In 1978, Herring et al. introduced a single-
stage technique whereby venous ECs were seeded onto Dacron grafts with enhanced 
patency in canine models [68]. Since this point, numerous methodologies have been used 
to gain a confluent monolayer of ECs: gravitational, hydrostatic, and electrostatic. The 
most basic and extensively studied of these is gravitational EC seeding. Coating the graft 
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surface prior to this method of seeding has been performed in many cases. For instance, 
Zilla and associates have looked into multiple ways in which to increase EC attachment 
onto e-PTFE grafts through lining the graft with fibronectin [69] and fibrin glue [70]. 
However, outcomes from these studies demonstrated insufficient cell density, poor 
adhesion under flow conditions, and failure to achieve confluence. Another major 
disadvantage of this technique is any surface that is not covered by ECs becomes highly 
thrombogenic. Poor adhesion of cells under flow conditions was due to a number of 
factors, one of which being cell seeding duration was too short (<2 hours) [71]. This was 
leading to a significant loss of cells upon implantation. Therefore, studies such as Shindo 
et al. and Prendiville et al. were performed to increase maturation time [72, 73]. 
Biological glues and adhesive proteins such as fibronectin, collagen, laminin, fibrin, FB 
matrix, and plasma have been extensively studied as further means to adhere ECs to the 
inner lumen surface of a vascular graft [74-80]. The necessity for an incubation period to 
allow for significant adhesion and maturation of ECs is related to the basic nature of the 
electrostatic interactions between the polymeric graft materials and the cells. Clinically 
successful vascular prosthetics such as e-PTFE are highly negatively charged, which can 
repel cells. Several in vitro studies have been performed utilizing the electrostatic seeding 
technique. Bowlin et al. found that when umbilical vein ECs were seeded onto e-PTFE 
through electrostatics, complete nodal area coverage of morphologically mature ECs was 
obtained within 16 minutes [81]. Using this same technique under flow conditions with a 
wall shear stress of 15 dynes/cm
2
 for up to 120 minutes revealed no significant loss of 
ECs [82]. However, problems associated with permanent synthetic graft material still 
pose major hurdles. Therefore, bioresorbable vascular grafts became of interest since they 
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deviate from the permanent scaffolding and resorb in situ while autologous tissue 
remodels the graft. 
 
 Scaffold-Based Approaches to Improve Vascular Grafts 
Bioresorbable grafts are advantageous due to the fact that a resorbable vascular 
prosthetic with adequate mechanical properties can be implanted and degraded gradually 
over a period of time, leaving behind no permanent synthetic materials to initiate a 
chronic foreign-body reaction [48]. Through the years, there have been many different 
approaches. Wesolowski et al. first introduced the concept of a bioresorbable vascular 
prosthetic in the early 1960s. These first bioresorbable incarnations were composed of a 
variety of Dacron  yarns, collagen coatings, and collagen fibers. The permanent Dacron  
provided mechanical stability, while the collagen added bioactivity to the structure and 
promoted the ingrowth of native tissue as it was degraded and remodeled [83, 84]. The 
1970s and „80s saw the advent of a number of different aliphatic polyesters (PLA, PGA, 
PDO, etc.). These polymers breakdown through hydrolysis in the body, and can have 
their rate of degradation tailored by altering their structures [48, 85-89]. While this 
preliminary work failed to result in a successful commercially available graft, it laid the 
foundation for current research in bioresorbable prosthetics and demonstrated the 
possibilities of in situ tissue engineering. Despite the ability of bioresorbable grafts to 
have products added to or subtracted from the created matrix to aid the body in 
regeneration, other approaches find that the body alone is not sufficient enough to sustain 
a fully regenerative capacity, and that much of that work should be done in vitro. This 
type of tissue engineering approach can be accomplished with the combination of cells 
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and specific scaffold materials. Regardless of approach, the way in which a scaffold 
material is designed is equally as important as the source of the cells that are utilized in 
the experimental procedures.   
 The ideal cell source should be non-immunogenic, functional and easy to achieve 
and expand in culture. Cells are arguably the most important element in any tissue 
engineering model. For an arterial replacement, a functional graft cannot be achieved 
without an endothelium-like interface to the circulating blood and vasoactive SMC within 
the wall [90]. Autologous ECs and SMCs isolated from patients themselves are usually 
the first choice. However, this procedure is quite limited in the number of cells that are 
able to come from a single biopsy punch of an autologous vascular tissue. Therefore, 
stem and progenitor cells become a more viable option as they have a higher capacity to 
expand in culture. Endothelial progenitor cells (EPC) typically circulate throughout the 
bloodstream and can be isolated using techniques such as those done by Asahara et al. 
[91, 92], where magnetic beads coated with antibodies such as CD34, AC133, or markers 
common to both early and more differentiated progenitors were used to capture EPC. 
Autologous bone marrow sources have also shown promise through studies that have 
been done by Shin‟oka et al. [93], seeding the cells onto a poly(D,L-lactide-co-ε-
caprolactone) (PLCL) copolymer and then implanting in humans. Campbell et al. have 
shown that the cells located in the peritoneal cavity display promise, where silicone 
tubing was implanted into the peritoneal and pleural cavities of dogs for 2-3 weeks, and 
cells from those cavities migrated onto the tubing, subsequently forming a biological 
graft material [94, 95]. Nieponice et al. has shown how muscle-derived stem cells are 
also a plausible autologous source for vascular tissue engineering, combining these cells 
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with poly(ester urethane) (PEUU) scaffolds through a vacuum seeding procedure and 
implanting them as an aortic interposition bypass graft [96]. Non-autologous cell sources 
also include those of embryonic stem cells, which have the capability to differentiate into 
several different cell types including those of the vasculature. 
 
Electrospinning 
 The resurgent interest in electrospinning in recent years has helped to rejuvenate 
the research of bioresorbable vascular grafts. One of the main attractions of 
electrospinning is the fact that it is a simple process, requiring little specialized 
equipment. A standard electrospinning setup consists of a high voltage power supply, 
syringe pump, grounded target, and a spinneret (typically a syringe fitted with a blunt tip 
needle, Figure 2.2). The process itself can be easily performed in a laboratory setting or 
scaled up for large-scale production with little modification. In brief, a polymer solution 
is drawn into the spinneret and charged with a large electric potential in the range of 
several kilovolts. A grounded target is placed a set distance from the charged polymer 
solution to create a static electric field. When the electric potential reaches a critical level, 
the electrostatic repulsions of the polymer solution overcomes the surface tension at the 
tip of the spinneret, and a fine jet of entangled polymer chains is drawn out. This jet 
whips through the air towards the grounded target, creating a dry fiber through the 
evaporation of the polymer‟s solvent. The electrospinning process has the capacity to 
produce fibers that range from 50 nm to 10 µm in diameter, collected on the grounded 
target, dependant upon the processing conditions of the polymer solution/solvent used 
[16, 97-100]. Apart from the simplicity of its setup, the versatility of the electrospinning 
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process has also made it ideal for tissue engineering. The process is compatible with a 
wide array of polymers, both natural and synthetic in origin, as well as the combination 
of any number of different polymers. Polymer solutions can be combined in a single 
reservoir, spun side by side from separate spinnerets, or layered sequentially to provide a 
large number of options for altering scaffold properties. In addition, electrospun scaffolds 
can be created in nearly any shape required, and can consist of fibers in an assortment of 
orientations [100]. Electrospinning provides researchers with the ability to create, not 
only flat sheets, but also the seamless tubes required for vascular applications. These 
tubes can be created in any diameter to fit the specifications of any vascular conduit. 
 
Figure 2.2. Schematic representation of a simple electrospinning setup utilizing a 
grounded rotating drum as a collection mandrel. 
 
 The combination of specific cell types and biomaterials to create a structure which 
mimics both mechanically and architecturally the native tissue is at the heart of the tissue 
engineering field. Vascular tissue engineering has looked at a myriad of scaffold-based 
approaches involving the use of pure polymer, polymer blends, and manufacturing co-
polymers to achieve its ideal goal. 
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Poly(glycolic acid), Poly(lactic acid), and Copolymer Blends 
 PGA is a biodegradable aliphatic polyester with a glass transition temperature 
between 35-40°C, melting point between 225-230°C, and a crystalline fraction of 44-55% 
Table 2.1). Within the field of vascular surgery, PGA was first used as a biomaterial for 
sutures in the 1970s [101, 102]. In 1983, Lauritzen was the first to conduct preliminary 
studies on PGA tubes as vessel grafts. This experiment suggested PGA tubes as a 
promising construct for instant and absorbable microvascular grafts [103]. Since then, 
various approaches to improving PGA grafts have been developed and extensively 
studied. Niklason et al. fabricated tubular PGA scaffolds with a chemically modified 
surface (NaOH) and seeded grafts with bovine SMCs exposed to pulsatile flow 
conditions for 8 weeks. After 8 weeks of culture, the gross appearance of the scaffolds 
was similar to native arteries with histology showing migration of SMCs forming a 
smooth luminal surface for EC seeding. After 4 weeks implantation in pigs, scaffolds 
showed 100% patency [104]. In order to minimize residual polymer fragments after 
culture, Prabhakar et al. treated PGA mesh tubes by exposing them to heat, 1.0M NaOH, 
and γ-irradiation to hasten degradation. Porcine carotid SMCs were cultured on treated 
PGA scaffolds under pulsatile conditions. After 8 weeks of culture, treatment with NaOH 
increased polymer degradation rate under hydrated conditions and NaOH and γ-modified 
scaffolds showed native vessel morphology, a more even distribution of SMCs, and fewer 
polymer residual fragments. It was also noted that the collagen content of some scaffolds 
were approximately similar to that of native vessels, however, the mechanical integrity of 
the engineered scaffolds was less than native [105]. Boland et al. were the first to publish 
results on electrospun PGA as a tissue engineering scaffold comprised of submicron fiber 
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diameters. In this study, HCl pretreated PGA scaffolds were incorporated into the 
surrounding tissue and showed increased cell proliferation rates when implanted in rats 
[106]. The above studies have demonstrated that independent of scaffold fabrication 
technique, PGA grafts with a chemically modified surface can serve as potential vascular 
grafts. More recently, Iwasaki et al. bioengineered a three-layered tubular scaffold where 
PGA, PCL, and PGA layered sheets were seeded with three types of vascular cells under 
pulsatile conditions to mimic artery structure, integrity, and blood flow. Results from this 
study demonstrated that the engineered vessels produced sufficient amounts of collagen 
and elastin and exhibited similar appearance, elasticity, and ultimate strength as native 
arteries [107].   
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Table 2.1. PGA, PLA, and Copolymer Blends. 
Biodegradable 
Polymer 
Manufacturing 
Method 
Improvement Cell Seeded Culture 
Condition 
Ref 
PGA      
Nikalson et al. Chemically modified w/ 
NaOH 
Cell attachment and 
proliferation 
SMCs Pulsatile and Pig 
Implant 
[104] 
Prabhakar et al. Mesh tube w/ NaOH, -
irradiation 
Cell attachment and 
proliferation 
SMCs Pulsatile [105] 
Boland et al. Chemically modified 
electrospun PGA w/ 
HCL 
Cell proliferation  __ Rat Implant [106] 
Iwasaki et al. PGA, PCL, PGA layered 
sheets 
Cell attachment, 
proliferation, 
collagen, and elastin 
content 
EC, SMC, FB Pulsatile [107] 
PLA/PLLA      
Stitzel et al. Electrospun PLA w/ 
wound collagen 
Cell attachment and 
orientation 
SMC Static [108] 
Wang et al. Electrospun PLA and 
silk-gelatin 
Mechanical strength __ __ [109] 
Zhu et al. Surface modified w/ 
gelatin/N-Maleic acyl-
chitosan 
Cell attachment, 
proliferation, and 
high expression of 
CD31 and vWF 
hUVEC Static [110] 
PGA-PLA      
Hibino et al. PGA and PCL/PLLA 
woven fabric 
No evidence of 
rupture, infection, 
calcification, or 
aneurysm 
__ Human Implant [111] 
Mooney et al. PGA mesh coated w/ 
PLGA 
Mechanical 
properties and cell 
proliferation 
SMC and EC Static and Rat 
Implant 
[112] 
Wen et al. 70:30 PLGA sponge Cell attachment and 
proliferation 
SMC and EC Static [113] 
Izhar et al. PELA coated filament-
wound Lycra 
Enhanced healing 
and mechanical 
properties 
__ Dog Implant [114] 
Roh et al. PGA mesh coated w/ 
P(CL/LLA) 
Pre-seeding led to no 
calcification, a neo-
intima, and neo-
tissue formation 
BMC Static and Lamb 
Implant 
[115] 
 
 PLA is a biodegradable, aliphatic polyester with a glass transition temperature 
between 60-65°C, melting temperature between 173-178°C, and crystallinity of 
approximately 37%. PLA can exist in several distinct isoforms, most commonly as poly-
L-lactic acid (PLLA). In the 1980s the first studies were conducted exploring the 
possibilities of PLA as a vascular graft coating [116] and PLLA as a microporous, 
compliant, biodegradable vascular graft [117-120]. In 2001 Stitzel et al. developed a 
tubular scaffold comprised of a helical wind of collagen fibers encompassed by a layer of 
electrospun PLA fibers. After 10 days incubation, SMC formed a 100% confluent 
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monolayer on the tubular scaffold oriented along the principle stress lines [108]. Within 
the past few years electrospun PLA and PLLA have been extensively studied and are 
considered an ideal biomaterial candidate for tissue engineering blood vessels. Wang et 
al. electrospun a tubular graft composed of PLA (outside layer) and silk fibroin-gelatin 
(inner layer) with a porosity of 82  2%, breaking strength (2.2 MPa), pliability (60.6%), 
suture retention strength (4.6 N), and a burst pressure strength of 1596 mmHg [121]. 
Whereas many PGA studies use surface modifications to achieve desired results, PLA 
can be more readily used “as is” to produce vascular engineered scaffolds. However, 
there are certain advantages to chemically modifying PLA surfaces. To improve EC 
biocompatibility, Zhu et al. grafted a gelatin/N-Maleic acyl-chitosan (gel/NMCS) 
complex on the surface of PLA films. This study concluded that gel/NMCS modified 
PLA enhanced human umbilical vein EC proliferation and expressed a higher structured 
CD31 and vonWillebrand Factor (vWF), ultimately suggesting photo-initiated grafting of 
gel/NMCS complexes as an effective method for modifying the surfaces of vascular 
grafts [110]. 
 PGA and PLA have also been combined to create novel biodegradable vascular 
tissue engineering scaffolds. Most recently in 2010, Hibino et al. developed a tubular 
woven fabric vascular scaffold composed of PGA and polycaprolactone (PCL)/PLLA 
which was implanted in 25 human patients as a extracardiac cavopulmonary conduit. 
After a mean follow up of 5.8 years, scaffolds showed no evidence of rupture, infection, 
ectopic calcification, aneurysm formation, or scaffold related mortality. One patient had 
partial thrombosis and four patients had scaffold stenosis but all were successfully treated 
[122]. PGA and PLA have been combined with each other as well as other polymers to 
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form new copolymers: PLGA, poly(ethylene glycol/lactic acid) (PELA), and PLLA-PCL 
to name a few. Overall, the versatility of PGA and PLA fuels the use of these polymers as 
practical materials for fabricating vascular grafts. Although, both these synthetic 
polymers have demonstrated promising results there are several drawbacks to using such 
materials. Both PLA and PGA are stiff and significantly different from native artery, 
which could lead to hyperplasia at the site of anastomosis. Additionally, PGA‟s quick 
degradation characteristics make it desirable for designing a functional artery and 
dangerous as an implant which could lead to aneurysm or rupture. 
 
Polycaprolactone and Copolymer Blends 
 PCL is a semicrystalline, non-toxic, tissue compatible biomaterial with a 
degradation rate of around 12 months (Table 2.2). Mechanically, PCL displays highly 
desirable characteristics for vascular grafts, mostly high strength and excellent 
compliance. Surface properties of biomaterials, such as surface roughness, affect cell 
behavior and may induce thrombotic clots in some cases. Researchers have found that 
rough and smooth surfaces will encourage different types of cell adhesion [123]. Some 
groups have attempted to modify the hydrophobic surface of PCL to provide more 
hydrophilic groups. Zhu et al. first looked to modify PCL‟s surface chemistry with 
poly(methacrylic acid) (PMAA) [124]. This was accomplished by immersing a PCL 
membrane in a quartz tube with 30% hydrogen peroxide, and subsequently exposing the 
tube to UV light. The photo-oxidized membrane was then placed in a copolymerization 
tube containing 4% PMAA and irradiated with UV, leading to a higher EC attachment 
when compared to non-modified grafts.   
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Table 2.2. PCL and Copolymer Blends. 
Biodegradable 
Polymer 
Manufacturing 
Method 
Improvement Cell Seeded Culture 
Condition 
Ref 
PCL      
Zhu et al. Surface modified PCL 
film w/ PMMA 
Cell attachment  EC Static [124] 
Serrano et al. Surface modified PCL 
film w/ NaOH 
Increased 
hydrophilicity and 
cell attachment 
EC and SMC Static [125] 
Ma et al. Surface modified 
electrospun PCL w/ 
carboxyl groups 
Increased 
hydrophilicity and 
cell attachment 
EC Static [126] 
Duling et al. Electrospun PCL Mechanical 
properties 
__ __ [127] 
Pektok et al. Electrospun PCL In situ degradation __ Rat Implant [128] 
Drilling et al. Different concentrations 
of electrospun PCL 
Optimized burst 
pressure 
__ __ [129] 
Lee et al. Thermal treatment of 
electrospun PCL 
Suture retention, 
burst pressure 
__ __ [130] 
Vaz et al. Electrospun PCL and 
PLA   
Cell attachment and 
mechanical 
properties 
FB and myoFB Static [131] 
Hanson et al. Dip casted PCL and PLA Mechanical 
properties 
__ Canine [132] 
Watanabe et al. 50:50 P(CL/LA) poured 
into PGA mesh 
Mechanical 
properties and cell 
attachment 
Mixed population 
from femoral vein 
Canine [133] 
 
Serrano et al. used a NaOH treatment of the PCL grafts to provide better 
adherence of vascular ECs and SMCs through increased hydrophilicity [125]. In this 
study, PCL films were prepared by hot pressing and then submerged in a solution of 2 N 
NaOH for two hours. Scanning electron micrographs (SEM) of cell morphology showed 
both cell types growing properly on NaOH treated films, but untreated films did not seem 
appropriate substrates to support cell growth by causing cytoplasmic retraction. Serrano 
et al. then followed this preliminary study up 3 years later, evaluating EPC adherence 
proliferation to NaOH treated films, and the effect of PCL on nitric oxide content [134]. 
EC-derived cells from EPCs were first characterized using classical markers CD31, von 
Willebrand factor, and endothelial nitric oxide synthase (eNOS) using flow cytometry, 
where CD31 is a clear marker of EC maturation. After 4 days, it was found that PCL-
NaOH films contained large numbers of cells on their surface; however, PCL films had 
significantly lower numbers, further demonstrating the benefits of NaOH treatment. 
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Furthermore, Ma et al. improved the surface chemistry of PCL through modification of 
electrospun fibers with air plasma treatment, introducing carboxyl groups on PCL 
nanofiber surfaces. These carboxyl groups were then used to bind gelatin to the surface, 
increasing hydrophilicity and increasing EC proliferation when compared to no treatment 
[126]. Surface modification of PCL films to increase hydrophilicity, definitively 
improved scaffold materials for enhanced cellular attachment. However, an implanted 
vascular graft will not respond well to a tubular film, leading to encapsulation with no 
cellular infiltration of the scaffold material. For this reason, porous scaffolds have been 
manufactured through the process of electrospinning. 
 Mechanically, PCL is a highly desirable material for vascular tissue engineering 
in addition to other soft tissue applications. Several studies have set out to characterize 
the mechanical behavior of PCL. Duling et al. punched out “dogbone” shapes from 
electrospun nanofibers to test for stress relaxation, loading response, tensile failure 
testing, and cyclic stress relaxation, comparing these results using Fung‟s quasilinear 
viscoelastic theory [127]. Others have looked at the degradation characteristics both in a 
rat descending aorta for 24 weeks (Pektok et al.) [128], and in vitro in Ringer solution 
stirred gently for 6 months (Bolgen et al.) [135]. Pektok et al. found that after 24 weeks 
molecular weight decreased by 20%, while Bolgen found that molecular weight 
decreased by only 5%, indicating that in situ degradation occurs faster. In these cases if 
degradation occurs too fast or too slow, then the vascular graft will either become too 
weak and develop an aneurysm or not dissolve out quickly enough causing other 
downstream affects. Therefore, optimization of graft mechanical and cellular parameters 
is necessary. Nottelet et al. demonstrated an optimal design for electrospun PCL grafts in 
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a rat model by electrospinning several combinations of solvent/polymer concentrations 
[136]. Drilling et al. optimized burst pressure results of electrospun PCL grafts through 
analyzing several different solvent/polymer concentrations, resulting in 5 mm diameter 
grafts that could withstand in excess of 2000 mmHg [129]. Lee et al. demonstrated 
increased mechanical properties through thermal treatment of electrospun PCL grafts, 
which resulted in increased suture retention and burst pressure, without much change in 
compliance [130]. While there are many studies surrounding the sole use of PCL as the 
vascular graft material, other studies have combined PCL and other synthetics by 
copolymerizing the two structures together or separately manufacturing them.  
 Vaz et al. selected two different polymers to be electrospun together, PCL and 
PLA, in a multilayered approach, characterizing their properties through uniaxial tensile 
testing, 3T3 mouse FB, and human venous myofibroblasts (myoFB) [137]. While this 
study produced good results, the addition of a stiff material such as PLA could 
significantly reduce compliance and increase the downstream affects of compliance 
mismatch. Williamson et al. created a more compliant, bi-layered structure from a PCL-
polyurethane (PU) composite graft by using gravity spun PCL fibers out of acetone and 
spinning PU fibers directly onto the PCL fibers [138]. In 1988, Hanson et al. looked into 
the mechanical properties of selected copolymers, PLA and PCL [132]. These vascular 
grafts were dip casted using three different kinds of copolymers to produce single layer 
and bi-layered grafts. These grafts were then tested for compliance, tensile strength, and 
kink resistance. Mechanical results looked promising except for compliance, which was 
significantly lower than a canine femoral artery, where this once again demonstrates the 
stiffness of PLA. Watanabe et al. synthesized a P(CL/LA) copolymer in a 50:50 
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combination to be poured into a PGA nonwoven fabric and subsequently freeze dried. 
Mechanical testing, cell seeding, and implantation of the vascular scaffold into the 
inferior vena cava of a canine were performed with promising results as an “ideal” 
venous scaffold with antithrombogenic activity [133]. However, a venous graft is not 
subjected to the same circumferential and shear stresses that occur in the arterial network. 
Several other PLCL copolymers have been used for vascular tissue engineering 
applications demonstrating the possible use of bone marrow cells (BMCs) seeded onto 
scaffolds and implanted into a non-human model [139, 140], and evaluating electrospun 
PLCL scaffolds with SEM, porosimetry, tensile testing, and cell culture analysis using 
human umbilical EC [141]. 
 
Polydioxanone 
 PDO is a colorless, crystalline, bioabsorable polymer that was developed 
specificially for wound closure sutures. PDO exhibits a crystalline fraction of 55% and a 
glass transition temperature between -10
o
C and 0
o
C (Table 2.3). Greisler et al. were the 
first to have published several results on PDO absorbable vascular prosthetics using a 
mesh tube with 250 µm fiber diameter and 400 µm pore size. Evaluations of these first 
took place in a rabbit aorta [89] at 2 weeks up to 12 months, displaying myoFB migration 
occurring in parallel to the macrophage-mediated degradation of the PDO structure. This 
study was followed with the aorta-iliac canine model using 70% PDO and 30% 
polypropylene. Results from the study of up to a 1 year implantation demonstrated 86% 
patency rates compared to Dacron
®
 and ePTFE which had a rate of 68% and 54%, 
respectively. An additional study examined prostacylin (PGI2) and thromboxane A2 
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(TxA2) production from the endothelium. The rationale for this was based on the 
importance of these components with the endothelium non-thrombogenic properties. This 
is attributed to a balance between PGI2 and TxA2 (or the PGI2/TxA2 ratio), where it is 
more desirable to have a higher PGI2 levels than TxA2 in native vessels. The results of 
Greisler‟s study demonstrated that the explanted PDO graft had the highest ratio of 
PGI2/TxA2 versus PGA and almost equal to native aorta control [142]. 
 Since Dr. Greisler‟s extensive research using animal models, PDO has only been 
used in a handful of studies. Teebken et al. performed a comparison study between EC 
seeded decellularized carotid arteries and woven 4 mm diameter PDO prostheses, 
concluding that decellularized vascular tissue had higher patency rates than that of PDO 
prostheses [143]. A few years later, Boland et al. produced a study on electrospinning 
PDO into non-woven nanofibers examining the effects of polymer concentration on fiber 
diameter, pore area, and mechanical properties [144]. This led to several studies out of 
the same lab to test PDO in combination with biopolymers such as elastin [20, 145-147], 
collagen [146, 148], and silk [149] to determine both cellular and mechanical behavior. 
Sell et al. developed PDO-elastin vascular conduits using a range of polymer-elastin 
blends and characterized them utilizing compliance, suture retention, uniaxial tensile 
testing, and cellular seeding with human dermal FB. Since compliance mismatch between 
the graft and native artery is one of the major causes of graft failure, the authors of this 
manuscript have tested several combinations of PDO and elastin in order to determine its 
mechanical behavior in vitro [20]. A difference in this study, compared to other 
publications of vascular graft compliance, was that compliance was determined under 
dynamic conditions mimicking physiological parameters, therefore providing a lucid 
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interpretation as to how the graft should perform in the body. In this study, it was 
determined that certain PDO/elastin blends closely matched those of native artery.   
 Mechanical properties, specifically compliance, are of utmost importance in order 
to prevent a mismatch and ultimately intimal hyperplasia at the site of anastomosis; 
however, chemical properties of the vascular materials once implanted inside the body 
must also be evaluated so as to determine the material‟s response to monocytes and 
macrophages in vivo. Garg et al. aimed to evaluate the angiogenic potential of PDO-
elastin vascular grafts to promote in situ arterial tissue regeneration by measuring the 
amount of vascular endothelial growth factor (VEGF), acidic fibroblast growth factor 
(aFGF), basic fibroblast growth factor (bFGF), and transforming growth factor beta-1 
(TGF-β1) released upon interaction between the macrophages and the polymer-elastin 
blend [150]. Results demonstrated that macrophages remained on the surface of high 
elastin content PDO-elastin blends, but penetrated both low elastin content blends and 
pure PDO grafts. As a consequence, at day 28 VEGF was high for all grafts, aFGF was 
found to remain largely independent of graft material, and TGF- β1 was gradually 
decreased from day 7 to day 21. Through these studies, PDO has proven itself to retain 
low thrombogenicity and excellent mechanical properties by itself and when blended 
with other biopolymers. However, more information still needs to be examined in regards 
to cellularization of the scaffold materials and degradation characterization.   
 
Polyester Urethane Urea 
 For engineering soft tissues such as the vascular system, elastic scaffolds are 
highly desirable since they are amenable to mechanical conditioning regimens that might 
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be desirable to tissue development [151]. Martz et al. developed one of the first small 
diameter vascular graft from Mitrathane, a polyether urethane urea (Table 2.3) [152]. 
However, after a subsequent study in a canine carotid artery, all grafts were occluded 
after 4 to 6 months [153]. Since then, polyurethanes have been redeveloped by Wagner 
and associates through synthesis of two kinds of biodegradable polyurethaneureas, 
namely PEUU and poly(ether ester urethane)urea (PEEUU) from PCL, polycaprolactone-
b-polyethylene glycol-b-polycaprolactone, 1,4-diisocyanatobutane and putrescine. Grafts 
were fabricated by thermally induced phase separation and subsequent solvent extraction. 
Hydrolytic degradation of the grafts demonstrated a clear loss in scaffold weight after 56 
days. Grafts were also conducive to SMC attachment and growth after 7 days in culture 
[151]. This sparked the use of PEUU by both the Wagner and Vorp labs using several 
different scenarios: electrospinning to form a whole tube [154], electrospinning on top of 
a porcine internal jugular vein as a reinforcement for venous graft replacements [155], 
thermally induced phase separation (TIPS) to create a tubular scaffold for cell seeding 
with muscle derived stem cells [156], a TIPS tubular scaffold with an additional 
electrospun PEUU layer on top [157], and a blended electrospun scaffold using PEUU 
and poly(2-methacryloyloxyethyl phosphorylcholine-co-methacryloyloxyethyl 
butylurethane) [158]. These studies have had excellent results in terms of mechanical 
properties associated with their application and cellular seeding and proliferation in vitro 
and in situ. However, one of the possible disadvantages of using PEUU, especially in 
human implantation models, is its cytotoxicity due to the urethane component as the 
scaffold material degrades.   
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Table 2.3. PDO and PEUU.  
Biodegradable 
Polymer 
Manufacturing 
Method 
Improvement Cell Seeded Culture 
Condition 
Ref 
PDO      
Greisler et al. 70:30 
PDO:Polypropylene 
Mesh Tube 
Lower thrombogenic 
properties compared 
to PGA 
__ Rabbit Aorta [142] 
Boland et al. Electrospun PDO Mechanical 
properties 
__ __ [144] 
Sell et al. Electrospun PDO and 
elastin 
Mechanical 
properties and 
compliance  
FB Static [20] 
Garg et al. Electrospun PDO and 
elastin 
Cell penetration of 
low elastin content 
Macrophage Static [150] 
Wolfe et al. Electrospun PDO Low thrombogenic 
potential  
Monocyte Static [159] 
PEUU      
Wagner, Vorp, et al. Thermally induced phase 
separation and 
electrospun PEUU 
Cell attachment, 
proliferation, and 
mechanical 
properties 
SMC and Pericytes Static and Vacuum 
Seeding 
[151, 
154-
158] 
 
Collagen 
Collagen is the most abundant protein in the human body, a key element of the 
ECM, and imparts structural integrity and tensile strength to tissues. Tissue disruption 
following injury requires collagen for the repair and restoration of structure and function. 
Excessive collagen deposition at a wound site results in loss of anatomical structure, 
function and fibrosis. Conversely, if insufficient amounts of collagen are deposited, the 
wound is weak and may rupture [160]. This confers directly towards vascular tissue 
engineering; a vascular graft can be initially strong due to a synthetic polymer, however, 
once degradation occurs to a point where that strength is lost, there must be something to 
take over the mechanical requirements. In this case, not enough collagen remodeling will 
cause the graft to develop an aneurysm and rupture. 
Collagen has been used in a variety of tissue engineering applications because of 
its predominance in the ECM, non-immunogenicity and available methods of isolation 
from a variety of sources (Table 2.4). However, the typical procedures used to isolate and 
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reprocess this natural scaffolding into an engineered material may compromise many of 
its biological and structural properties [5]. Collagen fibers also possess some unique 
structural properties important for tissue engineering: they transmit forces, dissipate 
energy, prevent premature mechanical failure and provide biological signals to adjacent 
cells that regulate functional responses. Additionally, collagen is resorbable, has high 
water affinity, low antigenicity, very good cell compatibility and ability to promote tissue 
regeneration [161]. These factors combine to make collagen one of the most ideal 
biopolymers available for tissue engineering applications. 
 In vascular tissue engineering, collagen alone has been used in a number of 
applications. In 1986, Weinberg and Bell were the first to pioneer the idea of living blood 
vessels produced in vitro using cell seeded collagen gel tubes [36]. The Weinberg and 
Bell arterial graft consisted of an adventitia of bovine FBs embedded in a collagen gel; a 
media of gelled collagen and bovine SMCs, and a lumen lined by ECs. One of the main 
limitations of this approach was the lack of mechanical strength, demonstrating a burst 
pressure of only 90 mmHg. Investigators thereafter have attempted a number of other 
strategies to increase burst pressure strength, and maintain the biological aspect using 
ECs and SMCs. Berglund et al. mixed collagen and human dermal FBs together in the 
form of gels, which were subsequently crosslinked under different conditions to impart 
higher mechanical strength, resulting in a burst pressure over 600 mmHg [162]. 
Cummings et al. performed a similar experiment using the same manufacturing protocol, 
but with higher concentrations of collagen and no cross-linking [163]. Matthews et al. 
forewent the collagen gel construct and used electrospinning. Cells were well 
incorporated into cylindrical collagen constructs placed in a 55 mL bioreactor with aortic 
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SMCs [164]. Collagen by itself provides a construct that is advantageous for cellular 
seeding, but comes with drawbacks mechanically. Therefore, synthetic biodegradables 
are highly desired to provide mechanical stability for collagen-based grafts. PCL and 
collagen constructs have been studied extensively and have been produced mostly 
through the form of electrospinning [165-167]. Each of the studies found that when PCL 
and collagen were combined, collagen provided increased cellular attachment and 
proliferation for FBs, ECs, and SMCs. Additionally, Ju et al. found that fiber diameter 
highly affected SMC penetration of the PCL/collagen scaffolds under static culture. Other 
synthetics that have been investigated include electrospun PDO/collagen [148], surface 
modified electrospun PLLA-co-CL with an air plasma coating of collagen [168], a porous 
collagen mold with electrospun PLGA [169], and a combined collagen gel/particulate 
leached PLCL graft [170], where each study has clearly shown the cellular benefits 
associated with the addition of collagen. Collagen is a very attractive protein to add to 
vascular grafts, increasing adhesive properties and cellular infiltration and penetration. 
However, mechanically it can add significant stiffness to the material; therefore the 
proper amounts of collagen need to be paid special attention when utilizing it. 
 
Elastin 
In vivo, elastin is a chemically inert, highly insoluble polymer composed of 
covalently cross-linked molecules of its precursor, tropoelastin, a soluble, non-
glycosylated and highly hydrophobic protein. Tropoelastin expression and subsequent 
elastin synthesis typically occurs in FBs, vascular SMCs, ECs, and chondrocytes [171].  
During the process of elastogenesis, tropoelastin is synthesized, preventing its premature 
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intracellular aggregation and protecting it from proteolytic degradation by binding a 67 
kDa galactoectin (elastin binding protein, EBP). This association lasts until the complex 
is excreted into the extracellular space. EBP then interacts with galactosugars of the 
microfibrils, dramatically decreasing its own affinity for tropoelastin. In order for proper 
elastogenesis to occur, the interaction of the N-terminal part of the microfibrillar-
associated glycoprotein with the C-terminal end of tropoelastin is required. Once aligned, 
lysyl oxidase deaminates and oxidizes the lysyl residues to allysine following the action 
of Cu
2+
. Cross-links are then formed by the reaction of the allysines with themselves or 
with an unmodified lysine [171-173].   
As a biomaterial, elastin is becoming more and more popular for tissue 
engineering applications as one of the main structural components of the vascular ECM 
(Table 2.4). The incorporation of elastin into biomaterials has been used in several 
different forms, including insoluble elastin occurring in autografts, allografts, xenografts, 
decellularized ECM, and in purified elastin preparations where the insoluble elastin is 
hydrolyzed to a soluble form of , , and  elastin [174]. Although insoluble elastin in its 
different graft forms could be considered a more “natural state,” there is an advantage to 
its solubility which makes handling and analysis of the material more straightforward. 
Additionally, elastin peptides influence signaling, chemotaxis, proliferation, and protease 
release via the elastin receptor [175]. Daamen et al. not only found that solubilized elastin 
induced angiogenesis, but also increased elastic fiber synthesis and displayed no signs of 
calcification when compared to grafts containing its insoluble form [176]. Leach et al. 
created -elastin discs using a diepoxy crosslinker, finding that vascular SMCs adhered 
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well to the substrates [177]. This is one of many studies that have proven soluble elastin 
to be an advantageous biopolymer. 
 As stated previously, tropoelastin provides the necessary building blocks to form 
native elastin in vivo. Li et al. demonstrated that recombinant human tropoelastin could 
be electrospun to form both nanofibers and microfibers, depending on the delivery rate 
[178]. In their study, both tropoelastin and solubilized -elastin were electrospun. The 
parameters were optimized and the final products were compared through microscopy, 
mechanical tensile moduli, and cellular activity with human embryonic palatal 
mesenchymal cells. Welsh et al. manufactured crosslinked elastin-like polypeptide films, 
and performed tensile testing where stress-strain curves produced the low stress toe 
region of native tissue J-curves [179]. Again, like collagen, elastin by itself will fail to 
perform properly under the physiological stresses imposed by the vasculature. 
Investigators have looked into the combination of elastin and synthetic materials. As 
mentioned previously, PDO/elastin grafts were electrospun and tested mechanically to 
find that certain blends emerged as comparable to native artery [20]. This study 
subsequently led to another blending PDO and elastin in a layered fashion with PDO 
sutures as reinforcement between each layer [145]. Elastin-like polypeptide has also been 
implemented into vascular tissue engineering. Nicol and Urry explored the possibility of 
incorporating cell recognition peptide sequences into ELPs in order to promote EC 
adhesion, finding that too small an amount of RGD sequence significantly decreased 
cellular attachment [180]. More recently, tropoelastin was combined with PCL to form a 
bi-layered vascular scaffold with pure electrospun tropoelastin on the inner layer and 
combined PCL/tropoelastin on the outer layer [181]. Results displayed enhanced EC 
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interaction, improved blood compatibility, excellent mechanical properties, and full cell 
penetration of the scaffold structure when implanted in situ. While elastin is known as an 
essential, key factor in vascular arteries, its addition to scaffold materials comes with 
both advantages and disadvantages. Mechanically, elastin enhances compliance and 
distensibility of scaffold material. From the cellular perspective, it has come with mixed 
results where specific types of elastin are conducive to cellular attachment and others are 
not. These factors must be considered when working with elastin as a biomaterial.   
 
Combined Elastin and Collagen 
As collagen and elastin are two of the most prevalent protein constituents in 
native vessel, it is only logical that they are often used in concert as tissue engineering 
scaffolds for vascular applications (Table 2.4). Berglund et al. looked to take their 
previous collagen gel study and enhance its biomechanical properties through the 
incorporation of organized intact elastin to form hybrid constructs [182]. Histological 
staining from the study revealed that both the collagen gel control and the 
collagen/elastin hybrid exhibited dense layers of cells along their outer walls. 
Additionally, elastin incorporation increased mechanical properties by 11 fold. Boland et 
al. [38], in an attempt to create a biomimicking layered vascular structure, first 
electrospun an 80/20 collagen type I/elastin tube on a 4 mm diameter mandrel. This tube 
was subsequently seeded with both FBs and SMCs. Another tubular scaffold of 30/70 
collagen type I/elastin was electrospun on a 2 mm diameter mandrel. This electrospun 
scaffold was then inserted into the 4 mm diameter scaffold and the lumen was filled with 
a SMC suspension. After 3 days in culture, a suspension of human umbilical vascular 
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endothelial cells (HUVEC) was injected into the lumen, and the entire construct was 
cultured for 2 more days. Histological examination revealed complete cellular infiltration 
into the three-layered construct after 21 days. The artificial intima was covered by 
morphologically mature ECs and SMCs were present throughout the media, and had 
begun to align circumferentially around the axis of the scaffold. The FBs and SMCs in 
the adventitia created a dense population throughout the outermost wall. This study 
proved that an electrospun scaffold that mimics the native ECM is highly beneficial in the 
field of vascular tissue engineering. However, the lack of synthetic polymers in the 
tubular structures did not allow for sustained mechanical viability.   
In a study by Buttafoco et al. [183], soluble collagen type I from calf skin and 
soluble elastin from bovine neck ligament were electrospun from aqueous acidic 
solutions in order to avoid the use of organic solvents. To ensure continuous and 
homogenous fibers, poly(ethylene oxide) (PEO) and sodium chloride (NaCl) was added. 
Meshes composed of fibers with diameters ranging from 220 to 600 nm were obtained by 
spinning the collagen/elastin solutions. Scaffolds completely devoid of PEO and NaCl 
were obtained by cross-linking with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS). SMC were successfully cultured on cross-
linked scaffolds and a confluent layer of cells was observed after 14 days on the surface 
of the different scaffolds. 
Combinations of collagen and elastin with synthetic polymers have also been used 
in order to create scaffold and graft materials with desirable mechanical properties, 
bioactivity, and sustained mechanical integrity. Nanofiber grafts were fabricated using a 
mixture of 40% collagen type I, 15% elastin and 45% PLGA by weight electrospun onto 
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a 4.75 mm diameter cylindrical mandrel. Compliance testing results showed that the 
diameter change was approximately 9% for native vessels and 12–14% for electrospun 
grafts under a physiologic pressure range. In vitro cell proliferation of SMC and EC 
showed an average of 82% of SMCs and 72% of ECs survived on the grafts [184]. 
In a similar study, an array of synthetic materials with 45% collagen, 15 % 
elastin, and 40% biodegradable synthetic (PLGA, poly(L-lactide) (PLLA), PCL, and 
poly(D,L-lactide-co- -caprolactone) (PLCL)) were electrospun. Tubular grafts were 
characterized through SEM, uniaxial tensile testing, and biocompatibility. Once again it 
was demonstrated that graft mechanical properties were improved with the addition of 
synthetic polymers. This study also demonstrated that in order for a graft to remain patent 
when using biopolymers such as collagen and elastin, the addition of a synthetic is 
necessary for sustained stability [185]. Recently studies have come out that have looked 
to mimic the natural architecture of blood vessels with the use of synthetic polymers, 
collagen, and elastin. McClure et al. used electrospun PCL, elastin, and collagen in 
different ratios to develop a cross-linked mechanically tunable vascular graft 
characterized by compliance, tensile properties, suture retention, and burst pressure 
strength [186]. Thomas et al. performed a similar study with the use of an uncross-linked, 
electrospun polyglyconate, elastin, and gelatin, demonstrating a distinctive tri-layered 
design [187]. Working with the natural polymers and architecture that are provided by 
Mother Nature could prove to be an advantageous method for vascular tissue 
engineering.   
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Table 2.4. Collagen, Elastin, and Collagen/Elastin Blends. 
Biopolymer Manufacturing 
Method 
Improvement Cell Seeded Culture 
Condition 
Ref 
Collagen      
Weinberg and Bell Collagen gel Cell proliferation SMC, FB, and EC Static [36] 
Berglund et al. Crosslinked collagen gel Mechanical strength FB Static [162] 
Cummings et al. High concentration 
collagen gel 
Mechanical strength  SMC Cyclic mechanical 
stimulation 
[163] 
Matthews et al. Electrospun collagen Collagen nanofibers 
for cell attachment 
and proliferation 
SMC Rotary Bioreactor [164] 
Elastin      
Leach et al. Crosslinked elastin discs  Cell attachment SMC Static [177] 
Li et al. Electrospun tropoelastin Mechanical elasticity 
and cell attachment 
Meschymal Stem 
Cell 
Static [178] 
Welsh et al. Elastin-like polypeptide 
film 
Stress-strain curve __ __ [179] 
Collagen and 
Elastin 
     
Berglund et al. Collagen and elastin gel Mechanical 
properties and cell 
proliferation 
FB Static [182] 
Boland et al. Electrospun collagen and 
elastin in three layers 
Cell proliferation and 
native arterial 
architecture 
FB, SMC, EC Rotary Bioreactor [38] 
Buttafoco et al. Electrospun collagen and 
elastin with PEO and 
NaCl additives 
Cell attachment and 
proliferation 
SMC Static [183] 
McClure et al. Crosslinked electrospun 
PCL, collagen, and 
elastin 
Mechanical 
compliance and burst 
pressure with  
tunable properties 
__ __ [186] 
Thomas et al. Uncrosslinked 
electrospun elastin, 
gelatin, polyglyconate 
Tunable properties __ __ [187] 
 
 
Decellularized Vessels 
 
 One obvious choice for vascular tissue engineering is finding a hollow tissue with 
the appropriate extracellular matrix components and removing cells from the construct 
(Table 2.5). Several types of decellularized tissues have already been developed 
including human veins [188], bovine ureters [189], canine arteries [190], and small 
intestine submuscosa (SIS) [191]. Results found varying signs of proximal and distal 
hyperplasia with a varying patency rate between 40 and 100%. Lantz et al. grafted dog 
jejunal submucosa as an autologous vascular graft and found that after 28 days the graft 
was histologically similar to native vessel [192]. More recently, Gui et al. developed a 
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decellularized human umbilical artery with a compliance of 4.3%/100 mmHg and a max 
burst pressure of 970 mmHg [193]. As most of the aforementioned decellularized 
matrices were collagen-based, there are some groups who have looked into elastin-based 
products. Lu et al. utilized the Rasmussen protocol [194] on aorta samples to obtain an 
elastin network [195]. The advantage of elastin-based scaffolds is their distensibility, 
which, according to the experiment, remained the same as native aorta and significantly 
higher than collagen-based aorta tested under the same conditions; however, tensile 
strength was severely decreased. Additionally, hDF studies revealed that elastin based 
scaffolds had a higher degree of cellular infiltration after 28 days in rotary culture. 
Berglund et al. used the Starcher and Galione extraction method [196] with carotid 
arteries [182]. These elastin grafts were repopulated using cells encapsulated in a 
collagen gel, cultured, and then tested mechanically. Positive aspects of decellularized 
tissues include a more “off the shelf” type graft with no maturation time. However, 
despite a readily available supply of artificial arteries is attractive, drawbacks include the 
inability to tailor the matrix content and architecture.   
 
Fully Biological Grafts 
 The concept of a completely biological living graft implies the ability to remodel, 
grow, self-repair and respond to the immediate environment (Table 2.5). The graft would 
also contain enough collagen and elastin proteins to display desirable viscoelastic 
properties, and would lack any synthetic foreign material that would initiate chronic 
inflammatory responses or be susceptible to infection [67]. L‟Heureux developed an 
approach to biological scaffolds using human FBs and vascular SMCs in sheet form, 
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which were subsequently wrapped around a PTFE coated  mandrel [197]. The assembled 
constructs required an 8 week maturation period and were then seeded with human ECs, 
resulting in burst pressures able to withstand 2000 mmHg. Recently, L‟Heureux and 
associates have performed a human trial using rolled cell sheets for radial artery, A-V 
shunts, and lower limb indications. This study demonstrated grafts that were able to 
withstand burst pressures in excess of 3000 mmHg while retaining an average 
compliance of 8.8%/100 mmHg after 6 months implantation [198]. Campbell et al. 
produced another graft through an inflammatory reaction, where a silastic tube was 
placed in the peritoneal cavity of rats and rabbits for 2 weeks and was covered in a 
layered fashion with myoFBs, collagen matrix, and a single layer of mesothelium [94]. 
Lengths of myoFB-rich tubes were then grafted by end-to-end anastomoses into the 
carotid artery of a rabbit and the abdominal aorta of a rat. In situ, cells responded to local 
environmental cues, remodeled, and produced structures similar to those of native vessel. 
More recently, Stickler et al. aimed to assess the possibility to strengthen these peritoneal 
cavity grafts, shortening the time for development [199]. This was achieved through the 
use of an implantable device which consisted of an inner stretchable tub, a perforated 
external tube and a transabdominal tube. So, as tissue grew onto the device, it was 
subjected to cyclic stretch to enhance growth. Mechanically, pulsed tubes displayed a 
significantly higher failure strength and failure strain compared to unpulsed tissue. This 
was most likely attributed to the higher organization of collagen in the circumferential 
direction. While work in the area of fully biological grafts has demonstrated promise in 
vascular tissue engineering, there are still some drawbacks to the process, including 
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culture time, risk of infection during the culture period, and a prolonged maturation time 
that takes away from “off the shelf” capabilities. 
Table 2.5. Decellularized and Fully Biological Grafts. 
Biopolymer Manufacturing 
Method 
Improvement Cell Seeded Culture 
Condition 
Ref 
Decellularized      
Lantz et al. Jejunal submucosa Histologically similar __ Canine implant [200] 
Gui et al. Umbilical artery Compliance and 
burst pressure 
__ __ [193] 
Lu et al. Aorta with elastin 
network 
Higher cell 
penetration  
FB Rotary Bioreactor [195] 
Berglund et al. Carotid artery with 
collagen gel 
Mechanical 
properties 
FB Static [182] 
Fully Biological 
Graft 
     
L‟Heureux et al. Rolled SMC sheets Mechanical 
properties and 
autologous cell use 
SMC Static [197] 
Campbell et al. Silastic tube in peritoneal 
cavity  
Structure similar to 
native vessel 
__ Rat Implant [94] 
Stickler et al. Silastic tube in peritoneal 
cavity with cylic strain 
Mechanical 
properties 
__ __ [199] 
 
 
Drug Delivery for Improved Vascular Grafts 
 
Delivery of growth factors from scaffolds has been gaining interest as a therapy 
for a variety of tissue engineering applications, including vascular graft regeneration 
(Table 2.6). Growth factors play a critical role in the communication and information 
transfer between cells and their environment by binding to specific receptors on cell 
surfaces. They modulate a variety of cell activities, including proliferation, 
differentiation, migration, adhesion, and gene expression. Due to their ability to play such 
a key role in cell activity, cell fate, tissue development, and repair, especially in the 
vascular system, it is no surprise that their use in therapies has been proposed. However, 
their success in clinical applications has been limited, partly due to the cost related to the 
purchasing of recombinant or isolated proteins. In addition, the delivery of one, or 
several, factors in clinical therapies is complicated, as there is limited knowledge behind 
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the signaling and release of growth factors that occurs between cells and the 
physiological environment. In addition, there are several parameters that must be 
considered, including the delivery vehicle, the quantity/concentration of factor to deliver, 
the duration of the delivery, and the ability to control the release both temporally and 
spatially [201-205]. Furthermore, the route of travel by the growth factor(s)/drug(s) once 
it is delivered is also an important parameter, particularly if there could be a potential 
detrimental effect downstream. 
 Growth factors that play key roles in the angiogenic process necessary for 
vascular graft regeneration include VEGF, FGF, platelet derived growth factor-BB 
(PDGF-BB), stromal cell-derived factor-1α (SDF-1α), TGF- , and angiopoietins-1 and 2 
(Ang-1 and 2). VEGF and bFGF are heparin-binding growth factors involved in the 
initiation of the process, promoting EC proliferation and migration. PDGF-BB recruits 
SMCs and pericytes which, along with TGF- , promote ECM deposition to stabilize 
neovessels [202]. SDF-1 plays an important role in angiogenesis as well by recruiting 
EPCs from the bone marrow [206]. For vascular applications, numerous studies have 
been performed on the delivery of these growth factors, either alone, or in concert with 
one or two others, with the use of different delivery vehicles, as well as different delivery 
methods.  
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Table 2.6. Biopolymers and Synthetic Polymers for Drug Delivery. 
Drug Delivery Drug Additive Improvement Cell Seeded Culture 
Condition 
Ref 
Biopolymers      
Pang et al. R136K to bind to 
collagen scaffolds 
Lower thrombogenic 
properties 
__ __ [207] 
Wissink et al. Immobilized heparin 
onto collagen scaffolds 
Increased amounts of 
bFGF to material and 
cell proliferation 
EC Static [208] 
Synthetic 
Polymers 
     
Thevenot et al. PLGA salt-leached 
scaffold injected with 
SDF-1  
Cell proliferation, 
angiogenesis, lower 
inflammatory 
response 
EPC and MSC Mouse Implant [209] 
Mooney et al. VEGF and PDGF-BB 
released from PLGA 
scaffolds 
Increased 
angiogenesis and 
maturation 
__ Hindlimb Ischemia 
Model 
[210] 
Saif et al. VEGF, HGF, Ang-1 
released form PLGA 
scaffolds 
Increased 
angiogenesis and 
maturation 
EPC Hindlimb Ischemia 
Model 
[211] 
 
Delivery Methods and Vehicles 
 Traditionally, growth factors are administered systemically (transdermal), orally, 
or intravenously. However, these methods of delivery are likely to be ineffective due to 
the short half-lives of the growth factors, their relatively large size, slow tissue 
penetration, and their potential toxicity at high systemic levels [202, 203]. For these 
reasons, polymeric materials, both natural and synthetic, are frequently used as delivery 
vehicles. Using polymers for this application allows for a more timely and spatially 
controlled delivery. Biomaterials used for this function must be nonimmunogenic, have 
degradation products that are soluble and nontoxic, and must be able to be produced 
sterile and free of infectious pathogens [204]. While natural polymers are beneficial due 
to their bioactive factor for cell recognition and degradation, synthetic polymers have 
very controlled and reproducible chemical and physical properties. Another attractive 
feature of natural polymers are that some have specific binding sequences for and 
intermolecular interactions with many angiogenic growth factors [212].  
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Natural Derived Polymers 
Natural polymers that have been previously used for delivery vehicles include 
alginate [213-215], agarose [216], chitosan [217, 218], gelatin [219, 220], fibrin [221], 
and collagen [222-225]. They are often formed as a gel, or as microspheres, and are 
usually processed by freeze-drying or cross-linking in an aqueous solution [226]. 
Often, fibrin glue, which is a mixture of fibrinogen and thrombin, is used 
therapeutically, as it serves as a temporary platform for the gradual development of 
granulation tissue. Clinical application of fibrin glue has been studied as a carrier of 
angiogenic growth factors to create a confluent endothelium on the luminal surface of 
synthetic vascular grafts [221, 227]. After coating e-PTFE grafts with fibrin glue and 
FGF-1, it was found to produce better EC retention and expansion after seeding, 
eliminating graft thrombogenicity and improving graft patency [228]. Recently, Pang et 
al. studied the affinity and distribution of a fusion protein consisting of R136K, a 
relatively thrombin-resistant mutant derivative of FGF-1, and a collagen-binding domain, 
to 3-D collagen scaffolds [207]. They found that R136K-collagen binding domain had a 
greater affinity for collagen scaffolds than either R136K or FGF-1, demonstrating a 1.7 
fold lower release rate. 
To suppress initial burst release often seen in hydrogel-type delivery systems, and 
still permit longer retention in the delivery carrier, heparinization has been proposed, 
either by covalent conjugation of heparin molecules, or the encapsulation of growth 
factor together with heparin-binding material within the delivery vehicle. Modifying the 
network structure, such as cross-linking with glutaraldehyde, has also been done, so as to 
couple the rate of release to the rate of matrix degradation [229, 230]. Other studies have 
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used EDC and NHS to cross-link collagen and heparin, or collagen and heparin sulfate, 
enhancing growth factor capture within the hydrogel, enhancing HUVEC expansion onto 
the graft [208], and producing a strong and stable vascularization throughout the hydrogel 
in a subcutaneous implant [231].  
 
Synthetic Derived Polymers 
 Synthetic matrices that studies have reported on have been composed of 
poly(vinyl alcohol) (PVA), poly(alpha-hydroxyester)s including poly(ethylene glycol) 
(PEG) [232], PLGA [233-238], PLLA, or PCL [239], polyanhydrides, and 
polyorthoesters [220, 240]. They are typically processed into porous grafts that provide 
mechanical support for cells or microspheres for injection and are fabricated by 
techniques such as solvent casting, gas foaming, particulate leaching, double emulsion, 
electrospinning, and rapid prototyping [226]. Synthetic matrices for this application must 
completely degrade and be resorbed into the body, and must temporarily act as 
mechanical support to allow cells to infiltrate and produce native ECM. 
A PLGA salt-leached scaffold injected with SDF-1α was implanted 
subcutaneously into mice to determine the ability of the scaffold to promote stem cell 
recruitment, reduce inflammatory response and fibrosis, and enhance angiogenic 
processes [209]. MSC migration and EPC engraftment near the SDF-1α incorporated 
scaffold were found to be enhanced after 7 days over a PLGA control scaffold. In 
addition, there was decreased inflammatory cell recruitment, with reduced fibrotic 
capsule formation and proinflammatory cytokines around the scaffold. Histological 
analysis illustrated improved angiogenesis by EPCs throughout the SDF-1α incorporated 
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scaffold over a PLGA control scaffold, with vessel-like formations occurring at the 
interface of the scaffold. The results from this study demonstrate the potential for these 
SDF-1α incorporated scaffolds to be used in vascular graft applications, as they elicit 
improved tissue response and regeneration.  
 Angiogenesis and tissue survival after implantation is essential for the survival of 
any implant, including tissue engineered vascular grafts.  Dual growth factor delivery 
from synthetic grafts was first reported by Mooney‟s group, where both VEGF and 
PDGF-BB were released with distinct kinetics from grafts of PLGA fabricated by a high-
pressure carbon dioxide process [210]. In looking at blood vessel size and distribution in 
a hindlimb ischemia model, relative to either growth factor delivered individually, both 
vessel size and distribution were improved when the delivery of the two growth factors 
were together. This demonstrates that therapies involving growth factor delivery for 
angiogenesis would benefit from the actions of multiple growth factors over just a single 
delivery. For this study, VEGF was responsible for the increase in blood vessel density, 
whereas PDGF contributed to the maturation and size of the blood vessels. Another study 
fabricated PLGA grafts from gas foaming and particulate leaching with VEGF and PDGF 
incorporated into different layers of the graft [241]. This layered graft system allowed 
compartmentalization of VEGF and PDGF and controlled spatial and temporal 
presentation of the growth factors.  
 Saif et al. took it a step further and incorporated three growth factors into a 
scaffold for delivery. In a murine hindlimb ischemia model, PLGA microparticles were 
fabricated containing VEGF, hepatocyte growth factor (HGF), and Ang-1 using a double 
emulsion technique [211]. These microparticles, along with cord blood-derived vascular 
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progenitor cells, were coadministered into the hindlimb of a mouse. This resulted in a 
robust enhancement of vascularization, superior to any single growth factor administered. 
Including increased muscular capillary density and enhanced number of conductant 
vessels, with sufficient vessel stabilization and maturation. 
 In the presence of TGF- β1, SMCs cultured on adhesive ligand-modified glass 
surfaces, specifically Arg-Gly-Asp-Ser (RGDS)-modified surfaces, increased matrix 
production. In addition, tethering TGF- β1 to PEGdiacrylate hydrogel with RGDS 
resulted in a significant increase in matrix production over the same amount of soluble, 
unmodified TGF- β1 incorporated into scaffolds, most likely due to the diffusion of the 
soluble growth factor into the culture medium [232]. 
The authors of this paper have successfully electrospun lyophilized PRP with 
PCL to form nanofibrous grafts [242]. As PRP contains various supraphysiologic, 
autologous growth factors and cytokines that enhance healing, its addition to a synthetic 
construct has the potential to increase the bioactivity of the graft and enhance 
regeneration through the release of growth factors contained within the PRP. Results 
from a protein assay have demonstrated successful release from the electrospun grafts for 
35 days, as well as quantifiable release of PDGF-BB over 14 days. The PRP containing 
grafts were also chemotactic towards macrophages, and significantly enhanced 
proliferation of adipose derived stem cells over synthetic grafts. These results are 
promising for the use of electrospun grafts incorporated with PRP as an improved 
therapeutic strategy for tissue engineering applications such as vascular grafts. 
 Other growth factors/drugs used to improve scaffolds for vascular graft 
applications include heparin [243], a known anticoagulant, insulin [244], nitric oxide 
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[245, 246], a known vasodilator and mediator of EC growth and function, cyclosporine 
[247], a potent immunosuppressive that inhibits SMC proliferation and intimal 
hyperplasia, and other antibiotics. A study by Javerliat et al. implanted vascular grafts 
preloaded with antibiotics, rifampin and tobramycin, into the infrarenal aortas of dogs 
[248]. The grafts implanted were: gelatin-sealed knitted polyester grafts used as controls, 
and antiobiotic-bonded gelatin-sealed knitted polyester grafts loaded with rifampin and 
tobramycin at normal doses, and twice the normal doses. After 21 days, histological 
analysis of the grafts revealed complete patency of all grafts, with no signs of local toxic 
response to the antiobiotics. Healing of the preloaded grafts, whether at standard or twice 
standard loading of antibiotics, was always similar to that of the conventional gelatin-
sealed grafts, with no signs of poor healing. These results are encouraging, seeing as how 
vascular prosthetic infections still remain a serious complication of vascular surgery.   
 
Conclusion 
 Despite the many obstacles to overcome in the creation of a successful vascular 
graft, research from the last 10 years has exponentially increased our knowledge and 
understanding of what is required of a vascular substitute. Biohybrid and tissue 
engineered vascular grafts have been investigated using material properties, complex 
tissue culture, and cell seeding techniques. Investigators have looked at several 
approaches to the issues that still prevent an ideal graft from being designed. At the 
present time, both in vivo and ex vivo solutions have significant drawbacks; however, 
through the combination of bioresorbables, biopolymers, drug delivery, and cells, we can 
surmount the setbacks and ameliorate these problems. 
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Chapter 3: SCAFFOLD CHARACTERIZATION OF AN 
ELECTROSPUN NOVEL CO-POLYMER 
 
 
Preface: The following manuscript is in Journal of Engineered Fibers and Fabrics. The 
included work demonstrates the capability of creating an electrospun nanofibrous 
structure from a novel copolymer and investigates the thermal and mechanical properties 
of the scaffolds. The scaffolds’ mechanical and thermal characteristics are different, 
depending on the ratio of monomers used to form the copolymer and can be tailored for 
different tissue engineering applications.  
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Abstract 
 Because tissue engineering scaffolds serve as a temporary environment until new 
tissue can be formed, their mechanical performance, thermal properties, and 
biocompatibility are critical for maintaining their functionality. The goal of this study 
was to electrospin scaffolds from copolymers containing varying amounts of 1,4-Dioxan-
2-one (DX) and D,L-3-Methyl-1,4-dioxan-2-one (DL-3-MeDX), and characterize their 
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mechanical and thermal properties. Image tool analysis of scanning electron micrographs 
revealed the presence of DL-3-MeDX causes the fiber diameter of the scaffold to 
decrease as compared to PDO. Uniaxial tensile testing revealed increasing amounts of 
DL-3-MeDX in the copolymer decreases scaffold peak stress, strain at break and 
toughness. Modulated differential scanning calorimetry was used for thermal analysis of 
the scaffolds and showed that increasing amounts of DL-3-MeDX causes a decrease in 
the melting as well as crystallization temperatures. Based on the results of the mechanical 
and thermal properties of these copolymer scaffolds, it is evident that these constructs 
could be functional in a variety of biomedical engineering applications. 
 
 
Introduction 
 
The combination of materials science and engineering with tissue engineering 
aims to restore, repair or replace diseased or damaged tissue. The design and fabrication 
of scaffolds are an essential task for functional, engineered tissue. A scaffold serves as a 
temporary cell adhesion and proliferation microenvironment until natural ECM 
biomacromolecules (proteins and proteoglycans) are generated by inoculated cells to 
form a tissue morphology resembling that of a native tissue. Electrospinning is a well 
known technique to fabricate micro to nanometer-scale scaffolds [249], and because it is 
relatively inexpensive, it has become increasingly popular. In the development of new 
scaffolding for tissue regeneration, there are several requirements that must be fulfilled. 
In addition to surface morphology, porosity, and sufficient mechanical performance and 
thermal properties, the material must be biocompatible and support cell adhesion, growth 
and differentiation. Amongst the most investigated biomaterials, PDO, a poly(ester-ether) 
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originally developed for use as a wound closure suture, has attracted a lot of interest 
because of its superior degradation rate of 6-12 months [144, 250]. PDO has shown 
higher strength retention, slower absorption rates and lower inflammatory response as 
compared to PGA (Dexon
®
) and PLGA (Vicryl
®
). In addition to its biocompatibility, its 
unique shape memory makes PDO particularly suitable for vascular tissue engineering 
[5].  
Previously, the thermal properties (glass transition, melting and crystallization 
temperatures) of various electrospun polymers have been reported. The first study to use 
differential scanning calorimetry (DSC) was published by Kim et al. [251]. This study 
concluded that the electrospinning of poly(ethylene terephthalate) (PET), poly(ethylene 
naphthalate) (PEN), and blends of PET and PEN caused an increase in crystallinity, but a 
decrease in glass transition temperature (TG) and crystallization temperature (TC). 
According to the authors, this was due to the thermal degradation (i.e. decrease in 
molecular weight resulting in decrease of chain entanglements) after spinning, and 
exchange reactions in the melt blends. Zong et al. investigated the thermal properties of 
electrospun poly(L-lactic acid) (PLLA) from dimethyl formamide using DSC [252]. It 
was reported that the electrospun PLLA nanofibers had lower TG, TC, and TM (melting 
temperature) compared to the corresponding values for PLLA resin. The study concluded 
that the electrospun PLLA scaffolds were non-crystalline, but had highly ordered 
polymer chains, and thus, the crystallization of PLLA was obstructed by the 
electrospinning process. Ramdhanie, et al. have previously reported on the mechanical 
and thermal properties of virgin and electrospun PGA, polylactic acid (PLA), and blends 
of these polymers [253]. It was found that the electrospinning process lowered the 
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crystallization temperature for both polymers; PLA decreased from 108 to 72 – 77 °C and 
PGA decreased from 68 to 49 °C. The glass transition and melting temperatures of the 
electrospun polymers and polymer blends remained the same as the virgin polymers, 
except for one of the blended ratios (PLA 25%:PGA 75%).   
To improve the processability of PDX, 1,4-dioxanone (DX) has often been 
copolymerized with glycolide (GA) or lactide (LA) and much of this work is covered in 
patents [254-257]. Using aluminium triisopropoxide (Al(O
i
Pr)3) as initiator, block 
poly(ε–caprolactone)-poly(1,4-dioxan-2-one) (PCL-PDX) copolymers have been 
prepared by Raquez et al. through sequential polymerization [258]. Thermal analysis of 
the copolymer revealed two glass transition temperatures (-65 °C for the PCL and -10 °C 
for the PDX), confirming immiscibility of the two blocks with each other. 
Poly(trimethylenecarbonate-co-ε-caprolactone)-block-poly(1,4-dioxan-2-one) [(PTMC)-
co-(PCL)]-b-(PDX) was prepared using the (PTMC)-co-(PCL) unit as macroinitiator in 
the presence of Sn(Oct)2 as a catalyst [259-261]. As soft segments, caprolactone (CL) and 
trimethylenecarbonate (TMC) moieties endow the PDX chain with enhanced flexibility 
and degradability, and excellent handling characteristics. Analysis of this copolymer 
revealed a lower TG and decreased mechanical properties compared to that of PDX, 
which can be explained by the decrease in crystallinity. Using dihydroxyterminated PEO 
of different molar masses as a macroinitiator, the triblock (PDX)-b-(PEO)-b-(PDX) has 
been previously formed in the presence of Sn(Oct)2 [262-265]. The addition of the PEO 
chains did not affect the thermal properties of the triblock. It is noteworthy that most of 
the above copolymers have not been subjected to electrospinning except the one recently 
reported by Shin et al. [261].  
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Lochee et al. recently reported on the synthesis of a derivative of DX monomer, 
R,S-3-methyl-1,4-dioxan-2-one (3-MeDX) using a novel synthetic route [266] and 
provided a detailed account of the homopolymerization of 3-MeDX, using a range of 
initiators including tin(II) octanoate. The same authors also reported on the preparation of 
a range of random copoly(ester-ether)s by the non-sequential polymerization of  1, 4-
dioxan-2-one with DL-3-methyl-1,4-dioxan-2-one using various initiator systems [266]. 
The stiffness of PDX can now be reduced by introducing small amounts of DL-3-MeDX. 
Indeed, the thermal properties of the copoly(ester-ether)s changed significantly with the 
percentage of MeDX units incorporated. For instance, a copolymer with 8 % (mole 
percent) of MeDX units exhibits a TM of 95.5 °C; this is about 15 °C lower than PDO 
homopolymer. Thus, the ability to tailor the PDO composition and subsequent properties 
(i.e. mechanical properties, biocompatibility, and degradation rates) will allow for the 
design of the next generation of tissue engineering scaffolds for application in 
regenerating such tissues as arteries, peripheral nerve, and bone. Overall, it is hoped that 
these novel compositions would allow for a significant enhancement of the current state 
of the field.  
This chapter reports for the first time on the successful electrospinning of fibers 
from a new family of poly(ester-ether)s obtained by random copolymerization of 1,4-
Dioxan-2-one (DX) and DL-3-methyl-1,4-dioxan-2-one (DL-3-MeDX) and on their 
mechanical and thermal characterization. The hypothesis of this study is that the addition 
of DL-3-MeDX will have an affect on the mechanical and thermal properties of the 
electrospun scaffolds. 
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Materials and Methods 
Copolymerization 
For polymerization, solvents used were purchased from Sigma Aldrich
® 
or 
Fischer Scientific, and were purified prior to use. DX and DL-3-MeDX were synthesized 
according to procedures previously described [266]. Briefly, freshly distilled DX and DL-
3-MeDX at various masses were transferred in a quick-fit tube under argon inside a glove 
box. 100 µL of a 2-ethyl tin (II) hexanoate solution in toluene (1.26 x 10
6
 mol; 500 ppm 
Sn) was added to the monomers via a syringe. The tube was placed in a preheated oil bath 
at 80 °C outside the glove box and polymerization was allowed to take place. After 24 
hours, the reaction was quenched through freezing in liquid nitrogen and the crude 
sample was dissolved in 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP) followed by 
precipitation in tetrahydrofuran (THF). The precipitate was washed several times with 
THF and dried under vacuum at room temperature before characterization. The 
composition and reduced viscosities of the copolymers synthesized are listed in Table 
3.1.  
 
Table 3.1. DX:DL-3-MeDX copolymer ratios and viscosities. 
Mole percentage of 
comonomeric units in 
purified copolymer 
a 
(%) 
ηred
b
 
[dLg
-1
]
 
 
  
DX DL-3-MeDX 
100 0 1.16 
94 6 0.93 
93 7 0.77 
91 9 0.88 
88 12 0.82 
80 20 0.95 
a
 Determined by 
1
H NMR 
b
 Reduced viscosity determined using CHCl3, concentration=0.2 g.dL
-1
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Electrospinning 
Varying compositions of P(DX:DL-3-MeDX) (80:20, 88:12, 91:9, 93:7, 94:6), as 
well as PDO (100:0 DX:DL-3-MeDX) were all dissolved in HFIP (TCI America Inc.) at 
different concentrations, ranging from 100-220 mg/ml, depending upon their optimal 
fiber forming ranges. For the electrospinning, 3 mL of each solution was loaded into a 3 
mL Becton Dickinson syringe, and placed in a KD Scientific syringe pump (model 
number 100) for dispensing at a specific rate (depending on ratio of copolymer). The 
positive voltage lead of a power supply (Spellman CZE1000R; Spellman High Voltage 
Electronics Corp.) was set to a certain voltage according to the copolymer ratio and was 
attached to a blunt 18 gauge needle on the syringe. A grounded mandrel (1.5 cm wide x 
7.6 cm long x 0.5 cm thick; 303 stainless steel) was placed a certain distance away from 
the needle tip and was rotated at 500 rpm and translated at 7.5 cm/s over 15 cm distance 
for collection of the fibers. Table 3.2 displays the different parameters used to electrospin 
the various ratios of copolymers. 
 
Table 3.2. Electrospinning parameters for different DX:DL-3-MeDX copolymer ratios. 
Copolymer 
ratio (DX:DL-
3-MeDX) 
Electrospinning 
concentrations 
(mg/ml) 
Pump 
rate 
(ml/hr) 
Airgap 
distance 
(cm) 
Vol-
tage 
(kV) 
100:0 100, 160, 220 2.5 20 22 
94:6 100, 160, 200 2 
93:7 
91:9 
88:12 120, 160, 200 0.5 28 20 
80:20 120, 160 
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Scaffold Characterization 
Scanning electron microscopy 
Fiber diameter characterization was accomplished using SEM (Zeiss EVO 50 
XVP) of each scaffold. Samples from each scaffold were mounted on an aluminum stub 
and sputter coated with gold for imaging. The average fiber diameter of each electrospun 
structure was determined from the SEM using UTHSCSA ImageTool 3.0 software 
(Shareware provided by University of Texas Health Science Center in San Antonio). 
Fiber diameter averages and standard deviations were calculated by taking the average of 
60 random measurements per micrograph.  
Uniaxial tensile testing 
Mechanical testing was performed on the electrospun scaffolds using a MTS 
Bionix 200 system (MTS Systems Corp., Eden Prairie, MN). Using a template, “dog 
bone” shaped samples (2.75 mm, 11.25 mm gauge length, thicknesses ranging from 
0.025 – 0.432 mm, n=3) were punched from the different constructs and were hydrated in 
phosphate buffered saline for one hour before testing. Peak stress, elastic modulus and 
strain at break values were determined for each scaffold. In addition, toughness was 
calculated in Matlab
TM
 using the stress and strain data.  
Differential scanning calorimetry 
Modulated DSC was performed on the virgin and electrospun copolymers and 
PDO using TA Instruments Q1000 Differential Scanning Calorimeter. Samples (2-5 mg) 
of the copolymers were placed into separate aluminum pans and the temperature was 
programmed using Thermal Advantage for Q Series
TM
 software (TA Instruments). Each 
sample was heated (±0.5 °C/40 sec) from -50 °C to 250 °C at a rate of 3 °C/min and then 
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cooled from 250 °C to -50 °C at the same rate. Data was then analyzed using Universal 
Analysis 2000 (TA Instruments).  
 
Statistical Analysis 
Statistical analysis was performed using JMP IN 4 statistical software (SAS 
Institute, Inc.) to determine significant differences between the results of mechanical 
testing of the electrospun copolymers. All analysis was based on a Kruskal-Wallis one-
way analysis of variance on ranks and a Tukey-Kramer pairwise multiple comparison 
procedure (α < 0.05).  The results are presented as mean ± standard deviation. 
 
Results and Discussion 
Scanning Electron Microscopy  
In this study, copolymers of DX and DL-3-MeDX in varying compositions 
(80:20, 88:12, 91:9, 93:7 and 94:6) and PDO were successfully electrospun from HFIP to 
form nano- to micron sized fibrous, non-woven mats (Figure 3.1A). For all copolymer 
scaffolds, the analysis of SEM verifies a linear relationship between polymer 
concentration and fiber diameter (Figure 3.1B). This relationship is expected, as it has 
been demonstrated in previous studies [5, 38, 144, 253, 267]. It should be noted that 
because only two concentrations of 80:20 DX:DL-3-MeDX were electrospun (120 and 
160 mg/ml), only two fiber diameters were calculated, and therefore, the degree at which 
the fiber diameter values fit the linear regression line (R
2
 value) could not be determined 
for this scaffold ratio. 
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Figure 3.1(a). SEM of electrospun a) 120 mg/ml 80:20 DX:DL-3-MeDX, b) 160 mg/ml 
80:20 DX:DL-3-MeDX, c) 120 mg/ml 88:12 DX:DL-3-MeDX, d) 160 mg/ml 88:12 
DX:DL-3-MeDX, e) 200 mg/ml 88:12 DX:DL-3-MeDX, f) 100 mg/ml 91:9 DX:DL-3-
MeDX, g) 160 mg/ml 91:9 DX:DL-3-MeDX, h) 200 mg/ml 91:9 DX:DL-3-MeDX, i) 
100 mg/ml 93:7 DX:DL-3-MeDX, j) 160 mg/ml 93:7 DX:DL-3-MeDX, k) 200 mg/ml 
93:7 DX:DL-3-MeDX, l) 100 mg/ml 94:6 DX:DL-3-MeDX, m) 160 mg/ml 94:6 DX:DL-
3-MeDX, n) 200 mg/ml 94:6 DX:DL-3-MeDX, o) 100 mg/ml PDO, p) 160 mg/ml PDO, 
q) 220 mg/ml PDO. Magnification 3000x for SEM a) – e). Magnification 1300x for 
SEMs f) – q). 
                 a)                               b) 
 
 
 
 
 
 
 
 c)         d)               e) 
 
 
 
 
 
 
 
 f)         g)              h) 
  i)         j)              k) 
 
 
 
 
 
 
  l)                               m)                              n) 
 
 
 
 
 
 
  o)                              p)                               q)                       
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Figure 3.1(b). Fiber diameter of the electrospun constructs as a function of polymer 
concentration illustrating the linear relationship between solution concentration and fiber 
diameter. R
2 
= 0.915 for 88:12 DX:DL-3-MeDX, R
2
 = 0.812 for 91:9 DX:DL-3-MeDX, 
R
2
 = 0.993 for 93:7 DX:DL-3-MeDX, R
2
 = 0.859 for 94:6 DX:DL-3-MeDX, R
2
 = 0.929 
for PDO. 
 
Table 3.3. Fiber diameters (µm) of electrospun DX:DL-3-MeDX and PDO scaffolds. 
     Concentration 
 
DX: 
DL-3-MeDX 
 
 
100 or 120 
mg/ml 
 
 
160 
mg/ml 
 
 
200 or 220 
mg/ml 
80:20 0.16±0.09 0.63±0.25 - 
88:12 0.20±0.11 0.28±0.12 0.54±0.37 
91:9 0.31±0.23 0.44±0.29 0.96±0.60 
93:7 0.37±0.25 0.76±0.38 0.95±0.57 
94:6 0.35±0.21 0.55±0.27 1.12±0.53 
100:0 0.40±0.22 0.94±0.49 1.13±0.96 
 
Figure 3.1B also shows that the fiber diameter decreases with increasing content 
of DL-3-MeDX. For instance, copolymer 88:12 (DX:DL-3-MeDX) has a fiber diameter 
as low as 0.2 µm. The unexpected high fiber diameter of 160 mg/ml 80:20 DX:DL-3-
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MeDX most probably results from its higher reduced viscosity and therefore higher molar 
mass compared to the other copolymers.  
Uniaxial Tensile Testing 
As mechanical properties are an extremely important characteristic of any 
biomedical material, the modulus, peak stress, strain at break, and toughness of the 
DX:DL-3-MeDX and PDO electrospun scaffolds were determined. Results from uniaxial 
tensile testing revealed the addition of DL-3-MeDX does alter the mechanical properties 
of the constructs, as illustrated in Figure 3.2.  
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Figure 3.2. Results of peak stress (a), modulus (b), strain at break (c), and toughness (d) 
of electrospun constructs of different ratios illustrating mechanical properties increase 
with increasing electrospinning concentrations, but decrease with increasing DL-3-
MeDX concentrations (with the exception of modulus, which does not follow a trend). * 
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represents statistical significance when compared to all other co-polymer ratios within the 
same electrospinning concentrations (p<0.05). 
 
Figure 3.2(a) reveals peak stress (Table 3.4) values for electrospun scaffolds of 
80:20 and 88:12 (DX:DL-3-MeDX) were 2-6 times lower compared to PDO. Statistical 
analysis of this data indicates no significant differences in peak stress values for scaffolds 
of 100 or 120 mg/ml. Peak stress results for 160 mg/ml 94:6 and 80:20 (DX:DL-3-
MeDX) constructs were significantly different from each other and from all other 160 
mg/ml scaffolds. In addition, peak stress results for 200 mg/ml 91:9 and 88:12 (DX:DL-
3-MeDX) copolymer scaffolds indicated significant differences from each other and from 
all other 200 and 220 mg/ml electrospun constructs.  In summary, the peak stress 
increases with increasing DX content. 
In comparison to other electrospun polymers, scaffolds of different DX:DL-3-
MeDX ratios have peak stress values similar to those of other polymers that have been 
previously electrospun in our lab. For electrospun PGA:PLA blends of varying ratios, and 
PDS (polydioxanone II violet monofilament sutures), peak stress values fell in the range 
of 4.50 – 10.0 MPa and 4.50 – 5.50 MPa, respectively [144, 253]. Natural polymers have 
also been electrospun and mechanically tested in our lab including PDO:collagen blends, 
PDO:elastin blends, and fibrinogen; these scaffolds exhibited peak stresses of 4.60 – 6.70 
MPa, 2.70 MPa, and 0.400 MPa, respectively [147, 148, 267].  
Results of modulus (Table 3.4) reveal there to be no obvious trends relating 
DX:DL-3-MeDX ratio with scaffold modulus (Figure 3.2(b)). Statistical analysis of 
modulus values for the electrospun copolymers and PDO reveals 100 mg/ml 91:9 
DX:DL-3-MeDX is significantly different from all other 100 and 120 mg/ml electrospun 
 71 
 
scaffolds, with the exception of 120 mg/ml 80:20 (DX:DL-3-MeDX). 160 mg/ml 94:6 
DX:DL-3-MeDX scaffolds have a modulus that is significantly different from 160 mg/ml 
91:9 DX:DL-3-MeDX, 93:7 DX:DL-3-MeDX, and PDO. The modulus results from 
electrospun constructs of 200 mg/ml 88:12 DX:DL-3-MeDX are significantly different 
from all other 200 and 220 mg/ml scaffolds. In addition, the moduli of 200 mg/ml 91:9 
DX:DL-3-MeDX scaffolds are statistically different from the moduli of 200 mg/ml 93:7, 
94:6, and 88:12 DX:DL-3-MeDX.  
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Table 3.4. Peak Stress, modulus, strain at break, and toughness values for DX:DL-3-
MeDX and PDO scaffolds. 
Scaffold Peak Stress 
(MPa) 
Modulus 
(MPa) 
Strain at 
break (%) 
Toughness 
(MJ/m
3
) 
120 mg/ml 
80:20 
1.11 ± 0.64 12.2 ± 8.13 21.0 ± 3.80 15.2 ± 9.95 
160 mg/ml 
80:20 
0.74 ± 0.38 14.0 ± 8.29 13.0 ± 3.31 2.87 ± 2.29 
120 mg/ml 
88:12 
0.09 ± 0.03 0.91 ± 0.34 42.4 ± 8.68 1.85 ± 0.75 
160 mg/ml 
88:12 
0.19 1.99 19.9 2.76 
200 mg/ml 
88:12 
0.16 ± 0.06 0.57 ± 0.15 61.0 ± 13.1 4.45 ± 2.04 
100 mg/ml 
91:9 
1.94 ± 0.61 18.6 ± 2.64 20.3 ± 11.6 21.7 ± 17.3 
160 mg/ml 
91:9 
2.90 ± 0.56 8.32 ± 1.01 198 ± 19.9 280. ± 187 
200 mg/ml 
91:9 
2.95 ± 0.94 12.5 ± 4.76 221 ± 23.9 440. ± 155 
100 mg/ml 
93:7 
0.97 ± 0.27 2.47 ± 0.23 74.8 ± 18.5 50.1 ± 22.6 
160 mg/ml 
93:7 
3.30 ± 0.24 9.38 ± 3.32 268 ± 56.7 532 ± 417 
200 mg/ml 
93:7 
6.31 ± 1.08 28.8 ± 6.69 264 ± 42.3 1020 ± 534 
100 mg/ml 
94:6 
0.87 ± 0.14 2.06 ± 0.21 63.3 ± 14.8 28.5 ± 6.85 
160 mg/ml 
94:6 
5.32 ± 0.72 24.2 ± 2.99 173 ± 44.8 1130 ± 430. 
200 mg/ml 
94:6 
5.71 ± 1.19 26.0 ± 7.24 199 ± 40.9 965 ± 162 
100 mg/ml 
PDO 
1.89 ± 0.92 5.23 ± 2.16 132 ± 59.7 218 ± 187 
160 mg/ml 
PDO 
3.44 ± 0.44 7.21 ± 2.27 397 ± 47.7 1190 ± 695 
220 mg/ml 
PDO 
5.55 ± 0.82 18.9 ± 4.17 328 ± 29.0 16300 ± 316 
 
The wide range of modulus results of the electrospun DX:DL-3-MeDX ratios 
were lower than most synthetic electrospun polymers that have previously been tested in 
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our lab, but similar to the moduli of the natural electrospun polymers. Electrospun 
PGA:PLA blends, and PDS scaffolds had moduli of 30.0 – 140. MPa and 8.00 – 15.0 
MPa, respectively [253]. Electrospun PDO:collagen had a moduli between 7.60 and 18.0 
MPa, 50:50 PDO:elastin had a modulus of 6.10 MPa and electrospun fibrinogen had a 
modulus of 0.300 MPa [147, 148, 267].  
Figure 3.2(c) reveals that strain at break values (Table 3.4) of electrospun 
DX:DL-3-MeDX constructs were approximately 8 times lower than those of electrospun 
PDO. Statistical analysis concludes strain at break of 100 mg/ml PDO is significantly 
different from 120 mg/ml 80:20 and 100 mg/ml 91:9 DX:DL-3-MeDX. Strain at break 
values for scaffolds of 160 mg/ml 80:20 DX:DL-3-MeDX and 160 mg/ml PDO are 
statistically different from each other and from all other 160 mg/ml scaffolds. In addition, 
strain at break for 160 mg/ml 94:6 DX:DL-3-MeDX scaffolds are significantly different 
than 160 mg/ml 93:7 DX:DL-3-MeDX, 80:20 DX:DL-3-MeDX, and PDO. Results of 
strain at break reveal 200 mg/ml 88:12 DX:DL-3-MeDX scaffolds are significantly 
different than all other 200 and 220 mg/ml electrospun constructs. In addition, 220 mg/ml 
PDO scaffolds have significantly different strain at break values than 200 mg/ml 88:12, 
91:9, and 94:6 DX:DL-3-MeDX. Results from mechanical testing conclude that with 
increasing amounts of DL-3-MeDX, there is a decrease in strain at break.  
Results of strain at break for the DX:DL-3-MeDX scaffolds also covered a wide 
range, and therefore, were similar to the strains at break found for previously electrospun 
synthetic and natural polymers at certain ratios. PGA, PLA and their copolymer blends 
had strains at break ranging from 90.0 – 200 % and electrospun PDS had strains at break 
of 170 % [144, 253]. PDO:collagen blends had strain to failure values between 56.5 – 
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186 %, electrospun 50:50 PDO:elastin exhibited strains at break of 80 %, and electrospun 
fibrinogen scaffolds had strains at break of 134 % [147, 148, 267]. 
Results from Figure 3.2(d) indicates toughness values of electrospun DX:DL-3-
MeDX were about 110 – 350 times lower than electrospun PDO scaffolds (Table 3.4). 
Statistical analysis reveals there is no significant difference in toughness between 
scaffolds of 100 and 120 mg/ml. Values of toughness for 160 mg/ml PDO are 
significantly different from those of 160 mg/ml 80:20 and 91:9 (DX:DL-3-MeDX). In 
addition, the toughness of 160 mg/ml 94:6 DX:DL-3-MeDX is significantly different 
from that of 160 mg/ml 91:9 and 80:20 DX:DL-3-MeDX. 220 mg/ml PDO has 
statistically different toughness from 200 mg/ml 91:9 and 88:12 DX:DL-3-MeDX, and 
200 mg/ml 88:12 has significantly different toughness from 200 mg/ml 93:7 DX:DL-3-
MeDX, 94:6 DX:DL-3-MeDX , and 220 mg/ml PDO. It should be noted that because of 
the fragility of the 160 mg/ml 88:12 DX:DL-3-MeDX scaffold, only one sample was 
tested, and therefore, statistical significance for this scaffold could not be determined. To 
conclude, as the amount of DL-3-MeDX increases, toughness decreases for all 
electrospinning concentrations. 
 
Differential scanning calorimetry 
In this study, we used modulated DSC to analyze the glass transition, melting, and 
crystallization temperatures of virgin and electrospun DX:DL-3-MeDX copolymers of 
different ratios, as well as PDO (Figures 3.3 and 3.4).  
The addition of DL-3-MeDX does not affect the TG, but does cause the TM and TC 
of the copolymers to decrease. TG values of copolymers ranged from -22.5 to -8.60 °C. 
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Increasing DL-3-MeDX content (6 – 20 %) decreased TC of copolymers from 78.1 – 81.2 
°C for 100 % DX to 48.0 – 50.9 °C for 80:20 DX:DL-3-MeDX. TM showed a similar 
trend decreasing from 106 – 107 °C for 100% DX to 71.0 – 74.4 °C for 80:20 DX:DL-3-
MeDX. According to literature, our results for the TG and TM of electrospun PDO were as 
expected [250].  
 
Figure 3.3. Modulated DSC thermograms for 160 mg/ml a) PDO b) 94:6 DX:DL-3-
MeDX c) 93:7 DX:DL-3-MeDX d) 91:9 DX:DL-3-MeDX e) 88:12 DX:DL-3-MeDX f) 
80:20 DX:DL-3-MeDX. 
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Figure 3.4. Graphical depiction of the glass transition temperatures (TG, top), 
crystallization temperatures (TC, middle) and melting temperatures (TM, bottom) for the 
different copolymer ratios and PDO illustrating the addition of DL-3-MeDX does not 
affect the TG, but does cause the TM and TC of the copolymers to decrease. 
 
The decrease in melting and crystallization temperatures is due to the increasing 
amorphous character of the copolymer as the DL-3-MeDX content increases. Indeed, the 
latter units disrupt the crystallinity of the polymer chains. It is well established that an 
increase in crystallinity leads to an increase in tensile strength and modulus [268]. Based 
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on the results from this study, it appears there is a linear relationship between the 
crystallinity of the electrospun fibers and their fiber diameter for copolymers with 
comparable molar masses: the greater the percent crystallinity, the larger the fiber 
diameter (Figure 3.5). Again, we note the peculiar behavior of copolymer 80:20 which, as 
depicted in Figure 3.5 (b), shows the lowest crystallinity but quite a high fiber diameter. 
As explained previously, this is due to the antagonist effects of reduced crystallinity and 
molar masses on fiber diameter. It has been explained that the enhancement of polymer-
polymer interactions can promote fiber formation due to the presence of inter-chain 
hydrogen bonding [269, 270]. Thus, enhanced crystallinity may imply increased chain-
chain interaction; the larger number of chains per unit volume directly translates to larger 
fiber diameters due to lower chain extensibility.  
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Figure 3.5. Effects of DX:DL-3-MeDX copolymer ratio and fiber diameter on percent 
crystallinity for scaffolds of 100 and 120 mg/ml (a), 160 mg/ml (b), and 200 and 220 
mg/ml (c). 
 
It should also be noted that the electrospinning process, as well as the different 
concentrations of electrospinning solution, did not affect the thermal properties of the 
DX:DL-3-MeDX and PDO scaffolds compared to their virgin counterparts, as illustrated 
in Figure 3.4. 
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In comparison to other electrospun synthetic copolymers, such as PLA, PGA, 
PLLA, PET and PEN, the electrospun DX:DL-3-MeDX scaffolds have glass transition 
temperatures lower than that of the other copolymers. PLA and PGA have TG of 30.0 – 
35.0 °C, PLLA has a TG around 60.0 °C, and PET and PEN have TG ranging from 70.0 – 
123 °C. Crystallization temperatures of electrospun DX:DL-3-MeDX (50.0 – 80.0 °C) 
are around the same range as or lower than other copolymers. PLA and PGA have TC of 
72.0 – 77.0 °C and 49.0 °C, respectively, PLLA has a TC of 103 °C, and PET and PEN 
have TC ranging from 130 – 219 °C. Melting temperatures for electrospun DX:DL-3-
MeDX (70.0 – 106 °C) are lower than that of other electrospun synthetic copolymers. 
Electrospun PLA and PGA have melting temperatures of 171 °C and 220 °C, 
respectively, PLLA has a TM around 150 °C, and electrospun PET and PEN have TM 
ranging from 252 – 272 °C [251-253]. 
 
Conclusion 
In this study, 1,4-Dioxan-2-one (DX) and DL-3-methyl-1,4-dioxan-2-one (DL-3-
MeDX) monomers were synthesized and copolymerized in varying ratios. The 
copolymers, as well as PDO, were dissolved in HFIP at different concentrations and 
electrospun to form scaffolds of different fiber diameters. These scaffolds were analyzed, 
and their fiber diameters, mechanical properties, and thermal properties were compared 
to those of PDO. The copolymerization of monomers can be beneficial in tissue 
engineering applications because of the ability to vary their mechanical, chemical, 
thermal and biological properties. The hypothesis stated at the beginning of this chapter 
was proven; the addition of DL-3-MeDX did affect the fiber diameter of the scaffold, as 
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well as the mechanical and thermal properties. To summarize, the fiber diameter of the 
electrospun fibers and their mechanical performance increased with increasing polymer 
concentration, polymer molar masses and crystallinity. The wide range of fiber diameters, 
as well as mechanical and thermal properties should allow for the construction of 
scaffolds to meet a variety of biomedical engineering applications, including bone 
regeneration and vascular graft design. More specifically, the mechanical properties of 
many of the copolymer ratios determined in this study fall within the range of the 
mechanical properties of native bone and femoral artery [20, 271]. In addition, PDO is 
known to have excellent shape memory, which may be a positive aspect for vascular 
grafts, as it can provide rebound and kink resistance [144]. Although mechanical 
properties are an important aspect of vascular grafts, other characteristics, such as 
biocompatibility, were not taken into consideration in this study, and should be evaluated 
in the future to confirm these materials could be used in vascular graft applications. 
Copolymers consisting of increasing MeDX content possess a lower crystallinity as 
compared to PDO and should allow for the control of biodegradability properties. This 
characteristic is useful in applications such as growth factor delivery [272]. Future 
analysis will include performing copolymer degradation studies and biocompatibility 
testing.  
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Preface: The following manuscript appeared in Journal of Biomedical Materials 
Research-Part A, 92(4), 1321-1328, 2009. The work included investigates the 
thrombogenic potential of various vascular graft materials by evaluation of tissue factor 
expression from monocytes using an In Cell Western assay.  
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Abstract 
The purpose of this study was to quantify the acute expression of tissue factor 
(TF) by monocytes upon interaction with electrospun bioresorbable constructs. A 
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minimal expression of TF will demonstrate the potential for scaffolds to be used as a 
vascular graft without enhanced risk of failure from acute thrombotic occlusion. 
Polydioxanone (PDO) (60, 80, 120, and 160 mg/mL) and polycaprolactone (PCL) (80, 
10, and 160 mg/mL) dissolved in 1,1,1,3,3,3 hexafluoro-2-propanol (HFIP) were 
electrospun to form fibrous scaffolds. Circular discs (10 mm diameter) of each scaffold 
were disinfected and seeded with human monocytes (50,000 cells/well). The discs were 
statically cultured under standard conditions (37ºC and 5% CO2), and removed after 24 
hours for TF analysis with an In-cell Western assay. Fiber diameter was calculated 
through ImageTool analysis of scanning electron micrographs. Acute monocyte 
interaction with scaffolds of PCL (120 mg/mL) resulted in the lowest amount of TF 
expressed (4 ng/disc), whereas scaffolds of 160 mg/mL PDO elicited the highest amount 
of TF expressed (51 ng/disc). TF levels expressed on all scaffolds were comparable to the 
amount expressed on e-PTFE (20 ng/disc). Preliminary data for TF expression on 
scaffolds of silk (70 mg/mL and 150 mg/mL) and silk:PCL (100 mg/mL, v/v) blends 
(50:50 and 70:30) resulted in values of TF expression ranging from 0-24 ng. Results from 
this study reveal electrospun grafts composed of PDO and PCL provide no greater risk of 
failure from an acute thrombotic occlusion due to TF expression when compared to that 
of the standard e-PTFE graft. 
 
 
Introduction 
 
Tissue factor (TF) is a 47 kDa membrane glycoprotein identified as the initiator of 
the coagulation cascade and more recently, has been shown to induce angiogenesis
 
[273-
275]. Monocytes are known to be the cell of origin of tissue factor, and can be activated 
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by endotoxins, mitogens, antigens, aggregated immunoglobulins, and adherence to 
different surfaces
 
[276, 277]. The binding of TF to factor VII of the coagulation cascade 
is the critical factor in the initiation of thrombosis. From here, factor X is either directly 
activated through the intrinsic pathway, or indirectly activated through factor IX of the 
extrinsic pathway, thereby causing the activation of factor IIa, cleaving fibrinogen to 
fibrin [273]. These fibrin monomers accumulate and the ending result is a clot, or 
thrombus. Within small diameter vascular prosthetics, this thrombus can grow large 
enough to occlude the lumen, and in worse cases, become fatal. 
Limited literature on the role of TF in inducing angiogenesis states that it may 
occur from two different methods. One mechanism is through the induction of signal 
transduction, specifically through the activation of p42/p44 MAP kinase [278], p38 MAP 
kinase and c-Jun-terminal kinase (JNK) [274, 279]. The MAP kinase family has been 
associated with cell proliferation, so TF:factor VIIa interaction may stimulate cell 
division, and thus, contribute to angiogenesis, although this explanation is ambiguous. 
Another possibility is that TF:factor VIIa interaction leads to RNA synthesis of FGF-5, 
heparin-binding EGF (hbEGF), interleukin-1β (IL-1β), MIP2a, LIF and interleukin-8 (IL-
8). hbEGF is a mediator of angiogenesis, IL-1β stimulates production of VEGF (a potent 
angiogenic growth factor) in vascular smooth muscle cells and IL-8 is a chemoattractant 
for many angiogenic cell types including monocytes, macrophages and smooth muscle 
cells [280]. IL-8 also induces proliferation of ECs [281]. In addition, the interaction 
between TF and factor VIIa causes an enhanced increase in cell protein synthesis, which 
may increase the production of those angiogenic factors as well [274].       
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Several methods for analyzing TF expression from monocytes have been used 
previously, including fluorescence-based assays, such as fluorescence confocal 
microscopy and fluorescence-activated cell sorter analysis, and immunoassays, such as 
protein immunoblotting and enzyme-linked immunosorbent assays [282-284]. A previous 
study done by Egorina et al. [285] proved tissue factor expression by monocytes could be 
quantified using an In-Cell Western (ICW) assay and is the motivation for this study. 
More specifically, in our lab, we are interested in quantifying the amount of TF expressed 
by monocytes during their interaction with electrospun bioresorbable vascular graft 
materials using an ICW assay. A minimal expression of TF produced by monocytes will 
demonstrate the potential for these materials to be used as a vascular graft without 
enhanced risk of failure from acute thrombotic occlusion.  
 The graft materials that were chosen for analysis were electrospun scaffolds of 
PDO and PCL. Although these polymers are synthetic and lack the bioactivity needed for 
ECM-cell signaling, their mechanical integrity and slow degradation rate make them 
attractive for use as tissue engineering constructs. Because of their synthetic nature and 
lack of bioactivity, the possibility of an over expression of TF by inflammatory cells is 
possible, and thus, there is an increased potential for acute thrombotic events. This is one 
complication that can arise when an electrospun construct is implanted as a vascular graft 
[286-288]. For this reason, we quantified the amount of TF expressed by monocytes at a 
24 hour time point to determine this risk. These levels were compared to the clinical 
standard, e-PTFE, which is a fairly non-thrombogenic synthetic vascular graft that is still 
being used after 50 years. 
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Because of the angiogenic role TF can have, the levels of TF expression produced 
by monocytes during their interaction with the electrospun scaffolds should ideally be 
angiogenic, and not have thrombogenic effects.  
One option of providing more bioactivity to electrospun scaffolds without 
compromising its mechanical integrity is to blend natural polymers with the synthetic 
polymers. Our lab has accomplished this with many natural polymers including collagen, 
elastin, fibrinogen, and silk [5, 20, 38, 289]. The hypothesis of this study is that 
electrospun scaffolds fabricated from synthetic and natural polymers will not have an 
enhanced expression of TF from monocytes compared to that of e-PTFE.  
Preliminary studies have been conducted to quantify monocyte TF expression 
during their interaction with electrospun silk and silk:PCL blended scaffolds and will be 
briefly discussed in this article. 
 
Materials and Methods 
Electrospinning 
 For this study, PDO (Ethicon, Inc.) was dissolved in HFIP (TCI America Inc.) at 
concentrations of 0.06, 0.08, 0.12, and 0.16 g/mL to produce scaffolds of different fiber 
diameters. PCL (Sigma Aldrich Co., 65kDa) was dissolved in HFIP at concentrations of 
0.08, 0.12, 0.16 g/mL for the same reasons as stated above.   
 Silk was extracted from the cocoons of Bombyx mori silkworms (The Yarn Tree) 
using a protocol previously described by Jin et al. [290]. The silk was dissolved in HFIP 
at concentrations of 0.07 and 0.15 g/mL. Blends of PCL (0.1 g/mL) and silk (0.1 g/mL) 
were combined at ratios of 50:50 and 70:30 (v/v, silk:PCL). 
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 For electrospinning, 5 mL of each solution was loaded into a Becton Dickinson 
syringe, and placed in a KD Scientific syringe pump for dispensing at a rate of either 4 or 
8 mL/h (4 mL/h for silk and silk blends, 8 mL/h for PDO and PCL). The positive voltage 
lead of the power supply (Spellman CZE1000R; Spellman High Voltage Electronics 
Corp.) was set to 22 kV and was attached to a blunt 18 gauge needle on the syringe. A 
grounded mandrel (2.5cm wide x 10.2cm long x 0.3 cm thick; 303 stainless steel) was 
placed 6 inches from the needle tip and was rotated at 500 rpm and translated at 7.5 cm/s 
over 15 cm distance for collection of the fibers. 
 
Scaffold Characterization 
 Scaffold characterization was accomplished using SEM (Zeiss EVO 50 XVP) of 
each scaffold type. The average fiber diameter of each electrospun structure was 
determined from the SEM using ImageTool 3.0 software (Shareware provided by 
University of Texas Health Science Center in San Antonio). Fiber diameter averages and 
standard deviations were calculated by taking the average of 60 random measurements 
per micrograph image.   
 
Scaffold seeding and culture 
 For scaffold seeding, 6 discs of 10 mm diameter of each scaffold type, along with 
the clinical standard, e-PTFE (Impra, Inc.), were punched out and disinfected by rinsing 
the discs in Ethanol for 10 minutes. Discs were then washed three times in sterile 
phosphate buffered saline for 3 minutes each rinse. The scaffolds were then placed flat in 
a 48-well culture plate and 8 mm cloning rings were placed on top of the scaffolds to 
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retain the cells during scaffold seeding. Human peripheral blood monocytes (ATCC CRL 
9855) were seeded on 5 of the 6 scaffolds at a density of 50,000 cells/well and 400 µL of 
macrophage serum-free medium supplemented with 0.5% penicillin – streptomycin (10 
U/mL) (Gibco) was added to each well (50 µL of cells in media incubated for 45 minutes, 
followed by the addition of 350 µL of media). For each scaffold type, three scaffolds 
were used as experimental samples, two scaffolds accounted for background 
fluorescence, and one unseeded scaffold with media added was used as a negative 
control. Scaffolds were statically cultured in standard conditions (37°C and 5% CO2) in 
an incubator for 24 hours before they were fixed in 10% formalin for quantification of TF 
expression. 
 
Quantitative immunofluorescence assay (ICW assay) 
 In order to begin the ICW assay, after 24 hours of allowing monocytes to adhere 
to scaffold surfaces, the cells and control scaffolds were fixed with 10% formalin for 20 
minutes. Scaffolds were carefully removed from the well plate they were cultured in and 
placed in a different well plate to avoid obtaining TF expression from cells that were not 
interacting with the scaffolds. Free aldehyde groups were quenched with three washes of 
25 mM glycine in PBS.  All scaffolds were blocked using Odyssey Blocking Buffer (LI-
COR Biosciences) for 1.5 hours at room temperature.  
 Standards used to quantify TF expression from monocytes consisted of purified 
full-length recombinant human coagulation factor III/TF (rhF3, 224 amino acids, 
purchased from R&D Systems, Inc.) spotted on an Immobilon-FL PVDF membrane 
(Millipore Corporation) at the amounts of 500, 250, 125, 62.5, 31.25, 15.63, 7.81, 3.91, 
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and 0 ng, diluted in 20 µL of sterile water. The membrane was blocked for 1 hour at 
room temperature using Odyssey Blocking Buffer.   
 After blocking, the scaffolds and membrane were washed five times with 0.1% 
Tween-20 in PBS and four scaffolds of each material (three experimental samples plus 
one negative control scaffold), along with the membrane, were incubated with polyclonal 
anti-human TF antibody (R&D Systems, Inc.) diluted in Odyssey Blocking Buffer 
overnight at 4ºC. Scaffolds and membrane were washed four times with 0.1% Tween-20 
in PBS, after which the signal from goat anti-human TF polyclonal antibody was detected 
with IRDye 800CW-conjugated donkey antigoat polyclonal antibody (Rockland, Inc.). 
To account for antibody background fluorescence, each sample was incubated in 
duplicate with secondary antibody only. Scaffolds and membrane were treated with the 
IR sensitive secondary antibody for 1 hour at room temperature without exposure to light. 
After washing, scaffolds and membrane were scanned using the 800 nm channel of the 
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) at an intensity of 
4.0. Fluorescence intensities were measured using circular gates that completely 
surrounded the scaffolds. Background fluorescence that was obtained from scaffolds 
incubated with secondary antibody only was subtracted from the signal intensities of the 
samples incubated with both primary and secondary antibodies.   
 
Statistical Analysis  
 Statistical analysis was performed using JMP IN 4 statistical software (SAS 
Institute, Inc.) to determine significant differences between the amounts of TF expressed 
by monocytes on different electrospun materials. All analysis was based on a Kruskal-
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Wallis one-way analysis of variance on ranks and a Tukey-Kramer pairwise multiple 
comparison procedure (α=0.05). The results are presented as mean ± SE.  
 
Results 
Scaffold Characterization 
 The results of electrospinning PDO at different concentrations are shown in 
Figures 4.1 and 4.2. For scaffolds of PDO, the analysis of the SEM verifies a linear 
relationship (R
2 
= 0.99) between polymer concentration and fiber diameter. For a 
concentration of 0.06 g/mL PDO, fiber diameters are 0.29 ± 0.14 µm. PDO scaffolds of 
0.08 g/mL result in fiber diameters of 0.69 ± 0.45 µm, 0.12 g/mL concentration exhibits 
fiber diameters of 1.39 ± 0.61 µm, and PDO concentrations of 0.16 g/mL produce fibers 
of 2.13 ± 0.66 µm. 
   
 
   
Figure 4.1. Micrographs of random electrospun structures produced from 0.06 g/mL (A), 
0.08 g/mL (B), 0.12 g/mL (C), and 0.16 g/mL (D) PDO in HFIP. All images taken at 
1000x magnification and an inserted scale bar is 10µm. 
 
A          B 
 
 
 
 
 
 
 
C       D 
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Figure 4.2. Results of fiber diameter analysis versus PDO concentration illustrating the 
linear relationship between fiber diameter and polymer concentration. 
 
 Figures 4.3 and 4.4 present the results of electrospinning PCL at concentrations of 
0.08, 0.12, and 0.16 g/mL. Analysis of scaffolds reveals fiber diameters of 0.29 ± 0.14 
µm, 0.48 ± 0.49 µm, and 0.94 ± 0.88 µm for scaffold concentrations of 0.08, 0.12, and 
0.16 g/mL respectively. Like scaffolds of PDO, a linear relationship exists (R
2
 = 0.9456) 
between polymer concentration and fiber diameter.  
       
Figure 4.3. Micrographs of electrospun PCL scaffolds produced from 0.08 g/mL (A), 
0.12 g/mL (B), and 0.16 g/mL (C) in HFIP at 1000x magnification. The scale bar 
represents 10µm. 
 
A       B     C 
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Figure 4.4. ImageTool analysis of PCL scaffolds reveal a linear relationship between 
polymer concentration and fiber diameter. 
 
Scaffold characterization of electrospun silk reveals fiber diameters of 0.72 ± 0.45 
µm and 3.46 ± 2.29 µm for concentrations of 0.07 and 0.15 g/mL. As silk concentration 
increases from 0.07 g/mL to 0.15 g/mL, fiber diameter increases. SEM are shown in 
Figure 4.5, along with fiber diameter analysis shown in Figure 4.6.  Silk:PCL blended 
scaffolds reveal fiber diameters of 0.63 µm for 50:50 and 0.99 µm for 70:30. Although it 
appears there may be a linear relationship between increasing silk volume and increasing 
fiber diameter, more ratios will need to be analyzed to confirm this (Figure 4.6). SEM 
images are shown in Figure 4.5.  
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Figure 4.5. SEM images of silk and silk:PCL scaffolds at 0.07 g/mL silk (A), 0.15 g/mL 
silk (B), 50:50 silk:PCL (C), 70:30 silk:PCL (D) at 1000x magnification. Scale bar 
represents 10 µm. 
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Figure 4.6. Fiber diameter analysis of scaffolds of different silk concentrations (A) and 
silk:PCL ratios (B). 
 
 
ICW Assay Results 
 To quantify the amount of TF expression present on the surface of monocytes, the 
PVDF membrane that was spotted with 0 to 500 ng of rhTF was scanned by the Odyssey 
system and fluorescent intensities were acquired. A standard curve was plotted and 
displays a linear relationship (R
2
 = 0.9324, y = 0.102x+0.25). These results are illustrated 
A           B   
 
 
 
C           D   
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in Figure 4.7 below. With the equation acquired from the standard curve, a quantified 
amount of TF expression was calculated for each scaffold concentration. 
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Figure 4.7. (a) Linear curve (R
2
 = 0.9324) obtained from dilutions of rhTF standards for  
 ICW assay. (b) Fluorescent intensity image of standards spotted on PVDF membrane 
from Odyssey Infrared System. 
 
ICW Assay Results for PDO and e-PTFE 
 The amount of TF expressed on scaffolds of PDO and e-PTFE ranged from 13.5 – 
84.9 ng. Specifically, e-PTFE scaffolds amounted in 13.5 ± 20.6 ng, 0.06 g/mL PDO 
resulted in 26.2 ± 18 ng, 0.08 g/mL PDO exhibited 22.8 ± 18.5 ng, 0.12 g/mL PDO 
expressed 54.9 ± 13.9 ng, and 0.16 g/mL PDO resulted in 84.9 ± 51.8 ng TF. PDO 
concentrations of 0.16 g/mL exhibited the highest amount of TF expressed by monocytes, 
and e-PTFE resulting in the lowest expression. These results are shown in Figure 4.8.  
Scaffolds of 0.08 g/mL PDO was the only concentration to result in a significantly 
different amount of TF expressed from that of 0.16 g/mL. TF expressions on all scaffolds 
of PDO were not significantly different from TF expression on scaffolds of e-PTFE. 
 
 
 
 500 ng           250 ng          125 ng 
  62.5 ng              31.25 ng     15.63 ng 
  7.81 ng             3.91 ng         0 ng 
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Figure 4.8. (a) TF fluorescence intensity of PDO and ePTFE scaffolds taken at 800nm,  
4.0 intensity. Numbers under scaffolds of PDO are represented in g/mL. Top row  
displays fluorescence of experimental samples, while bottom row displays background  
fluorescence control scaffolds. (b) Quantified TF expression on scaffolds of PDO and e- 
PTFE. (*) denotes statistically different TF amount from that of 0.16 g/mL PDO. 
 
ICW Assay Results for PCL Scaffolds 
 Scaffolds of the highest concentration of PCL, 0.16 g/mL, resulted in the highest 
expression of TF from monocytes (10.2 ± 19.9 ng), while 0.12 g/mL PCL exhibited the 
lowest amount (4.2 ± 5.6 ng). PCL scaffolds of 0.08 g/mL resulted in TF expression of 
7.48 ± 0.57 ng. These results are shown in Figure 4.9. From statistical analysis, scaffolds 
of 0.08 g/mL and 0.12 g/mL PCL resulted in significantly different amounts of TF 
expressed from those of 0.16 g/mL PDO scaffolds.  
 
 
 
 
 
 
 
 * 
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Figure 4.9. (a) Quantified TF expression on scaffolds of PCL. (b) TF fluorescence 
intensity of PCL scaffolds taken at 800nm, 4.0 intensity. Numbers under PCL scaffolds 
are represented in g/mL. Top row displays fluorescence of experimental samples, bottom 
row displays background fluorescence from control scaffolds. 
 
Preliminary Results for Scaffolds of Silk and Silk:PCL Blends  
 Scaffolds of silk at a concentration of 0.07 g/mL appear to cause no expression of 
TF from monocytes in 24 hours. Silk scaffolds of 0.15 g/mL result in 6.4 ng of TF 
expression, while silk:PCL blends at ratios of 50:50 and 70:30 exhibit 5.4 and 24.2 ng of 
TF, respectively. These results are shown in Figure 4.10. 
A)              B) 
   
        
          0.07            0.15           50:50           70:30 
                
 
Figure 4.10. (a) Fluorescent intensity image obtained from Odyssey Infrared System at 
800 nm, 4.0 intensity. Numbers below scaffolds of silk represent concentrations in g/mL. 
Top row illustrates fluorescence of experimental samples, while bottom row displays 
background fluorescence from control samples. (b) Graph displays quantified amount of 
TF expression from scaffolds of silk and silk:PCL blends. 
n=1 
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Discussion 
 In this study, acute TF expression from the surface of monocytes during their 
interaction with electrospun constructs was successfully quantified using an ICW assay. 
Fiber dimension analysis from SEMs using ImageTool 3.0 revealed a linear relationship 
between polymer concentration and electrospun fiber diameter. These results are shown 
in Figures 4.2, 4.4, and 4.6. Although the quantified amount of TF expressed on different 
scaffold materials did not follow a specific trend, it can be concluded that scaffolds of 
larger fiber diameters caused higher amounts of TF expression, while electrospun 
constructs of smaller fiber diameters resulted in lower amounts of TF expressed. These 
results can be seen in Figures 4.8, 4.9, and 4.10. 
 The amount of TF expressed by monocytes on scaffolds of PDO ranged from 22.8 
- 84.9 ng (Figure 4.8). PCL scaffolds elicited TF expression in the amounts of 4.2-10.2 ng 
(Figure 4.9). Preliminary results acquired for TF expression on scaffolds of silk and 
silk:PCL blends revealed levels ranging from 0 - 24.2 ng (Figure 4.10). While the 
formation of acute thrombotic occlusions are a risk of implanted electrospun vascular 
grafts, the data from this study reveals electrospun scaffolds of PDO and PCL provide no 
greater risk from an acute thrombotic occlusion than that of the current standard, e-PTFE.  
Statistical analysis validates that the amount of TF expressed on scaffolds of PDO and 
PCL is not significantly different compared with that of e-PTFE. The addition of natural 
polymers to synthetic based grafts provides more bioactivity to the graft, reducing the 
potential for thrombotic events to occur. Further analysis will need to be completed to 
verify the preliminary results of the low expression of TF on scaffolds of silk and 
silk:PCL blends. 
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 Angiogenic properties of TF have recently been declared. TF may educe 
upregulation of specific angiogenic chemokines and growth factors as well as migration 
and differentiation of endothelial cells. In vitro experiments have shown levels of TF 
around 3.6-60 µg to be angiogenic [275]. The levels of acute TF expressed on the 
electrospun scaffolds from this experiment are below these limits, confirming that they 
may be non- thrombogenic. Further experimentation will need to be done to determine if 
the levels of TF expressed on electrospun scaffolds are angiogenic.  
 The ICW assay was performed using a sensitive fluorescent based antibody that is 
detectable by infrared. The sensitivity of the technique is remarkable in that it can pick up 
signals from as little as 10
 4 
cells. Scanning in the infrared region of the spectrum also 
greatly diminishes the biological auto-fluorescence, which may be a potential issue in the 
visible region. This reduced auto-fluorescence increases the signal-to-noise ratio and 
makes the assay more accurate.  
 
Conclusion 
This study provides a positive insight for the ability of electrospun grafts to be 
successfully used in tissue engineering applications without an increased risk of failure 
due to an acute thrombotic occlusion compared to that of the current vascular graft 
material used clinically. The hypothesis of this study was proven: TF expression from 
monocytes cultured on electrospun scaffolds was not significantly enhanced compared to 
TF expression from monocytes cultured on e-PTFE scaffolds. However, results from this 
study do not confirm that these electrospun materials would not elicit the formation of a 
thrombosis, and further testing needs to be completed to determine this possibility. 
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Overall, 0.16 g/mL PDO scaffolds caused the highest expression of TF (84.9 ± 51.8 ng) 
from monocytes, while scaffolds of 0.07 g/mL silk expressed the lowest expression (0 
ng). The results from silk scaffolds will need to be investigated further, as this is 
preliminary data. The results from this in vitro experiment will need to be further 
correlated with in vivo models to confirm the reduced potential for thrombotic events to 
occur from these electrospun constructs. 
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Chapter 5: CREATION OF ELECTROSPUN PLATELET-
RICH PLASMA NANOFIBERS 
 
 
Preface: The following manuscript appeared in Journal of Tissue Science and 
Engineering, 2(2), 1-7, 2011. The work included demonstrates the feasibility of 
enhancing the bioactivity of a bioresorbable vascular graft by electrospinning nanofibers 
from platelet-rich plasma. Various aspects of the electrospun structures are investigated, 
including scaffold characterization and cellular interaction. 
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Abstract 
Activated platelet rich plasma (aPRP) contains supraphysiologic amounts of 
autologous growth factors and cytokines known to enhance wound healing and tissue 
regeneration. Here we report the first results of electrospinning nanofibers from aPRP to 
create fibrous scaffolds that could be used for various tissue engineering applications. 
Human PRP was created, activated by a freeze-thaw-freeze process, and lyophilized to 
form a powdered preparation rich in growth factors (PRGF). It was dissolved in HFIP at 
different concentrations to form fibers with average diameters of 0.3 – 3.6 µm. A 
sustained release of protein from the PRGF scaffolds was demonstrated up to 35 days, 
and cell interactions with the PRGF scaffolds confirmed cell infiltration after just 3 days. 
As electrospinning is a simple process, and PRGF contains naturally occurring growth 
factors in physiologic ratios, creating nanofibrous structures from PRGF has the potential 
to be beneficial for a variety of tissue engineering applications.  
 
Introduction 
The creation of tissue engineering scaffolds through the process of 
electrospinning has yielded promising results for the field of regenerative medicine over 
the last decade. These scaffolds can replicate the sub-micron scale topography of the 
native ECM, through the creation of nanoscale, non-woven fibers, using a number of 
natural and synthetic polymers. Using the process of electrospinning it is also possible to 
control the alignment and orientation of the created fibers, creating scaffolds that can be 
easily customized for nearly any tissue in the body. This control over fiber orientation, 
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coupled with the diverse array of polymers conducive to being electrospun, allows for the 
tissue engineer to create structures with tailorable mechanical properties. Additionally, 
these scaffolds exhibit high surface area-to-volume ratios, high porosities, and variable 
pore-size distributions that mimic the native ECM and effectively create a dynamic 
structure capable of sustaining the passive transport of nutrients and waste throughout the 
structures [5, 100, 291-295].   
However, despite the porosity and flexibility afforded by the electrospinning 
process, it is still considered to be quite challenging to promote cellular penetration into 
the depth of an electrospun structure, with cells preferring to proliferate and migrate 
across the surface of the scaffold rather than venture inside it [296-299]. While a number 
of rather novel techniques have been employed to increase cellularization of electrospun 
scaffolds [154, 297, 299], nothing has been proven to be useful for tissue engineering 
applications, nor to date become common practice in the field. The incorporation of 
growth factors into electrospun matrices for tissue engineering has the potential to 
enhance scaffold bioactivity, by supplying appropriate physical and chemical cues to 
promote cellular proliferation and migration, thereby increasing the cellularization of the 
structures [291, 300, 301]. By replicating the role of the native ECM in the normal wound 
healing cascade, that is serving as a reservoir of soluble growth factors critical to 
regeneration and providing a template for tissue repair, it may be possible to accelerate 
cellularization and tissue repair [292, 300]. 
PRP is a supraphysiologic concentration of platelets suspended in plasma 
intended to serve as an autologous source of concentrated growth factors and cytokines. 
The use of PRP has been growing rapidly in the clinical world, as activated-PRP (aPRP) 
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has been proven effective in accelerating healing in a number of tissues: osteochondral 
defects [302-304], tendon/ligament injuries [302-308], and chronic skin wounds (diabetic 
and pressure ulcers) [303, 304, 309, 310]. The creation of aPRP is a relatively simple 
procedure that can be performed bedside, typically involving a blood draw and 
centrifugation to concentrate the platelet portion, followed by a platelet activation step 
and the delivery of the aPRP to the site of injury. There have been several methods 
reported in the literature on successfully activating and delivering aPRP to an injury site, 
with most involving the creation of a platelet gel using thrombin [302-304, 311] or CaCl2 
[302-304, 312]. These aPRP gels can then be easily applied to wound sites through 
injection or topical application.   
The basis behind the use of these aPRP gels is that through the activation of the 
platelets, the alpha and dense granules contained within the platelets release an array of 
growth factors and cytokines critical to mediating normal wound healing [302, 304, 312-
314]. The milieu of growth factors and cytokines released from the aPRP are in 
physiologically relevant ratios, albeit in concentrations several times higher than that of 
normal blood due to the linear relationship between platelet and growth factors 
concentrations [315]. Activated PRP has been shown to contain platelet derived growth 
factor (PDGF), transforming growth factor-β (TGF-β), VEGF, fibroblast growth factor 
(FGF), epidermal growth factor (EGF), and others in elevated concentrataions [302, 304, 
305, 309, 312-314]. Activated PRP has also been shown to contain a number of 
macrophage and monocyte mediators such as RANTES (Regulated upon Activation, 
Normal T-cell Expressed, and Secreted), lipoxin, and an array of interleukins capable of 
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mediating inflammation [313]. In addition, the plasma portion of the PRP contains the 
proteins albumin, fibrinogen, a number of immunoglobulins, and more [316-318]. 
While the incorporation of growth factors and cytokines into electrospun scaffolds 
to modify cellular response is not new, the majority of studies have previously 
investigated single or multiple growth factors from isolated or recombinant sources. This 
method can be prohibitively expensive and difficult to deliver physiologically relevant 
concentrations [301, 302, 319], while aPRP has proven an efficient and cost-effective 
method for acquiring a number of highly concentrated factors. The purpose of this study 
was to create an electrospun scaffold that would harness the reparative potential and 
bioactivity found in aPRP, namely the growth factor and cytokine milieu contained 
within, by lyophilizing aPRP and creating PRGF suitable for electrospinning. Utilizing 
the plasma proteins contained within the PRGF, namely fibrinogen which has been 
successfully electrospun in the past [21, 289, 320, 321], it was hypothesized that pure 
lyophilized PRGF could be electrospun into a stable scaffolding material for tissue 
engineering applications. Such a scaffold, containing a concentration of multiple growth 
factors and cytokines, would have the potential to promote cellularization of the structure 
while providing a sustained release of growth factors capable of providing a chemotactic 
gradient for cellular recruitment. 
 
Methods 
Creation of aPRP and PRGF 
 Fresh human whole blood from 3 donors was purchased (Biological Specialty 
Corp., Colmar, PA, USA), pooled, and used in a SmartPReP
®
 2 (Harvest Technologies 
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Corp., Plymouth, MA, USA) centrifugation system to create PRP per manufacturers 
protocol. A small aliquot of both pooled whole blood and PRP were sent to the Harvard 
Immune Disease Institute‟s Blood Research laboratory to determine their respective 
platelet concentrations. PRP was then subjected to a freeze-thaw-freeze (FTF) cycle for 
platelet lysis and activation. Briefly, PRP was placed in a -70  C freezer for 24 hrs 
followed by a 37  C waterbath for 1 hr, and then returned to the -70  C freezer for 24 hrs.  
This method has previously been found to contain the same, and in some cases, higher 
levels of bFGF and VEGF as thrombin and CaCl2 aPRP (data not published). Frozen 
aPRP was then lyophilized for 24 hrs to create a dry PRGF powder which was finely 
ground in a mortar and pestle prior to use.   
 
Creation of Electrospun PRGF Scaffolds 
PRGF was dissolved in HFIP (TCI America Inc., Portland, OR, USA) at different 
concentrations, ranging from 80-280 mg/ml, to determine the optimum fiber forming 
concentration range. HFIP was used as the solvent because, not only is it the most widely 
used solvent in our lab, but it also is very versatile in creating nanofibrous scaffolds from 
a variety of natural and synthetic polymers without much difficulty. In addition, 
previously published studies performed by our lab, as well as many others, have shown 
electrospun scaffolds fabricated from HFIP are biocompatible [20, 38, 106, 144, 242, 
299, 320, 322]. Once in solution, PRGF was loaded into a 3 mL Becton Dickinson 
syringe, and placed in a KD Scientific syringe pump (model number 100, Holliston, MA, 
USA) for dispensing at a rate of 2.5 ml/hr. A blunt 18 gauge needle was placed on the 
syringe, and the positive voltage lead of a power supply (Spellman CZE1000R; Spellman 
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High Voltage Electronics Corp., Hauppauge, NY, USA) was attached to the needle and 
set to 25 kV. A grounded mandrel (1.9 cm wide x 7.6 cm long x 0.5 cm thick; 303 
stainless steel) was placed 15 cm away from the needle tip and was rotated at 500 rpm 
and translated at 7.5 cm/s over 15 cm distance for collection of the fibers.  
 
Scaffold Characterization 
SEM and Fiber Diameter 
 Fiber diameter characterization was accomplished using SEM (Zeiss EVO 50 
XVP, Peabody, MA, USA) of each scaffold. Samples from each scaffold were mounted 
on an aluminum stub and sputter coated with gold for imaging. The average fiber 
diameter of each electrospun structure was determined from the SEM images using 
UTHSCSA ImageTool 3.0 software (Shareware provided by University of Texas Health 
Science Center in San Antonio). Fiber diameter averages and standard deviations were 
calculated by taking the average of 60 random measurements per micrograph.   
Protein Release Kinetics 
From scaffolds of 100, 150, and 200 mg/ml PRGF, 10 mm diameter discs were 
punched, disinfected with a 30 minute soak in ethanol, followed by three 10 minute rinses 
in PBS, and placed in a 48 well plate with 500 µl of PBS. On days 1, 4, 7, 10, 14, 21, 28 
and 35, PBS was retained and kept in a -70 °C until ready for evaluation. A generic 
protein assay (BCA Protein Assay, Thermo Scientific Pierce, Rockford, IL, USA) was 
performed on samples to quantify the concentration of total protein released from the 
PRGF scaffolds.  
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Gel Electrophoresis 
Gel electrophoresis was performed to analyze the molecular weight of the 
proteins in PRGF, platelet poor plasma (PPP), and  electrospun PRGF scaffolds and 
compare them to those of fibrinogen (FBG, Sigma Aldrich, St. Louis, MO, USA) and 
bovine serum albumin (BSA, Sigma Aldrich, St. Louis, MO, USA) controls. Briefly, 2 
mg BSA, FBG, PRGF, and 100, 150, 200 mg/ml PRGF scaffolds were solubilized in a 
reducing agent containing laemmeli buffer with 5 % β-mercaptoethanol. Samples were 
boiled for 3-5 minutes to further ensure they were solubilized, and 10 µL of each sample 
was placed in duplicate in each lane of 4-15% polyacrylamide 18-well gels (Criterion 
Bio-Rad, Hercules, CA, USA). A molecular weight protein ladder (20 µL, Sigma 
Aldrich, St. Louis, MO, USA) was run to provide a molecular weight basis for protein 
identification and comparison. Samples were run at constant voltage of 120 V over 2 
hours.  After the 2 hours, the gels were stained with Coomassie Blue, and evaluated by 
the Bio-Rad Gel Doc
TM
 2000 system.  
Fluorescent Based Assay 
 FBG concentration was quantified in the PRGF electrospun scaffolds, as well as 
in aPRP, blood and PPP by using a fluorescent based assay. Scaffolds of 100, 150, and 
200 mg/ml electrospun PRGF (10 mm diameter discs, n=4) were placed in a 48 well plate 
and blocked with Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE, USA) for 
1 hour at room temperature. Simultaneously, human FBG from reference plasma (Fisher 
Scientific, Pittsburgh, PA, USA) was diluted in DI water at concentrations of 76, 38, 19, 
9.5, 4.75, 2.38, 1.19, 0.59, and 0 mg/dl and was blotted on a PVDF membrane, along 
with aPRP, PPP, blood, and PRGF diluted in water at 10, 5, and 1 mg/ml. The membrane 
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was blocked in Odyssey Blocking Buffer for one hour at room temperature. After 
blocking, standards and samples were incubated in anti-human fibrinogen antibody 
(Millipore, Billerica, MA, USA) at room temperature for 1.5 hours. All samples and 
standards were then washed four times with 0.1% Tween-20 in PBS, after which the 
signal from mouse anti-human fibrinogen antibody was detected with goat anti-mouse 
IgG secondary antibody tagged with a fluorescent 800 nm marker (ThermoScientific, 
Pittsburgh, PA, USA). To account for antibody background fluorescence, each scaffold 
was incubated with secondary antibody only. Samples and standards were incubated in 
the secondary antibody for 1 hour at room temperature without exposure to light. After 
washing, the samples were scanned using the 800 nm channel of the Odyssey Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE) at an intensity of 3.5. Fluorescence 
intensities were measured using circular gates that completely surrounded the scaffolds 
and well plates. Background fluorescence that was obtained from samples incubated with 
secondary antibody only was subtracted from the signal intensities of the samples 
incubated with both primary and secondary antibodies. 
 
Evaluation of Cell Interaction 
 To determine the interaction of human cells on electrospun PRGF scaffolds, 10 
mm diameter discs were punched from scaffolds of 100, 150, and 200 mg/ml PRGF, 
disinfected (30 minute soak in ethanol followed by three 10 minute rinses in PBS), and 
placed in a 48 well plate. A sterile Pyrex cloning ring (10 mm outer diameter, 8 mm inner 
diameter) was placed on top of each scaffold to prevent them from floating, and to ensure 
all cells stayed on the surface of the scaffold during culture. Each scaffold was seeded 
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with either 100,000 human adipose derived stem cells (hADSC) isolated from medical 
waste lipoaspirate [323] in 500 µl of complete media (DMEM low glucose supplemented 
with 10% FBS and 1% penicillin/streptomycin, Invitrogen, Carlsbad, CA, USA) or 
100,000 human umbilical artery smooth muscle cells (hSMC, Lonza, Basel, Switzerland) 
in 500 µl of complete media (SMGM-2 bullet kit, Lonza, Basel, Switzerland). Controls 
consisted of scaffolds in complete media without cells. Media was changed every third 
day, and on days 3 and 10, scaffolds were fixed in 10% Formalin and cryosectioned for 
4‟,6-diamidino-2-phenylindole (DAPI) staining. 
 
Statistical Analysis 
 Statistical analysis was performed using JMP
®
IN 8.0 statistical software (SAS 
Institute, Inc., Cary, NC, USA) and was based on a Kruskal-Wallis one-way analysis of 
variance on ranks and a Tukey-Kramer pairwise multiple comparison procedure (α=0.5). 
Graphical depictions of mean data were constructed with Microsoft Excel 2007, with 
error bars representing standard deviations. 
 
Results and Discussion 
Creation of aPRP and PRGF 
 It was determined by Harvard Immune Disease Institute‟s Blood Research 
Laboratory that the PRP created by the SmartPReP
®
 2 centrifugation system resulted in a 
5.5 fold increase in platelets compared to the pooled whole blood used in this study (955 
x 10
3
 platelets/µl versus 175 x 10
3
 platelets/µl). This result is in agreement with 
published data [324], and based upon the linear relationship between platelet count and 
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growth factor concentration, a resulting similar fold increase should present in platelet 
derived growth factor concentrations [315]. 
  
Electrospun Scaffold Characterization 
SEM and Fiber Diameter 
SEM characterization of the electrospun PRGF scaffolds is shown in Figure 5.1.  
The micrographs illustrate the nanofibrous structures of each scaffold starting around 100 
mg/ml, with the appearance of a large range of fiber diameters for the different PRGF 
concentrations, as well as increased void space as PRGF concentration increases. Fiber 
diameters for the scaffolds range from 0.28 ± 0.29 µm for 100 mg/ml PRGF to 6.37 ± 
4.81 µm for 280 mg/ml PRGF (Figure 5.2). Statistical analysis reveals the average fiber 
diameters for 100 and 175 mg/ml PRGF are significantly different from all other 
scaffolds, with the exception of 125 and 150 mg/ml PRGF. Average fiber diameters for 
scaffolds of 200, 220, and 250 mg/ml PRGF are significantly different from all other 
scaffolds, but not each other. Scaffolds of 280 mg/ml PRGF have significantly greater 
fiber diameters from those of all other scaffolds. This linear relationship between 
polymer concentration and fiber diameter is expected, as it has been well established 
previously [5, 21, 38, 144, 325]. The broad range of fiber diameters produced during the 
electrospinning process allows for flexibility in the fabrication of electrospun scaffolds 
for different tissue engineering applications. 
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Figure 5.1. (Left) SEM of electrospun PRGF scaffolds taken at 500x, scale bar represents 
50 µm. (Right) SEM of electrospun PRGF scaffolds taken at 3000x, scale bar represents 
5 µm. 
 
Figure 5.2. Graph of mean fiber diameters for electrospun PRGF scaffolds of different 
concentrations illustrating the linear relationship between PRGF concentration and fiber 
diameter. * denotes statistical significance. 
 
Protein Release Kinetics 
The quantified protein release results from electrospun PRGF scaffolds are shown 
in Figure 5.3, demonstrating protein release from PRGF scaffolds was detectable over 35 
days. The release kinetics illustrates a peak release of protein on day 1 for all scaffold 
concentrations, followed by a distinct decrease in release for days 4-21. Unexpectedly, at 
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day 28, protein release increases for all scaffolds. By day 35 protein release has 
decreased, however, compared to days 4-21, overall release has increased. Surprisingly, 
100 mg/ml PRGF scaffolds had the highest release of protein over the 35 days compared 
to the other scaffolds, releasing 370 µg/ml of protein at day 1 and 175 µg/ml by day 35.  
Scaffolds of 150 and 200 mg/ml PRGF had similar release kinetics over the 35 days (185 
– 49 µg/ml and 194 – 96 µg/ml for the 150 and 200 mg/ml PRGF scaffolds, respectively). 
The initial burst release from scaffolds at day 1 is expected, as PRGF from the surface of 
the scaffolds is released. The high protein release from scaffolds of 100 mg/ml PRGF 
over the other scaffolds may be explained by the scaffold‟s smaller fiber diameters. 
Although not specifically investigated in this study, other previously published studies 
have demonstrated similar results, and explain that with smaller fiber diameters there is 
less distance for molecules to traverse to reach the fiber surface, hence, more protein 
release from the fibers over time [326-329]. The rise in protein release after day 21 may 
be due to fiber degradation of the PRGF scaffolds occurring around 28-35 days and 
subsequent release of entrapped proteins. Although degradation may have started to occur 
around day 28, the electrospun scaffolds were still very much intact at 35 days. This 
outcome was unexpected, as most electrospun natural polymers degrade rapidly in 
solution and need to be cross-linked or co-spun with a synthetic polymer to increase their 
stability [147]. Statistical analysis revealed protein release at day 1 and day 28 from all 
PRGF scaffolds was significantly greater than protein release from those respective 
scaffolds at all other time points (days 4, 7, 10, 14, 21, and 35). For scaffolds of 100 
mg/ml PRGF, protein release at days 1, 4, and 35 was significantly different from that at 
all other time points for that respective scaffold (days 7, 10, 14, and 21).  
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Figure 5.3. Quantification of generic protein released from pure PRGF scaffolds over 35 
days. * indicates significant differences, p < 0.05, for days 1 and 28 when compared to all 
other time points for each material, but not each other. # indicate statistically significant 
differences, p < 0.05, between days 1, 4, and 35 when compared to other time points, but 
not each other. Minimum level of detection was 17 µg/ml. 
 
Gel Electrophoresis 
The results from the gel electrophoresis technique are illustrated in Figure 5.4.  
The electrophoretic pattern of FBG appears as expected, as it has been previously 
determined that the alpha, beta and gamma chains have average molecular weights of 
around 68, 58 and 50 kDa, respectively [330]. BSA also exhibits a pattern that would be 
expected, with a distinct band around 67 kDa [318, 331, 332]. The electrophoresis results 
of PRGF resembles those of BSA and the FBG alpha chain, with a distinct band around 
68 kDa. This band is also likely to be representative of hemoglobin, which has a 
molecular weight of 68 kDa. PRGF also illustrates a faint band around 80 kDa, which is 
representative of different glycoprotiens, including transferrin, and plasminogen, and a 
distinct thick band at 14 kDa, indicating the presence of multiple chains of haptoglobin 
and transthyretin [318]. These results are not surprising, due to the fact that plasma 
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contains large amounts of these proteins. Interestingly, PPP has a similar electrophoretic 
pattern to that of both FBG and BSA, with the triple banding that is typically seen with 
FBG and the distinct band at 70 kDa that is characteristic of BSA. Additionally, PPP has 
additional banding around 80, 25, 18, and other faint bands between 25 – 50 kDa. These 
bands most likely represent a multitude of components, including different kinds of 
glycoproteins (similar to PRGF), various IgG light chains, multiple haptoglobin chains 
and various lipoproteins (both LDL and HDL) [318]. The fact that PPP is made up of 
mostly albumin, fibrinogen, and immunoglobulins is understandable, due to the fact that 
these components are the most prevalent proteins in blood. 
 
Figure 5.4. Electrophoretic patterns of molecular weight standards, FBG, PRGF, PPP, 
PRGF scaffolds of 100, 150, and 200 mg/ml and BSA in the 4-20% polyacrylamide gels. 
  
Fluorescent Based Assay 
The PVDF membrane that was spotted with 0 to 76 mg/dl of human FBG was 
scanned by the Odyssey system and fluorescent intensities were acquired. The standard 
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curve obtained is shown in Figure 5.5, illustrating a linear relationship (R
2
 = 0.96, y = 
1.58x +13.8). Using the standard curve equation, the amount of FBG in each sample was 
determined.   
 
 
Figure 5.5. Linear curve (R
2
 = 0.96) obtained from dilutions of human FBG standards for 
fluorescent assay. 
 
The amount of FBG expressed on scaffolds of pure PRGF ranged from 30-51 mg/dl 
(Figure 5.6, right). Specifically, 100 mg/ml PRGF amounted in 51 mg/dl FBG, 150 
mg/ml PRGF contained 43 mg/dl FBG, and 200 mg/ml PRGF had 30 mg/dl FBG. PRGF 
diluted in water at 10, 5 and 1 mg/ml resulted in 67, 37, and 21 mg/dl FBG, respectively. 
Blood and PPP contained the highest amount of FBG (423 and 440 mg/dl, respectively), 
while aPRP contained only 234 mg/dl FBG. The values of FBG that were quantified in 
blood, aPRP, and PPP were expected, and are consistent with previously published data 
[324, 333, 334]. The reason behind why 200 mg/ml PRGF contained less amounts of 
FBG than 100 mg/ml PRGF is not completely understood, and will need to be 
investigated further in future studies. 
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Figure 5.6. (Left) FBG fluorescence intensity of 100, 150, and 200 mg/ml pure PRGF 
scaffolds, 10, 5, and 1 mg/ml PRGF in PBS and blood, aPRP and PPP taken at 800 nm, 
3.5 intensity. (Right) Quantified FBG expression on scaffolds, PRGF in water, blood, 
aPRP and PPP. 
 
 The authors speculate the presence of FBG and hemoglobin in PRGF may be the 
reason why this protein is stable enough to form electrospun nanofibers. More 
specifically, Factor XIII, a stabilizing enzyme of the blood coagulation system that cross-
links fibrin, may explain why the electrospun PRGF scaffolds were still intact during the 
protein release study, even after 35 days in culture. This speculation is based on previous 
studies, which have demonstrated the ability of FBG and hemoglobin to form electrospun 
nanofibers from HFIP [21, 335]. In addition to the methods presented in this study, the 
presence of FBG, albumin, and hemoglobin in electrospun PRGF scaffolds was further 
confirmed by mass spectrometry. 
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Cell Interaction 
 Results from DAPI staining of hADSCs cultured on pure PRGF scaffolds reveals 
cell penetration into the scaffolds after as little as 3 days (Figure 5.7). As PRGF 
electrospinning concentration increases from 100 to 200 mg/ml, it appears there is greater 
cell migration into the scaffolds, potentially due to the increase in average fiber diameter 
and subsequent increase in scaffold void space. Regardless, after 10 days it is evident 
hADSCs have migrated through the entire thickness of the PRGF scaffolds for all 
concentrations. 
hSMC interaction with PRGF scaffolds is shown in Figure 5.8, demonstrating 
after only 3 days there is cell migration throughout the entire 200 mg/ml PRGF scaffold.  
100 mg/ml PRGF scaffolds demonstrated little penetration of hSMC into the scaffold, 
with most cells remaining on the surface of the scaffold even after 10 days. Scaffolds of 
150 and 200 mg/ml PRGF had complete cellular migration throughout the entire scaffold 
by day 10. Surprisingly, hSMC cultured on 150 mg/ml PRGF completely migrated from 
the surface of the scaffold into the middle region in only 10 days.  
The reason for this rapid migration of cells into the scaffold may be two-fold: the 
presence of an array of chemokines and growth factors found in concentrated amounts in 
aPRP is most likely chemotactic towards multiple cell types, and the increased void space 
as PRGF electrospinning concentration increases allows cells to easily migrate into the 
scaffold. Although not investigated in this manuscript, a previous study conducted by the 
authors has confirmed the release of RANTES and PDGF-BB from electrospun PRGF 
fibers (data not published). The release of these growth factors and cytokines, as well as 
many others contained within PRGF that have been previously shown to be chemotactic 
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and induce cell proliferation, is most likely the reason for enhanced cell infiltration within 
the scaffolds. Although it was not directly analyzed in this study, from the SEMs it 
appears the difference in fiber diameters between the PRGF concentrations affects the 
porosity of the scaffolds, with increased void space occurring as PRGF concentration 
increases.    
 
 118 
 
 
Figure 5.7. DAPI staining of ADSCs cultured on electrospun scaffolds of pure PRGF at 
days 3 and 10. Images at 20x. 
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Figure 5.8. DAPI staining of SMC cultured on electrospun scaffolds of pure PRGF at 
days 3 and 10. Images at 20x. 
 
 
Conclusion 
This manuscript demonstrates, for the first time, the feasibility of creating a 
nanofibrous scaffold from aPRP. As PRP has gained recent popularity in the clinical 
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setting due to its ability to enhance healing and promote regeneration in an array of 
tissues clinically, it may prove beneficial when used as a tissue engineering scaffolding 
material. Not only was the hypothesis proven that pure lyophilized, electrospun PRGF 
scaffolds could be stable for extended periods of time in vitro, but they also exhibited a 
sustained release of proteins known to be important for tissue regeneration for up to 35 
days. Additionally, despite the fact that electrospinning is often criticized for its 
perceived lack of cellular penetration, electrospun PRGF scaffolds promoted rapid 
cellular infiltration due to the presence of a milieu of growth and chemotactic factors 
inherent to aPRP. While this preliminary evaluation of electrospun PRGF demonstrated 
its tissue engineering potential in an in vitro setting, its true benefit may be seen in an in 
vivo scenario where multiple regenerative cell types can act concomitantly on the 
scaffolds in a manner similar to the natural healing cascade through the sustained 
chemotactic and growth factor gradients eluted. 
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Chapter 6: INCORPORATION OF PLATELET-RICH 
PLASMA INTO ELECTROSPUN SCAFFOLDS 
 
Preface: Parts of the following chapter are taken from the manuscript “Incorporating 
Platelet-Rich Plasma into Electrospun Scaffolds for Tissue Engineering Applications” 
appearing in Tissue Engineering: Part A, 17(21 and 22), 2011. The complete manuscript 
can be found in Appendix A. This chapter investigates the potential to create, lyophilize, 
and incorporate platelet-rich plasma into electrospun PCL scaffolds to create a delivery 
vehicle for a number of growth factors and cytokines known to enhance regeneration and 
wound healing without compromising scaffold mechanical properties.  
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Abstract 
 PRP therapy has seen a recent spike in clinical interest due to the potential that the 
highly concentrated platelet solutions hold for stimulating tissue repair and regeneration. 
The purpose of this study was to incorporate PRP into a well-known electrospun polymer 
to determine the effect on scaffold mechanical properties and to show the release kinetics 
of growth factors eluted from the structures. PRP underwent a freeze-thaw-freeze process 
to lyse platelets, followed by lyophilization to create a powdered PRGF, which was 
subsequently added to the electrospinning process. Release of protein from scaffolds over 
time was quantified, along with unaxial tensile testing. Protein assays demonstrated a 
sustained release of protein from PRGF containing scaffolds at up to 35 days in culture. 
Mechanical integrity of the scaffold was not affected by the addition of PRGF at certain 
concentrations, and was retained over a 28 day period. The incorporation of PRGF into 
electrospun structures may prove beneficial in a number of tissue engineering 
applications. 
 
Introduction 
PRP therapy is a method of collecting and concentrating autologous platelets, 
through centrifugation and isolation, for the purpose of activating and releasing their 
growth factor-rich - and dense granules. The discharge of these concentrated granules 
releases a number of growth factors and cytokines in physiologically relevant ratios, 
albeit in concentrations several times higher than that of normal blood, that are critical to 
tissue regeneration and cellular recruitment. Some of the more highly concentrated 
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factors found within PRP include PDGF, TGF-β, VEGF, FGF, EGF [302, 304, 305, 309, 
312-314].  
Clinically, PRP therapy has been used to stimulate tissue growth and regeneration 
in a number of different tissues; effectively accelerating the healing response in patients 
suffering from osteochondral defects [302-304], tendon/ligament injuries [302-308], and 
chronic skin wounds (diabetic and pressure ulcers) [303, 304, 309, 310]. Typically, these 
procedures involve a blood draw and centrifugation to concentrate the platelet portion, 
followed by a platelet activation step and the delivery of the activated PRP to the site of 
injury. There have been several methods reported in the literature on successfully 
activating and delivering PRP to an injury site, with most involving the creation of a 
platelet gel using thrombin [302-304, 311] or CaCl2 [302-304, 312]. These PRP gels can 
be easily applied to wound sites through injection or topical application.   
However, studies have shown that the use of thrombin as a clotting agent can 
result in a rapid activation of platelets and a bolus release of growth factors, with 70% of 
growth factors released within 10 minutes of clotting, and nearly 100% released within 1 
hour [302]. This “dumping” method fails to maximize the cell stimulating potential of the 
PRP growth factors as most are cleared before they can take effect [336]. Growth factor 
release from PRP gels can be slowed when the gel is formed with CaCl2 rather than 
thrombin. The addition of CaCl2 to PRP results in the formation of autogenous thrombin 
from prothrombin and the eventual formation of a loose fibrin matrix that will secrete 
growth factors over 7 days [302]. 
Other techniques have been evaluated for further sustaining the release of growth 
factors from PRP and include the use of gelatin gel microspheres [337], lyophilized PRP 
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[338-341], and alginate beads [336]. The injection of PRP gelatin gel microspheres in a 
mouse ischemic hind limb model demonstrated sustained release of the PRP potent 
angiogenic components as illustrated by an increase in perfusion, capillary density, and 
mature blood vessel density [337]. Alginate beads were shown to be successful in 
delivering (based on cell proliferation) PRP-derived growth factors and cytokines over 
the course of 14 days [336]. The use of freeze-dried PRP in a dermal wound has been 
shown to significantly increase cellular proliferation (up to 21 days), tissue regeneration 
and angiogenesis in a mouse dermal wound [338-341]. Collectively, these studies 
demonstrate the importance of keeping PRP-derived growth factors and cytokines in the 
wound site and slowly releasing them as the wound site becomes infiltrated with 
reparative cells. 
While a number of individual growth factors and/or cytokines have been used 
previously in an array of sustained release tissue engineering and regenerative medicine 
applications with positive results, the use of either single or multiple isolated growth 
factors/cytokines is often prohibitively expensive, and it can be difficult to replicate 
physiologically relevant quantities [302]. The purpose of this study was to attempt to 
harness the reparative potential found in PRP, namely the growth factor and cytokine 
milieu contained within, and apply it to tissue engineering through the creation of a PRP 
eluting electrospun scaffold. It was hypothesized that the inclusion of lysed and 
lyophilized PRP would create an effective PRGF capable of being introduced into the 
electrospinning process to create a scaffold capable of a sustained release of growth 
factors, without compromising mechanical properties. 
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Materials and Methods 
Creation of PRP and PRGF 
 Fresh human whole blood from 3 donors was purchased (Biological Specialty 
Corp.), pooled, and used in a SmartPReP
®
 2 (Harvest Technologies Corp.) centrifugation 
system to create PRP per manufacturers protocol. A small aliquot of both pooled whole 
blood and PRP were sent to the Harvard Immune Disease Institute‟s Blood Research 
laboratory to determine their respective platelet concentrations. PRP was then subjected 
to a freeze-thaw-freeze (FTF) cycle in a -70° C freezer for cell lysis and activation. 
Centrifuge tubes containing PRP were placed in a -70  C freezer for 24 hrs followed by a 
37  C waterbath for 1 hr, and then returned to the -70  C freezer for 24 hrs. The degree of 
activation of the FTF lysed PRP, and thrombin (Recothrom, ZymoGenetics Inc.) and 
10% CaCl2 (American Regent) activated PRP was quantified through an enzyme-linked 
immunosorbent assay (ELISA) analysis of VEGF and bFGF (Antigenix America Inc.). 
Frozen PRP was then lyophilized for 24 hrs to create a dry PRGF powder which was 
finely ground in a mortar and pestle prior to use.   
 
Creation of PRGF Incorporated Electrospun Scaffolds 
Polycaprolactone (PCL, Lakeshore Biomaterials, 125 kDa) was dissolved in 
1,1,1,3,3,3 hexafluoro-2-propanol (HFIP, TCI America Inc.) at a concentration of 100 
mg/ml. PRGF was then added in concentrations of 10 or 100 mg of PRGF per ml of 
electrospinning solution (PCL:PRGF(10) and PCL:PRGF(100), respectively) and allowed 
to dissolve completely into solution. As a means to reduce the thrombogenicity of the 
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electrospun material and to slow the release of growth factors from the fibers, sodium 
heparin salt from porcine submucosa (Sigma Aldrich) was dissolved in distilled water at 
0.05% or 0.5% (wt.:vol. of electrospinning solution), which correlates to around 100 
U/ml or 1000 U/ml, respectively, of electrospinning solution, and then added to PCL 
electrospinning solutions with and without PRGF [342, 343]. As PRGF can be 
successfully electrospun by itself from HFIP at a concentration of 200 mg/ml [344], 
PRGF fibers were also integrated into PCL scaffolds using two separate syringes of PCL 
and PRGF electrospinning solutions at 90° from each other targeting the same collection 
mandrel (PCL:PRGF). Heparin was also added to the PCL:PRGF scaffold solutions 
separately, so there was an equivalent amount of heparin as the other scaffolds overall. 
Control scaffolds contained no PRGF and no heparin. 
All solutions were electrospun onto a grounded rectangular stainless steel mandrel 
(1.9 cm wide x 7.5 cm long x 0.5 cm thick) rotating at 400 RPM and translating at 6 cm/s 
over a distance of 12 cm, using a Becton Dickinson syringe fitted with a blunt tip 18 
gauge needle and a KD Scientific syringe pump. PCL solutions with and without PRGF 
and heparin were electrospun using a charging voltage of +22 kV, an air gap distance of 
15 cm, and a flowrate of 5 ml/hr. PCL:PRGF used charging voltages of +22 and +25 kV 
for the PCL and PRGF solutions, respectively, an air gap distance of 15 cm from each 
syringe to the collecting mandrel, and a flowrate of 2.5 ml/hr for each solution. 
 
Scaffold Characterization 
Samples from each of the electrospun constructs was characterized through SEM 
(Zeiss EV050) to ensure the fibrous nature of the structures. Average fiber diameters and 
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pore areas were calculated by taking 60 random fiber measurements or pore area 
measurements from the SEM image using ImageTool 3.0 software (Shareware provided 
by UTHSCSA). 
 Uniaxial tensile testing was performed on dog-bone shaped samples (overall 
length of 20 mm, 2.67 mm at its narrowest point, gage length of 7.5 mm, n=5) punched 
from each of the electrospun scaffolds. All specimens were cultured in complete media 
(DMEM low glucose supplemented with 10% FBS and 1% penicillin/streptomycin) at 
standard conditions (37°C, 5% CO2) for 1, 7, 14, 21, or 28 days. At each time point, 
samples were uniaxially tested to failure at a rate of 10 mm/min (1.33 min
-1
 strain rate) 
using an MTS Bionix 200 testing system with a 100 N load cell (MTS Systems Corp.). 
Peak stress, modulus, and strain at break were calculated using TestWorks version 4. 
 Endotoxin levels of the scaffolds were detected using a Limulus Amebocyte 
Lysate Endosafe
®
 Endochrome-k kit (Charles River Laboratories). From each of the 
electrospun materials, 6 mm diameter discs were punched (n=3), disinfected (30 minute 
soak in ethanol followed by three 10 minute rinses in PBS), and placed in a 96 well plate 
in 100 µL reagent water (provided by the kit). Samples were cultured in standard 
conditions overnight, after which the reagent water was aspirated and analyzed for 
endotoxin levels. 
 
Quantification of Protein Release Kinetics 
 To determine the effect heparin had on the protein release kinetics from the 
scaffolds, 10 mm diameter disks were punched (n=3), disinfected (30 minute soak in 
ethanol followed by three 10 minute rinses in PBS), and placed in a 48-well plate with 
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500 µl of PBS. The PBS was changed and retained for evaluation on days 1, 4, 7, 10, 14, 
21 and 28.  In addition, 500 µl of PBS with PRGF (1 mg/ml) and heparin (0.05% and 
0.5%) was placed in a 48-well plate and retained after 1 day for analysis. Samples at each 
time point were subjected to a generic protein assay (BCA Protein Assay, Thermo 
Scientific Pierce) to quantify the concentration of total protein released. 
Based upon these results, specific ELISAs (TGF-  (Promega), PDGF-BB 
(Antigenix America Inc.), RANTES (Antigenix America Inc.), VEGF (Antigenix 
America Inc.), Lipoxin (LXA4, Neogen), and SDF-1  (Antigenix America Inc.)) were 
run on the retained samples (days 1, 4, 7, 10, 14, and 21) to detect proteins found in PRP. 
 
Statistical Analysis 
 All statistical analysis was based on a Kruskal–Wallis one-way ANOVA on ranks 
and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with 
the JMP IN 8.0 statistical software package (SAS Institute, Inc.). Graphical depictions of 
mean data were constructed with Microsoft Excel 2007, with error bars representing 
standard deviations. 
 
Results 
Creation of PRP and PRGF 
 Based upon the platelet counts performed at the Harvard Immune Disease 
Institute‟s Blood Research laboratory, it was determined that the pooled whole blood 
used for this study contained 175 x 10
3
 platelets/µl, while the PRP created with the 
 129 
 
SmarPReP
2
 system yielded 955 x 10
3
 platelets/µl. This 5.5 fold increase in platelets is 
consistent with published data [324], and should result in a similar fold increase in 
growth factor concentration based upon the linear relationship between platelet and 
growth factor concentration [315].   
The results of the bFGF and VEGF ELISAs (Figure 6.1) reveal the FTF method 
of activation, essentially lysing platelets to release their α and dense granule contents, to 
be as effective, if not more so, than the traditional PRP activation techniques of thrombin 
and CaCl2 for releasing growth factors. The FTF activation method resulted in average 
growth factor concentrations of 0.4 ng/ml for bFGF, and 1.6 ng/ml for VEGF. Using the 
traditional CaCl2 and thrombin activation methods bFGF values were 0.8 and 0 ng/ml, 
respectively, while the VEGF values were 0.3 and 0.7 ng/ml, respectively. While there 
were few statistical differences between the different methods in the bFGF ELISA, with 
only the CaCl2 activated different from the thrombin activated, the VEGF ELISA results 
demonstrated clearly that the FTF method was significantly greater than the other 
activation methods. It should be noted that the thrombin activation method resulted in an 
instantaneous gel, making it difficult to obtain liquid samples for ELISA analysis. The 
CaCl2 activated PRP contained visible floating thrombi, but was mostly liquidous, while 
the FTF activated PRP was completely liquid with no evidence of thrombus formation. 
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Figure 6.1. Results of PRP activation method on bFGF and VEGF concentration.  * 
indicates significant differences between activation methods, p < 0.05. Minimum levels 
of detection for bFGF and VEGF were 0.11ng/ml and 0.04 ng/ml. 
 
Characterization of Electrospun Structures  
Scanning Electron Microscopy 
SEM images of the scaffolds are displayed in Figure 6.2, illustrating the fibrous 
nature of the scaffolds with and without the incorporation of PRGF and heparin. Mean 
fiber diameters for these scaffolds are depicted in Figure 6.3, and range from 0.25 µm for 
PCL scaffolds with 0.05% heparin to 0.92 µm for PCL control scaffolds. The addition of 
PRGF alone did not have a significant effect on fiber diameter, however, when heparin 
was added at 0.05% or 0.5%, PCL:PRGF(100) scaffolds had significantly larger fiber 
diameters than other scaffolds containing heparin. With the exception of scaffolds with 
100 mg/ml PRGF, the addition of heparin (both 0.05% and 0.5%) resulted in significantly 
smaller fiber diameters compared to scaffolds without heparin. The significant decrease 
in fiber diameter is most likely accredited to an increase in charge density on the surface 
of the ejected polymer jet during electrospinning. The increased charge density of heparin 
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(as Na
+
 salt) causes greater elongation and thinning forces on the jet as it travels through 
the electric field, resulting in smaller fiber diameters [342]. It is evident from the images 
that with increasing amounts of PRGF added, there are both large and small fiber 
diameters present. This divergent population of fiber diameters in scaffolds with PRGF is 
also illustrated through the large standards of deviation that were determined for those 
structures. While the addition of PRGF to the scaffolds does not have an affect on fiber 
diameter, it does have a linear affect on average pore area; as PRGF content is increased, 
pore area increases as well (Figure 6.3). The addition of 100 or 200 mg/ml PRGF to PCL 
scaffolds resulted in significantly increased pore areas over the control and 10 mg/ml 
PRGF containing samples. With the addition of heparin (both 0.05% and 0.5%), scaffolds 
with 100 mg/ml PRGF had significantly increased pore areas over all other scaffolds with 
heparin. PCL control scaffolds and PCL:PRGF scaffolds not containing heparin had 
significantly greater pore areas than their heparin incorporated counterparts. In previous 
electrospinning studies, the correlation between average pore area and average fiber 
diameter has been well documented [144, 321, 325]. This same correlation is observed 
here for the PCL:PRGF(100) scaffolds: as fiber diameter increased, pore area increased. 
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Figure 6.2. SEM images of PCL scaffolds with and without heparin and PRGF. 
Magnification is 3000X. 
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Figure 6.3. (Top) Average fiber diameters of PCL and PRGF incorporated scaffolds with 
and without heparin. * indicates statistical significance (p<0.05) between scaffolds with 
and without heparin. # indicates statistically significant differences, p<0.05, between 
PCL:PRGF(100) scaffolds with 0.05% or 0.5% heparin and other scaffolds with 0.05% or 
0.5% heparin. (Bottom) Average pore areas for PCL scaffolds containing PRGF and 
heparin. * indicates statistical significance (p<0.05) between scaffolds with and without 
heparin. # indicates statistically significant differences, p<0.05, between 
PCL:PRGF(100), PCL:PRGF scaffolds and all other scaffolds without heparin, and 
between scaffolds of PCL:PRGF(100) with 0.05% or 0.5% heparin and all other scaffolds 
with 0.05% or 0.5% heparin. 
 
Uniaxial tensile testing 
The results from the uniaxial tensile testing performed on scaffolds incorporated 
with PRGF are depicted in Figure 6.4. Peak stress ranged from approximately 0.25 MPa 
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for scaffolds of PCL:PRGF(100) to 3.5 MPa for scaffolds of PCL:PRGF(10). The 
addition of PRGF did not affect the peak stress of the structures, except when added at 
100 mg/ml. These results were not surprising, as traditionally the combination of biologic 
proteins in large concentrations (collagen, elastin, fibrinogen, etc.) with electrospun 
polymers regarded for their tensile strength typically results in significantly reduced 
mechanical strength [20, 148, 345]. Surprisingly, there were no differences in peak stress 
values for any of the structures over the 28 days. This result, although opposite of what 
normally occurs over time when a natural component or polymer is added to 
electrospinning solutions, is encouraging, and may indicate these materials will retain 
their mechanical integrity in vivo as well. 
The modulus for the PCL and PRGF containing scaffolds ranged from 
approximately 2.5 MPa for structures containing 100 mg/ml PRGF to about 13 MPa for 
PCL scaffolds. Similar to the results of peak stress, in general, the addition of PRGF did 
not affect the modulus of the constructs, except when added at 100 mg/ml. PCL scaffolds 
did have a significantly higher modulus at day 1 and 7 than that of PRGF containing 
scaffolds at those time points (except PCL:PRGF at day 7). In addition, modulus did not 
significantly decrease over the 28 day time point for any of the scaffolds, illustrating the 
ability of the PCL and PRGF incorporated scaffolds to retain their mechanical strength 
over time. Strain at break values for the scaffolds ranged from 30% for PCL:PRGF(100) 
to around 140% for scaffolds of PCL:PRGF(10). Again, in general, with the exception of 
PCL:PRGF(100), the addition of PRGF did not have a significant effect on the strain at 
break and all scaffolds had a consistent strain at break over the 28 days. Scaffolds of 
PCL:PRGF(10) had significantly higher strain at break than all other scaffolds at all other 
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time points, except PCL:PRGF(10) scaffolds at day 1. PCL:PRGF(100) constructs had a 
significantly different strain of break at day 1 than at day 28.  
 
Figure 6.4. Results of peak stress (top), modulus (middle), and strain at break (bottom) 
for PCL and PRGF incorporated scaffolds. For peak stress, # indicates statistically 
significant differences, p < 0.05, between PCL:PRGF(100) scaffolds and all other 
scaffolds at all other time points, except for PCL:PRGF at day 1. For modulus, ^ 
indicates statistically significant differences (p<0.05) between PCL (day 1) and all other 
PRGF incorporated scaffolds at day 1. & indicates statistical significance (p<0.05) 
between PCL scaffolds at day 7 and all other scaffolds at day 7 time point, except 
PCL:PRGF. # denotes statistically significant differences, p < 0.05, between 
PCL:PRGF(100) scaffolds and all other scaffolds at all other time points. For strain at 
break, % denotes statistical significance (p<0.05) between scaffolds of PCL:PRGF(10) at 
days 7, 14 and 28 over all other scaffolds at all other time points, except PCL:PRGF(10) 
scaffolds at day 1. # indicates statistically significant differences (p<0.05) between 
PCL:PRGF(100) scaffolds and PCL:PRGF(10) scaffolds at all time points. * indicates 
statistical significance (p<0.05) between PCL:PRGF(100) scaffolds at day 1 versus day 
28.  
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 Uniaxial tensile testing results from that performed on scaffolds with and without 
heparin are shown in Figure 6.5 (a-d). Over all, the results for peak stress, modulus and 
strain at break for all scaffolds revealed the addition of heparin did not significantly affect 
the mechanical integrity of the scaffolds. For PCL:PRGF, the addition of heparin did 
significantly decrease the peak stress and modulus of the scaffolds, while for 
PCL:PRGF(100) scaffolds, the addition of heparin significantly increased the peak stress 
and strain of break of the constructs. Similar to scaffolds without heparin, electrospun 
PCL and PRGF incorporated structures with 0.05% or 0.5% heparin did not significantly 
lose their mechanical strength over the 28 day time period, indicating little to no 
degradation was occurring over the time course of the experiment. The peak stress, 
modulus and strain at break for PCL scaffolds with heparin (0.05% and 0.5%) are similar 
to those for PCL scaffolds without heparin (Figure 6.5(a)), with no statistically significant 
differences observed. Additionally, scaffolds incorporated with heparin retained their 
mechanical strength over the 28 days, with statistical analysis revealing no significant 
differences for peak stress, modulus, or strain at break between the different time points 
tested for each scaffold type.  
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Figure 6.5(a). Results of peak stress (top), modulus (middle), and strain at break 
(bottom) for PCL scaffolds incorporated with and without heparin (0.05% and 0.5%).  
 
Figure 6.5(b) shows the mechanical testing results for scaffolds of PCL:PRGF(10) 
with and without 0.05% and 0.5% heparin. Similar to PCL scaffolds, for peak stress, 
modulus and strain at break, there were no significant differences between scaffolds with 
and without heparin tested at the same time point, as well as between days 1-28 for each 
scaffold type.  
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Figure 6.5(b). Unaxial tensile testing results for PCL:PRGF(10) scaffolds with and 
without heparin (0.05% and 0.5%) illustrating peak stress (top), modulus (middle), and 
strain at break (bottom). 
 
Results from uniaxial tensile testing of PCL:PRGF(100) scaffolds with and 
without heparin (0.05% and 0.5%) are displayed in Figure 6.5(c). Statistical analysis 
revealed PCL:PRGF(100) scaffolds without heparin have a significantly lower peak 
stress at all time points than those equivalent scaffolds with 0.05% and 0.5% heparin 
(except PCL:PRGF(100)+0.05% heparin scaffolds at days 14 and 21). Analysis of 
modulus results revealed no significant differences between scaffolds with and without 
0.05% and 0.5% heparin. Scaffolds with 0.05% and 0.5% heparin tested at day 28 had a 
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significantly higher strain at break than PCL:PRGF(100) scaffolds without heparin tested 
at all time points (except day 1). For peak stress, modulus and strain at break, however, 
there were no significant differences observed between the different time points tested for 
each scaffold type, illustrating their ability to retain their mechanical strength over 28 
days. 
 
Figure 6.5(c). Peak stress (top), modulus (middle), and strain at break (bottom) results 
for scaffolds with 100 mg/ml PRGF incorporated with and without heparin (0.05% and 
0.5%). # denotes statistical significance (p<0.05) between PCL:PRGF(100) scaffolds 
without heparin and PCL:PRGF(100) scaffolds with heparin (except 
PCL:PRGF(100)+0.05% heparin at days 14 and 21). * signifies statistically significant 
differences between PCL:PRGF(100) scaffolds with heparin (0.05% and 0.5%) tested at 
day 28 and PCL:PRGF(100) scaffolds without heparin at all time points tested, except 
day 1. 
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The values determined for the peak stress, modulus and strain at break of 
PCL:PRGF scaffolds are shown in Figure 6.5(d). PCL and PRGF co-spun scaffolds 
without heparin exhibited significantly increased peak stress over the same scaffolds with 
heparin for their respective time points, with the exception of PCL:PRGF scaffolds tested 
at days 1 and 21. Similar results were seen with modulus; scaffolds without heparin had 
significantly increased modulus over PCL:PRGF scaffolds with heparin between the 
specific time points tested, except PCL:PRGF scaffolds at days 1 and 28. No significant 
differences were observed between the time points tested of each type of scaffold for the 
peak stress and modulus. Strain at break results revealed no statistically significant 
differences between PCL and PRGF co-spun scaffolds with and without heparin for their 
respective time points (except PCL:PRGF scaffolds and PCL:PRGF+0.5% heparin tested 
at day 28). In looking at differences between days 1 – 28, PCL:PRGF+0.5% heparin 
scaffolds tested at day 28 had significantly decreased strain at break than 
PCL:PRGF+0.5% heparin scaffolds tested at day 1 and 7.  
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Figure 6.5(d). Unaxial tensile testing results for PCL and PRGF co-spun scaffolds with 
and without heparin (0.05% and 0.5%) illustrating peak stress (top), modulus (middle), 
and strain at break (bottom). # denotes statistically significant differences (p<0.05) 
between scaffolds with and without heparin (0.05% and 0.5%) for peak stress and 
modulus (except for scaffolds of PCL:PRGF tested at days 1 and 21, and days 1 and 28, 
respectively). * signifies significant differences, p<0.05, between PCL:PRGF scaffolds 
with 0.5% heparin and without heparin tested at day 28. % represents statistical 
significance between PCL:PRGF+0.5% heparin scaffolds tested at day 28 and those 
tested at days 1 and 7. 
 
 Table 6.1 shows a comparison of the range of mechanical properties determined 
for the electrospun materials in this study to that of a native femoral artery and e-PTFE. 
The table illustrates that electrospun PCL constructs incorporated with PRGF and heparin 
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are comparible to that of the native femoral artery, and therefore, could withstand 
physiological pressure if implanted as a vascular graft.  
Table 6.1. Mechanical properties of electrospun PCL:PRGF:heparin scaffolds compared 
to native femoral artery [346, 347] and e-PTFE [348]. 
Graft Material Peak Stress (MPa) Modulus (MPa) Strain at Break (%) 
Femoral artery 1 – 2  9 – 12 63 – 76  
e-PTFE 6 – 15  42 – 60  20 – 30  
PCL 1.5 – 2.5  1 – 1.5  60 – 90  
PCL:PRGF(10) 3 – 5  6 – 12  100 – 150  
PCL:PRGF(100) 0.2 – 0.7  1.5 – 2.9  25 – 40  
PCL:PRGF 0.5 – 2.5  2 – 8  40 – 90  
 
Endotoxin levels 
 Levels of endotoxin detected for PCL and PRGF incorporated scaffolds with and 
without 0.05% and 0.5% heparin are displayed in Figure 6.6 and are below the acceptable 
levels of endotoxin for standard clinical applications as determined by the U.S. 
Pharmacopeia (0.5 Endotoxin units (EU)/ml) [349]. It should be noted that the endotoxin 
levels for PRGF and heparin in water are above the standard acceptable limit for medical 
devices; however, several proteins and anticoagulants contained within the PRGF 
(including citrate dextrose, fibrinogen and globulins), as well as heparin itself, have 
separate acceptable endotoxin limits, of which the levels displayed in Figure 6.6 all fall 
below [349]. Furthermore, the levels of endotoxin detected for PCL and PRGF 
incorporated scaffolds with and without heparin are far below (1800 fold less) that used 
to activate macrophages (100 ng/ml lipopolysaccharide (LPS) which corresponds to 1100 
EU/ml).  
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Figure 6.6. Endotoxin levels detected for PRGF and heparin incorporated scaffolds, 
heparin in water and in PRGF in water (0.05% and 0.5%). 
 
Quantification of Release Kinetics from PRGF and Heparin Incorporated Scaffolds 
Protein release 
The results of quantified protein release from PRGF containing scaffolds are 
shown in Figure 6.7. The results of this study demonstrated that scaffolds containing high 
concentrations of PRGF (PCL:PRGF(100) and PCL:PRGF) released detectable amounts 
of protein over 35 days in culture. The protein release from PRGF containing scaffolds 
peaked at day 1, decreased by about half on days 4 and 7, and reached a plateau that was 
sustained for the remainder of the duration. PCL:PRGF(100) had the highest release of 
protein at all time points (0.22 mg/ml – 0.05 mg/ml). Surprisingly, PCL:PRGF scaffolds 
released a lower amount of protein over the 35 days, even though the concentration of 
PRGF incorporated was the same as that of PCL:PRGF(100) scaffolds. Minimal protein 
release was detected for PCL control scaffolds and scaffolds containing 10 mg/ml PRGF 
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over the 35 days, indicating that the protein detected was in fact due to PRGF release and 
not simply an artifact of scaffold degradation.   
Statistical analysis revealed protein release at day 1 from scaffolds of 
PCL:PRGF(100) to be significantly greater than protein release from those respective 
scaffolds at all other time points (day 4-35). Additionally, scaffolds of PCL:PRGF(100) 
had significantly greater release at day 4 than day 35. The initial burst of release from the 
scaffolds at day 1 was expected as PRGF from the surface of the scaffolds was released. 
Remarkably, after the first day there was still a sustained release of protein from scaffolds 
of PCL:PRGF(100) that continued throughout the 35 days, presumably due to the 
degradation of the polymer scaffolds and subsequent release of entrapped proteins.   
 
Figure 6.7. Quantification of generic protein released from PRGF containing scaffolds 
over 35 days. * indicates a significant difference, p < 0.05, for day 1 when compared to 
all other time points for each material. # indicate statistically significant differences, p < 
0.05, between day 4 and day 35 of PCL:PRGF(100). Minimum level of detection was 
14.3 µg/ml. 
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The results from the BCA protein assay to determine the effect the addition of 
heparin had on protein detection from PRGF in PBS and protein release from scaffolds 
are illustrated in Figure 6.8. The addition of heparin to PRGF dissolved in PBS at 1 
mg/ml did have a significant effect on amount of protein detected. The addition of 
heparin at increasing amounts to 1 mg/ml PRGF had a linear effect on the amount of 
protein detected; with increasing amounts of heparin incorporated, protein detection was 
decreased (Figure 6.8, Day 1). Statistical analysis revealed the addition of heparin at 
0.5% to 1 mg/ml PRGF resulted in a statistically significant difference in protein 
detection compared to that of 1 mg/ml PRGF without heparin. These results indicate 
heparin may bind to specific growth factors contained within PRGF, thereby hindering 
their release and overall detection.  
In contrast to the results seen from PRGF dissolved in PBS at 1 mg/ml, the 
addition of heparin at 0.05% and 0.5% to electrospun PRGF incorporated scaffolds does 
not appear to affect the amount of protein released from the constructs over 21 days 
(Figure 6.8). With the exception of PCL:PRGF and PCL:PRGF(100) scaffolds at days 1 
and 4, respectively, there were no statistically significant differences in amount of protein 
released from PRGF containing scaffolds with and without heparin. On day 1, 
unexpectedly, PCL:PRGF scaffolds with 0.05% heparin had a significant increase in 
protein release compared to PCL:PRGF scaffolds without heparin. On day 4, 
PCL:PRGF(100) scaffolds without heparin had significantly higher protein release than 
those same scaffolds with heparin incorporated at both 0.05% and 0.5%.  These results 
may imply heparin was not incorporated into the electrospun scaffolds consistently, 
thereby producing contradictory results from that explained above.  
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Figure 6.8. Protein release from PRGF dissolved in PBS (1 mg/ml) and PRGF 
incorporated scaffolds with and without 0.05% and 0.5% heparin over 21 days. * denotes 
statistical significance (p<0.05) between PRGF with and without heparin and when 
comparing the same type of scaffold with and without heparin. Minimum levels of 
detection were 0.001 mg/ml for protein detected at days 1, 4 and 7 and 0.009 mg/ml for 
protein detected at days 10, 14 and 21 (red dashed line). 
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Growth factor release 
Quantification of TGF-β, RANTES, and PDGF-BB from the PRGF containing 
scaffolds revealed detectable cumulative release over 21 days (Figure 6.9(a)) with 
kinetics similar to those of the protein assay results described previously. These growth 
factors were also detectable in whole blood (WB), PRP, PPP and PRGF dissolved in PBS 
at 10 mg/ml, 5 mg/ml and, for TGF-β and RANTES, 1 mg/ml. TGF-β release was highest 
from scaffolds of PCL:PRGF(100). Release at day 1 was 0.5 ng/ml, with cumulative 
release increasing thereafter until day 21. Release from PCL:PRGF scaffolds increased 
from day 1 to day 7, but plateaued throughout the rest of the 21 days. Cumulative TGF-β 
release from scaffolds was not significantly different over the 21 days. 
Much like the release of TGF-β from the scaffolds, PDGF-BB release was highest 
from scaffolds of PCL:PRGF(100), with release at day 1 of 0.15 ng/ml, and increasing 
cumulatively thereafter. PCL:PRGF scaffolds elicited PDGF-BB release of 0.03 ng/ml at 
day 1, but was not released at any time points thereafter. PDGF-BB release at day 1 from 
scaffolds of PCL:PRGF(100) was significantly higher than release from those same 
scaffolds at all other time points (days 4-21). For PCL:PRGF(100), PDGF-BB release at 
day 4 was significantly higher than that of days 10-21, and release at day 7 was 
significantly different from that of all other time points, except day 10.  
Scaffolds of PCL:PRGF(100) had the highest release of RANTES, with 3 ng/ml 
released at day 1, with gradual increase in release thereafter. RANTES release from 
PCL:PRGF scaffolds had a peak of 0.5 ng/ml at day 1, but did not release any detectable 
amounts after day 4. Statistical analysis revealed no significant differences between 
RANTES release over the 21 days from PRGF incorporated scaffolds. It is unusual that 
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the level of PDGF-BB and RANTES found in WB and PRP was found to be similar, as 
growth factors in PRP should be around 5 times more than that of WB. One reason for 
this may be due to the storage of the PRP at 2-8°C over 24-48 hours. Because many of 
the growth factors have a short half life, they may have become inactivated over that 
time. 
Similar to the protein assay results, TGF-β, PDGF-BB, and RANTES were 
undetectable from both the PCL control scaffolds and the scaffolds containing 10 mg/ml 
PRGF at all time points. The results of the statistical analysis illustrated that in general, 
the release of RANTES and TGF-β that occurred at all time points is not significantly 
different, demonstrating a sustained release of growth factors from the scaffolds over the 
21 day period as the polymer fibers begin to degrade. This is also true for PDGF-BB 
release after day 7. 
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Figure 6.9(a). Cumulative release of TGF-β, PDGF-BB, and RANTES from PRGF 
incorporated scaffolds. Minimum levels of detection for TGF-β, PDGF-BB and RANTES 
were 0.011 ng/ml, 0.003ng/ml and 0.001ng/ml, respectively (red dashed line). * and # 
indicate statistically significant differences, p < 0.05, between day 1 and day 4, 
respectively, and all other time points. % indicates statistical significance, p < 0.05, 
between day 7 and all other time points, except day 10. 
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 In contrast to TGF-β, PDGF-BB and RANTES, VEGF, SDF-1α, and LXA4 
release from PRGF incorporated scaffolds was not detectable at any time point (Figure 
6.9(b)). This result may be explained by the fact that these growth factors are contained 
in PRP in smaller concentrations, and therefore, their release from electrospun scaffolds 
is most likely lower than the ELISA kits‟ minimum levels of detection [313, 337]. VEGF, 
SDF-1α and LXA4 levels in PRP were 0.458 ng/ml, 0.130 ng/ml, and 0.246 ng/ml, 
respectively. These values are in agreement with previously published data. PRGF 
dissolved at 10 mg/ml and 5 mg/ml contained detectable levels of all three growth 
factors, while only LXA4 was detectable in 1 mg/ml PRGF. 
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Figure 6.9(b). Levels of VEGF, SDF-1α, and LXA4 from PCL and PRGF incorporated 
scaffolds, PRGF in media (10, 5 and 1 mg/ml), WB, PRP and PPP. Minimum levels of 
detection (dashed red line) are 0.011 ng/ml, 0.013 ng/ml, and 0.013 ng/ml for VEGF, 
SDF-1α and LXA4, respectively. 
 
Discussion 
 This present study provides a proof-of-principle for the incorporation of a 
powdered PRGF derived from human PRP into electrospun scaffolds of PCL. Through a 
number of evaluation methods, we were able to demonstrate that PRGF retained its 
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physiologic activity after lyophilization and through the electrospinning process, 
subsequently releasing a number of growth factors while retaining scaffold mechanical 
integrity over 28 days.  
The use of PRP in clinical applications has been gaining in popularity as a means 
to stimulate tissue repair and regeneration with very minimal risk to the patient. 
However, the “black box” approach taken by many of the clinicians utilizing PRP leaves 
much to be done in the realm of basic science to fully understand and standardize the 
practice. To date, the collection of whole blood and the concentration and isolation of 
platelets to make PRP has been proven effective in vitro for stimulating cellular activity 
in a number of formats, both in liquid [311, 350-356] and in lyophilized PRGF form 
[338-341]. 
To the best of the authors‟ knowledge, this manuscript serves as the first instance 
of a powdered PRGF being incorporated into an electrospun tissue engineering scaffold 
to serve as a controlled release vehicle for such a concentrated growth factor and cytokine 
milieu. While electrospun scaffolds have been used as growth factor delivery systems in 
the past [301, 319, 357-360], they have typically been limited to the incorporation of only 
a small number of growth factors due in part to the cost associated with purchasing the 
recombinant or isolated proteins [357]. The incorporation of a cost-effective PRGF 
protein array into an electrospun structure has the potential to deliver a multitude of 
growth factors, cytokines, and chemokines in physiologically relevant ratios. Such a 
platelet-based growth factor cocktail would essentially replicate the necessary factors 
found in a site of normal wound healing and promote the formation of healthy tissue 
through the stimulation of the healing cascade [300]. The results presented in this 
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manuscript demonstrated the potential of such a sustained release vehicle through the 
detection of various growth factors. Heparin was also incorporated as a means to bind to 
different growth facors and interleukins and modulate their release from the PRGF 
incorporated electrospun constructs. 
With the creation of individual PRGF fibers within the electrospun scaffolds 
containing high concentrations of PRGF (PCL:PRGF(100)), the loss of mechanical 
strength was not surprising. These PRGF fibers, consisting of natural proteins, lack 
inherent mechanical strength [344]. Similar in composition to electrospun collagen or 
fibrinogen [321, 345], which performs best mechanically when blended with synthetic 
polymers, and the presence of which can significantly decrease scaffold mechanical 
strength, the PRGF fibers may be best utilized in a role of enhancing scaffold bioactivity 
rather than load bearing. Surprisingly, even with the incorporation of large amounts of 
PRGF and/or heparin, the electrospun scaffolds were able to retain their mechanical 
integrity over the 28 days, demonstrating little to no degradation occurring. The addition 
of a natural polymer generally causes a quicker degradation of a scaffold; however, 
because PRGF consists mainly of a fibrinogen backbone, this may be assisting in fiber 
stabilization [361]. This stability of the PRGF fiber was also demonstrated in the 
PCL:PRGF co-spun scaffold, where even when PRGF was incorporated in large 
amounts, the mechanical properties fell in between that of PCL and PCL:PRGF(100) 
scaffolds. The mechanical properties of these scaffolds were found to be comparible to 
those of native femoral artery, illustrating these scaffolds may withstand physiological 
pressures if implanted as a vascular graft.  
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As demonstrated in the protein release assays conducted herein, detectable levels 
of proteins were released from the electrospun scaffolds for up to 35 days in vitro. The 
addition of heparin, while not affecting protein release from electrospun PRGF 
containing constructs, did have a reverse effect on protein detection in 1 mg/ml PRGF; a 
significant decrease in protein detection was observed with increasing amounts of 
heparin. This result was expected, and can be explained by the binding of growth factors 
by heparin. With more heparin added, more growth factors become bound, hindering 
their release and detection by the assay. 
While it can be assumed that a large percentage of the released proteins were in 
fact albumin and other blood proteins, not growth factors, the fact that RANTES, PDGF-
BB, and TGF-β were detectable in electrospun materials at up to 21 days attests to the 
sustained release nature of the structures. VEGF, SDF-1α, and LXA4 release from 
electrospun constructs was not detectable, however, quantification of these growth factors 
in PRP as well as in PRGF dissolved in PBS alludes to the fact that their release from 
electrospun scaffolds may be too small to detect by ELISAs, but may still be sensed by 
cells. RANTES, PDGF-BB, and TGF-β release were analyzed as they are three of the 
more highly concentrated proteins contained within PRP/PRGF[313], however, it can be 
interpolated that other factors such as PDGF-ab, FGF, and EGF will be released in the 
same fashion. The nature of the release demonstrated from the electrospun scaffolds may 
prove to be effective in proposed in vitro and in vivo follow-up studies at enhancing 
migration of cells from surrounding tissues, with a large burst of protein creating a 
substantial chemotactic gradient, followed by a sustained release of protein to promote 
cell proliferation, and scaffold infiltration and remodeling. The incorporation and 
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subsequent release of albumin, while seemingly inconsequential, may in fact serve as a 
protectant for the cytokines and chemokines included in the PRGF. The hydrophilic 
albumin molecules have been demonstrated in the literature to have the potential to 
encapsulate smaller proteins, and effectively shield them from potential denaturation 
[362, 363]. However, it is important to note that the electrospinning process may alter the 
molecular structures of the different components in PRP, thereby effecting growth factor 
bioactivity. In performing TGF-β ELISAs, TGF-β was only detectable in PRGF and PRP 
after performing an acid activation technique, while it was detectable in electrospun 
constructs without activation. Although this ELISA was the only one to specifically 
detect this change, other growth factors are likely to be effected by the electrospinning 
process as well, and may not have been detected by ELISAs. Further analysis of the 
components contained with electrospun PRGF incorporated scaffolds, PRP and PRGF, 
either by performing gel electrophoresis or a similar technique, may confirm this 
explanation. 
 In conclusion, this study demonstrated proof of the hypothesis in that PRP was 
able to be subjected to a FTF process, lyophilized to create PRGF, and incorporated into 
electrospun scaffolds of PCL. In addition, this PRGF was released from the electrospun 
scaffolds in a controlled fashion over a period of 35 days in culture, and the scaffolds 
retained their mechanical strength in vitro. In addition, endotoxin levels were not elevated 
by the addition of PRGF or heparin above the acceptable limit for standard clinical 
applications as determined by the U.S. Pharmacopeia. Additional studies are needed to 
determine what effect the presence of PRGF will have in vivo on the release of growth 
factors and mechanical stability of the electrospun structures. 
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Chapter 7: EVALUATION OF ANGIOGENIC POTENTIAL 
OF INCORPORATED PLATELET-RICH PLASMA 
SCAFFOLDS 
 
 
Preface: Parts of the following chapter are taken from the manuscript “Incorporating 
Platelet-Rich Plasma into Electrospun Scaffolds for Tissue Engineering Applications” 
appearing in Tissue Engineering: Part A, 17(21 and 22), 2011. The complete manuscript 
can be found in Appendix A. The included work investigates the potential for 
incorporated PRP/PRGF scaffolds with and without heparin to enhance scaffold 
bioactivity and promote regeneration and angiogenesis through cellular migration, 
proliferation, and sprout formation.  
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Introduction 
   When an artery is injured, similar to any tissue, a complex set of events takes place, 
beginning with clot formation and acute inflammation, development of granulation tissue, 
and in ideal cases, ending with complete tissue regeneration, but in most cases, scar 
formation [364]. After a biomaterial has been implanted into the body, a different 
response is elicited. First, a nonspecific adsorption of proteins takes place on the surface 
of the implant, ranging from natural to denatured conformations, causing the foreign 
body reaction to begin. Several cell types that are normally present during wound healing 
are chemoattracted to the biomaterial, including platelets, monocytes and macrophages, 
and adhere to the surfaces. Because these graft implants are significantly larger than the 
macrophages themselves, they are unable to phagocytose the foreign material, and reside 
at the implant sight, often times forming into multinucleated foreign body giant cells. 
While these macrophages reside at the wound site, interaction with these biomaterials and 
the environment drives them towards different phenotypes, with very different 
characteristics (Figure 7.1). Pro-inflammatory macrophages, also called classical 
macrophages, or M1s, were first established as being activated by interferon-gamma 
(IFN-γ), an angiogenesis inhibitor chemokine. The M1 macrophage has been shown to 
act pro-inflammatory, immunogenic and pro-destructive [365-368] and secrete copious 
amounts of inflammatory cytokines, including, but not limited to IL-23 and TNF-α [369, 
370]. M2, or alternative activated macrophages, were first described by Gordon et al., 
and are characterized as anti-inflammatory, tolerogenic, inflammation resolving, and 
tissue restorative. They possess the ability to facilitate tissue repair and regeneration, and 
in addition, promote angiogenesis and tissue remodeling [367, 369-371] by releasing pro-
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angiogenic growth factors (FGF, TGF-β, granulocyte macrophage-colony stimulating 
factor (GM-CSF), VEGF) and cytokines (IL-1, IL-6, IL-8), that chemoattract additional 
pro-regenerative cells, such as ECs [365, 368]. Alternative activated macrophages are 
stimulated by, and also produce, high levels of IL-4, IL-10, and IL-13, which are all 
down regulators of pro-inflammatory properties of macrophages. M2 macrophages also 
produce large amounts of arginase, an amino acid whose end degradation products 
function to mediate the production of collagen, enhance tissue repair, and induce cell 
proliferation [366, 368, 372-376]. Their inflammation resolving capabilities are thought 
to be due to LXA4 in the environment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Schematic describing macrophage phenotypes and their roles in inflammation 
and wound healing. Reprinted from [369]. 
 
In previous studies, macrophage phenotype has been directly correlated to the 
healing outcome of an implanted biomaterial; an implant that is dominated by M1s has 
resulted in chronic inflammation and the formation of a fibrotic capsule, while a wound 
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site that promotes an M2 response results in immunoregulation and constructive tissue 
remodeling [370, 371]. Although it may appear that the ideal scenario would be to have 
all M2s residing at a wound site, it has been demonstrated that macrophage activation is 
plastic, rapid and fully reversible under the influence of different microenvironments, 
suggesting there is a balance in macrophage activation of both phenotypes that allows for 
wound resolution [368, 376]. 
 
Angiogenesis 
Angiogenesis, or the formation of new vessels from pre-existing vessels, is a 
complex process that involves the interaction between vascular cells and the surrounding 
ECM. In wound healing, angiogenesis serves to restore vascular perfusion to damaged 
tissues. This process is critical in order for tissue regeneration and healing to take place, 
especially that of an implanted electrospun bioresorbable vascular graft. As stated 
previously, angiogenesis begins indirectly through the release of factors from 
inflammatory cells, as they are the first cell type to the site of implantation. The secretion 
of growth factors and chemokines initiate the wound healing process, recruiting various 
pro-angiogenic cells to the implant site where, in order for angiogenesis to take place, 
they must be able to migrate and infiltrate through capillaries or tunnels that have been 
created through by macrophages. ECs are the main cell type involved in angiogenesis and 
repair of vascular implants, as they penetrate the basement membrane and migrate into 
the graft where they form functional new vasculature in response to stimuli from 
inflammatory cells. This involves extravasation through the graft wall, proliferation, 
sprout and lumen formation and branching of sprouts to form networks [377]. Capillaries 
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that are formed vascularize the construct, providing a blood supply to deliver oxygen and 
nutrients through the graft, so further regeneration can occur [378]. In addition, ECs from 
the periphery of the graft must migrate through to the luminal side, aiding other EPC and 
EC from the blood stream in creating an EC lining. It is important to recognize that 
angiogenesis is more than a simple response by one cell type to growth factors, but 
rather, results from an intricate and complex balance between inflammatory and vascular 
cells in response to pro- and antiangiogenic agents, whose expression might vary between 
neighboring microenvironments [379].  
In this study we investigate the potential for electrospun PCL incorporated with 
and without PRGF and heparin to promote EC proliferation, migration (chemotaxis), and 
sprout formation. In addition, macrophage phenotype, as determined by TNF-α and IL-10 
release, in response to electrospun bioactive vascular graft materials was investigated 
over time. The hypothesis of this study is that the release of PRGF from electrospun 
scaffolds will chemoattract pro-regenerative type macrophages; the corollary to this being 
that the PRGF incorporated scaffolds will promote proliferation and migration of ADSCs 
in vitro. The ability of macrophages to be driven towards a pro-regenerative phenotype 
on these structures, and the preliminary investigation of  EC sprout formation in the 
presence of PRGF, will provide insight into the potential for this vascular graft to become 
successfully regenerated. 
 
 
 
 
 162 
 
Materials and Methods 
Creation of PRP and PRGF  
The same PRP/PRGF that was created and used in Chapter 7 was also used for 
this study. 
Chemotactic Effect of PRGF 
 To determine the role that powdered PRGF had on macrophage and EC 
chemotaxis, and to demonstrate that lyophilized PRGF retained viable chemotactic 
proteins, PRGF was dissolved in either macrophage media (RPMI 1640, supplemented 
with 10% FBS, 1% pennicillin/streptomycin) or complete EC medium (M199 Media 
supplemented with 10% FBS, 1% penicillin/streptomycin, Glutamax 100x, G418, heparin 
sodium salt (50 µg/ml), and endothelial cell growth supplement (ECGS, 50 µg/ml)) in a 
range of concentrations (0, 0.1, 1, 5, and 10 mg/ml). Using a 24-well Transwell plate with 
8 µm diameter pores (Corning, Inc.), 600 µl of PRGF containing media was placed in the 
bottom wells, while the top insert was seeded with 50,000 murine peritoneal 
macrophages (ATCC, TIB 186) or human pulmonary microvascular endothelial cells 
(HPMEC, received generously from Dr. C.J. Kirkpatrick) in 200 µl of control media for 
72 or 168 hours (n=3). Following the duration of the experiment, an MTS assay 
(Promega) was performed to determine the average number of cells that had migrated to 
the bottom well. 
 
Chemotactic Effect of PRGF and Heparin Incorporated Scaffolds 
To determine the role that the electrospun PRGF constructs with and without 
heparin had on macrophage and EC chemotaxis, 10 mm diameter disks were punched, 
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disinfected (30 min. soak in ethanol followed by three 10 min. rinses in PBS) and placed 
in the bottom of a 24-well Transwell plate (8 µm diameter pores, Corning, Inc.). The 
bottom wells consisted of 600 µl macrophage or EC media, along with control media 
with and without 1 mg/ml PRGF and 0.05% or 0.5% filtered heparin. The top insert was 
seeded with 50,000 murine peritoneal macrophages or HPMEC in 200 µl of control 
media for 72 or 168 hours (n=3). Following the time duration, the average numer of cells 
that had migrated was determined by performing an MTS assay (Promega). 
 
Proliferative Effect of PRGF on Endothelial Cells 
To determine the effect PRGF had on EC proliferation, PRGF was dissolved in 
complete EC medium in a range of concentrations (0, 0.1, 1, 5, and 10 mg/ml). HPMEC 
were seeded at a density of 50,000 cells/well in 500 µL media (n=3). At days 1, 4 and 7, 
an MTS assay (Promega) was performed to determine the average cell number.  
 
Effect of PRGF and Heparin Incorporated Scaffolds on Cell Proliferation 
To determine the mitogenic potential of PRGF and heparin incorporated scaffolds 
on macrophages, 10 mm diameter disks were punched from each scaffold, disinfected (30 
min. soak in ethanol followed by three 10 min. rinses in PBS) and placed in a 48-well 
plate (n=3). Each scaffold was seeded with 50,000 murine peritoneal macrophages 
(ATCC, TIB 186) in 500 µl macrophage media. Control wells consisted of macrophages 
cultured on tissue culture polystyrene (TCPS) in media with and without 1 mg/ml PRGF 
(TCPS:PRGF). On days 1, 4 and 7, macrophage proliferation was analyzed using an MTS 
assay (Promega). 
 164 
 
This study was then replicated with HPMEC. Similar to the macrophages, 
disinfected 10 mm diameter disks of each scaffold were placed in a 48-well plate and 
were seeded with 25,000 cells/well in 500 µl complete EC media. HPMEC proliferation 
was determined by performing an MTS assay at days 1, 4 and 7. 
 
Released PRGF Effect on Cell Proliferation 
To determine the mitogenic potential of the PRGF released from the electrospun 
scaffolds that were cultured in the presence or absence of macrophages on HPMECs and 
ADSCs, 10 mm diameter disks of each electrospun material were punched, disinfected 
(30 min, soak in ethanol followed by three 10 min. rinses in PBS), and placed in a 48-
well plate (n=3). Each well was then seeded with 300,000 human peripheral blood 
macrophages (ATCC, CRL9855) in 500 µl MSFM, as well as in a control TCPS well 
containing MSFM with and without 1 mg/ml PRGF added (TCPS:PRGF). The 
macrophage conditioned media was removed daily and used as a media supplement for 
HPMECs and ADSCs (200 µl MSFM with 300 µl HPMEC media or ADSC media 
(DMEM low glucose, 10% FB, 1% penicillin/streptomycin, (Invitrogen)) cultured on 
TCPS (25,000 cells/well) in a separate 48-well plate. HPMEC and ADSC proliferation 
was analyzed using an MTS Assay (Promega) at days 1, 4, and 7. 
This study was then replicated without the use of macrophage conditioned media 
to isolate the impact of the released PRGF on HPMEC and ADSC proliferation. That is, 
disinfected 10 mm diameter disks of each electrospun material were placed in a 48-well 
plate with 500 µl HPMEC or ADSC culture media. Media was removed daily and used as 
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a supplement for HPMECs or ADSCs cultured at 25,000 cells/well. HPMEC and ADSC 
proliferation was determined with an MTS Assay (Promega) at days 1, 4, and 7.  
 
Evaluation of Cell Interaction 
 To determine the response of human cells on the PRGF containing scaffolds, 10 
mm diameter disks from each electrospun scaffold were punched, disinfected (30 min. 
soak in ethanol followed by three 10 min. rinses in PBS), and placed in a 48-well plate. 
Each scaffold was then seeded with 25,000 HPMEC in 500 µl EC media or 50,000 
human ADSC cultured in 500 µl ADSC culture media. Media was changed every third 
day, and HPMEC samples were removed from culture and fixed in 10% buffered 
formalin at day 14 for DAPI staining, while ADSC samples were removed from culture 
and fixed in buffered formalin on days 7 and 21 for Hematoxylin and Eosin (H&E) 
staining.  
 
Effect of PRGF and Heparin Incorporated Scaffolds on Chemokine Release from 
Macrophages 
To determine the release of M1 and M2 chemokines from macrophages cultured 
on the PRGF and heparin containing scaffolds, 10 mm diameter discs were punched, 
disinfected, and placed in a 48-well plate. Each scaffold was then seeded with 50,000 
murine peritoneal macrophages in 500 μl macrophage media. In addition, macrophages 
were also seeded on TCPS without and with 1 mg/ml PRGF (TCPS:PRGF) and 0.05% 
and 0.5% heparin. For positive controls, macrophages were cultured on TCPS in media 
containing 100 ng/ml lipopolysaccharide (LPS, Sigma-Aldrich) plus 20 ng/ml IFN-γ 
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(PeproTech, for M1 polarization) or 20 ng/ml IL-4 (PeproTech, for M2 polarization). 
Macrophages were cultured in standard conditions (37°C, 5% CO2) and supernatant was 
collected on days 1, 4, 7, and 14. Simultaneously, an MTS assay was performed to 
determine macrophage number on days 1, 4, 7, and 14. TNF-α (Antigenix America, Inc.) 
and IL-10 (PeproTech) ELISAs were performed per manufacturer‟s protocol to quantify 
the amount of M1 (pro-inflammatory, TNF-α) and M2 (pro-regenerative, IL-10) 
chemokine being released. These results were normalized to amount of chemokine 
released (ng/ml) per 10,000 cells.   
 
In vitro angiogenesis bead assay 
 A preliminary in vitro angiogenesis bead assay was performed, similar to that of 
Chen, et al. [380]. After Cytodex
®
 microcarrier beads (Sigma) were autoclaved and 
hydrated overnight, 10 µl of bead solution was placed in a 15 ml tube and rinsed three 
times with complete EC medium before being mixed with approximately 1 million 
HPMEC. The tube was incubated in standard conditions (37° C, 5% CO2), with inversion 
of the tube occurring every half hour over 3 hours to ensure cells attached to the beads. 
The media was then removed from the centrifuge tube, placed in a flask and incubated 
overnight. After incubation, beads were rinsed in PBS and transferred back to a 15 ml 
tube. Once the beads had settled to the bottom, any remaining media was removed, and 
beads were washed once more with PBS. After allowing the beads to settle to the bottom 
of the tube a second time, the beads with adherent cells were resuspended in a collagen 
gel solution (80% liquid Purecol with 10% 0.1M NaOH and 10% 10X PBS) containing 
1000 KIU/ml aprotinin (Sigma). Simultaneously, 250 µl of collagen gel solution with 
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aprotinin was placed in the bottom of a 24 well plate and incubated at standard conditions 
until gelation occurred. Once the first layer was gelled, 250 µl of cell suspension was 
placed on the first collagen gel layer and was incubated for 2 hours to again allow for 
gelation. PRGF was then dissolved in EC media (0, 0.1, 1, 5 and 10 mg/ml) and 500 µl 
was placed on top of the gel solution containing the cell covered beads and incubated in 
standard conditions for 6 days. At days 1, 4 and 6, images were captured using a Nikon 
Eclipse TE200 microscope with a Dage-MTS digital camera. Three images were taken 
for each PRGF concentration at each time point. To quantify the percentage of HPMEC 
sprouts per bead, a circular grid was overlayed onto each bead, dividing it into 36 
sections. All sprouts extending from the surface of the beads were counted, summed, and 
divided by 36 to determine the percentage of sprouts for each bead. In addition, the 
length of each sprout extending from the surface of the beads was quantified using 
ImageTool 3.0 software (Shareware provided by UTHSCSA). Results are presented as 
average sprout length per bead (n=3).  
 
Statistical Analysis 
 All statistical analysis was based on a Kruskal–Wallis one-way ANOVA on ranks 
and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with 
the JMP IN 8.0 statistical software package (SAS Institute, Inc.). Graphical depictions of 
mean data were constructed with Microsoft Excel 2007, with error bars representing 
standard deviations. 
 
 
 168 
 
Results 
Chemotactic Effect of PRGF on Macrophages and HPMEC 
 The results of macrophage chemotaxis in response to a dose of PRGF dissolved in 
media are shown in Figure 7.2. Macrophage chemotaxis increased with the amount of 
PRGF, except for 0.1 mg/ml. While a trend is somewhat apparent, the only value that was 
significantly different from the group was the 10 mg/ml PRGF concentration, potentially 
indicating an ideal concentration for stimulating macrophage chemotaxis. 
 
Figure 7.2. Results of macrophage chemotaxis in response to PRGF dose. * indicates 
statistically significant differences, p < 0.05, compared to all other groups. 
 
 HPMEC chemotaxis results in response to different concentrations of PRGF 
dissolved in media are illustrated in Figure 7.3. With the exception of 1 mg/ml, HPMEC 
chemotaxis appeared to significantly increase with increasing concentrations, however, 
the results obtained from the MTS assay for the amount of HPMECs that did migrate for 
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10 mg/ml and 5 mg/ml PRGF seems questionable. Compared to the 50,000 cells that 
were originally seeded on the insert, the fact that 250,000 HPMECs migrated to the 
bottom wells seems almost impossible. The reason for this may have been due to excess 
PRGF left in the well at the time of the experiment, which may have skewed the results 
of the MTS assay. 
 
 
Figure 7.3. HPMEC chemotaxis to PRGF dissolved in media at different concentrations. 
*signifies statistical significance, p<0.05, compared to all other concentrations. 
 
Chemotactic Effect of PRGF and Heparin Incorporated Scaffolds 
Results from the Transwell assay to determine the chemotactic effect of heparin 
and PRGF incorporated scaffolds on macrophages is illustrated in Figure 7.4. PRGF 
containing scaffolds did not have a significant chemotactic effect on macrophages over 
PCL control scaffolds. This may be due to the duration of the experiment; because of 
limited amounts of nutrients in the top inserts of the Transwells, cells may have migrated 
to the bottom wells within the 72 hours regardless of PRGF concentration. In contrast, the 
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addition of heparin at 0.05% and 0.5% did have a significant effect on macrophage 
chemotaxis. Specifically, macrophage chemotaxis was significantly decreased for TCPS 
with heparin compared to TCPS without heparin. Surprisingly, PCL:PRGF(10) scaffolds 
not containing heparin had a significantly lower chemotactic effect than those same 
scaffolds with 0.05% heparin. As mentioned previously, the increase in chemotaxis of the 
PCL:PRGF(10) heparin containing scaffolds may be due to the inconsistent inclusion of 
heparin throughout the scaffolds.  
 
Figure 7.4. Effect of heparin and PRGF on macrophage chemotaxis. * denotes statistical 
significance (p<0.05) between material groups with and without heparin.  
  
The results of HPMEC chemotaxis in response to heparin and PRGF containing 
scaffolds over 168 hours is displayed in Figure 7.5 and illustrates there are no significant 
differences in chemotaxis between scaffolds and TCPS with and without heparin. 
Additionally, there were no significant differences in chemotaxis for scaffolds with and 
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without PRGF, alluding to the fact that electrospun PRGF and heparin containing 
scaffolds may not be chemoattractant towards HPMECs.  
 
Figure 7.5. HPMEC chemotaxis in response to PRGF and heparin. 
 
 
Proliferative Effect of PRGF on Endothelial Cells 
 Results from the MTS assay performed to determine the effect of PRGF on 
endothelial cell proliferation are illustrated in Figure 7.6. At day one, there are no 
differences in cell proliferation, however, at day 4, HPMECs cultured in PRGF at 5 and 
10 mg/ml are statistically different from those cultured in media control. By day 7, 
HPMECs cultured in 0.1, 1, and 5 mg/ml PRGF are significantly different than cells 
cultured in media control.  
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Figure 7.6. Results of HPMEC proliferation over 7 days when cultured in PRGF in 
media at different concentrations. # and $ signifies statistical significance in proliferation 
over media control at day 4 and day 7, respectively (p<0.05). 
 
PRGF and Heparin Incorporated Scaffolds’ Effect on Cell Proliferation 
Proliferation of macrophages when cultured on PCL and PRGF incorporated 
scaffolds with and without heparin are shown in Figure 7.7. There were no significant 
differences comparing macrophages cultured on PRGF incorporated scaffolds versus 
PCL control over the 14 days (Figure 7.7, top). Cells cultured on TCPS with 1 mg/ml 
PRGF had significantly greater proliferation at day 4 than those cultured on TCPS control 
at day 4. Although PRGF caused a significantly higher proliferation of macrophages at 
day 4, PRGF incorporated scaffolds as well as TCPS:PRGF did not cause significantly 
greater proliferation than their controls, implying PRGF may not have an impact on 
macrophage proliferation. 
 The incorporation of heparin at different concentrations had some effect on 
macrophage proliferation, as illustrated in Figure 7.7, bottom (represented by $, ^, @, +); 
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however, it was inconsistent between the two different amounts of heparin. At day 1, 
PCL+0.05% heparin and PCL:PRGF(10)+0.5% heparin scaffolds had significantly 
increased proliferation over PCL+0.5% and PCL:PRGF(10)+0.05% heparin scaffolds. At 
day 4, PCL and TCPS:PRGF with 0.05% heparin had significantly higher proliferation 
over their substrate counterparts with 0.5% heparin. PCL:PRGF(10) and PCL:PRGF 
scaffolds with 0.05% heparin had statistically significant proliferation at day 7 over their 
scaffold counterparts with 0.5% heparin. At day 14, TCPS:PRGF+0.5% heparin had 
significantly higher proliferation than TCPS:PRGF+0.05% heparin. There were 
significant differences (denoted by *, #, %, &) in cell proliferation when comparing 
macrophages cultured on PRGF incorporated scaffolds and TCPS:PRGF with heparin to 
cells cultured PCL control scaffolds and TCPS, however, there were no consistent 
significant increases or decreases in proliferation between any of the PRGF incorporated 
scaffolds and TCPS and control groups. Macrophages cultured on PCL:PRGF(100) 
scaffolds with heparin had significantly lower proliferation at days 1 and 4 then PCL 
control scaffolds with heparin. TCPS:PRGF with heparin (0.05% and 0.5%) had 
significantly greater proliferation at day 14 than those cultured on TCPS control with 
heparin. These results demonstrate the incorporation of PRGF and/or heparin to PCL 
scaffolds does not have a direct effect on the proliferation of macrophages. In both cases, 
there were no consistent increases or decreases in macrophage number over the 14 day 
time period. 
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Figure 7.7. Top: Proliferation of macrophages cultured on PCL and PRGF containing 
scaffolds over 14 days.  # signifies statistical significance, p<0.05, between cells cultured 
on TCPS and TCPS:PRGF at day 4. Bottom: Macrophage proliferation results when 
cultured on PCL and PRGF incorporated scaffolds with heparin (0.05% and 0.5%). *, #, 
%, & denotes statistical significance (p<0.05) of cell proliferation between scaffolds and 
TCPS incorporated with PRGF and heparin and PCL and TCPS with heparin control 
groups at days 1, 4, 7 and 14 respectively. $, ^, @, + signifies statistical significance, 
p<0.05, between scaffolds of the same material groups with 0.05% or 0.5% heparin for 
days 1, 4, 7, and 14 respectively. 
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Results of HPMEC proliferation are illustrated in Figure 7.8. Statistical analysis 
revealed cells cultured on scaffolds with 100 mg/ml or 200 mg/ml PRGF had 
significantly lower proliferation than those cultured on PCL control scaffolds on days 1, 4 
and 7 (Figure 7.8, top). Also on day 7, HPMECs cultured on TCPS with 1 mg/ml PRGF 
in media had significantly higher proliferation than those cultured on TCPS control, 
while at day 14, cells cultured in TCPS:PRGF had significantly lower proliferation than 
those cultured on TCPS. HPMEC proliferation on scaffolds incorporated with PRGF at 
high concentrations may be explained by increased cell infiltration into the scaffolds 
(investigated in Figure 7.13 below). If cells have penetrated into electrospun scaffolds, 
the MTS solution does not have adequate time to diffuse into the cells within the 
scaffolds, and therefore, the assay does not provide accurate results. Additionally, 
activated TGF-β1 present in the electrospun PRGF incorporated scaffolds may also be the 
reason for low HPMEC proliferation. TGF-β1 has been shown to be inhibitory to EC 
proliferation at levels ranging from 10 pg/ml – 10 ng/ml [381] and the electrospun 
PCL:PRGF(100) scaffolds analyzed in Chapter 6 had detectable TGF-β1 levels ranging 
from 0.6 – 1 ng/ml over 21 days (Figure 6.8(a)). Although TGF-β1 was also detectable in 
PRP and PRGF in media, this was only possible after subjecting the PRP and PRGF to an 
acid activation treatment (data not published). The significantly lower proliferation that 
was observed with cells cultured in TCPS:PRGF over those cultured in TCPS at day 14 
may be due to cell apoptosis caused by a loss of nutrients because of cell confluency.  
The addition of heparin at different amounts to electrospun scaffolds did not have 
a significantly consistent effect on HPMEC proliferation over the 14 days (Figure 7.8, 
Bottom). There were no significant differences at day 1 between scaffolds of the same 
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type with different amounts of added heparin. At day 4, PCL:PRGF(10)+0.5% heparin 
scaffolds and TCPS+0.05% heparin elicited significantly higher proliferation than their 
counterparts with 0.05% and 0.5% heparin. At day 7, PCL+0.05% heparin and 
PCL:PRGF(10) and TCPS:PRGF with 0.5% heparin added resulted in significantly 
greater proliferation than their same substrate counterparts with 0.5% or 0.05% heparin. 
By day 14, only scaffolds of PCL:PRGF(10)+0.5% heparin had significantly enhanced 
cell proliferation over PCL:PRGF(10)+0.05% heparin. Compared to PCL controls at day 
1, PCL:PRGF(100) scaffolds with heparin had significantly lower proliferation. At day 4, 
PCL:PRGF(100) scaffolds with heparin and PCL:PRGF+0.05% heparin scaffolds elicited 
significantly lower proliferation then PCL control scaffolds, while TCPS:PRGF with 
heparin elicited significantly higher proliferation over TCPS control with 0.5% heparin. 
On day 7, PCL:PRGF(100) and PCL:PRGF scaffolds with heparin both resulted in 
significantly decreased proliferation over PCL control scaffolds with heparin, whereas 
TCPS:PRGF with heparin elicited significantly higher proliferation compared to TCPS 
control with heparin. PCL:PRGF(100) scaffolds with heparin resulted in significantly 
lower proliferation at day 14 compared to PCL+0.05% heparin control scaffolds. The 
decrease in proliferation seen on scaffolds with a high concentration of PRGF, again, is 
most likely due to the activated TGF-β1 being released. The fact that PCL:PRGF(10) 
scaffolds with 0.5% heparin had significantly increased proliferation over their 
counterparts with 0.05% heparin may be explained by the large amount of heparin 
available to bind to more growth factors, and therefore, more growth factors available for 
cells to detect. However, that is the only scaffold type that followed that trend. Previous 
studies that have investigated the effect of heparin on EC proliferation have reported 
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varying results as well. One study concluded that the proliferative effect of heparin on 
ECs was variable between 7 identical experiments: EC proliferation was stimulated in 
four of the experiments, but was unaffected in the other three [382]. Heparin ranging 
from 5 U/ml – 500 U/ml has been shown to enhance EC proliferation in other studies, but 
only when bound with a growth factor such as FGF-1, or ECGS [383, 384]. In the 
instance where heparin was bound to FGF-1, mitogenic activity only took place when the 
bond between the FGF-1 and heparin was broken [383]. Seeing as how the heparin added 
to scaffolds in this study was around 100 U/ml and 1000 U/ml, and was most likely 
bound to several growth factors in the PRGF, one might expect an increase in HPMEC 
proliferation on scaffolds with 0.5% heparin. The inconsistency in proliferation, however, 
was not specifically investigated, and further studies will need to be completed to 
determine the effects of heparin on HPEC proliferation. 
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Figure 7.8. Top: Proliferation of HPMECs when cultured on PCL and PRGF containing 
scaffolds without heparin. *, #, %, & denotes statistical significance (p<0.05) of HPMEC 
proliferation when compared to PCL or TCPS control for days 1, 4, 7 and 14, 
respectively. Bottom: Proliferation of HPMECs when cultured on PCL and PRGF 
incorporated scaffolds with 0.05% or 0.5% heparin. *, #, %, & indicates significant 
differences, p<0.05, compared to cell proliferation on PCL and TCPS control substrates 
with heparin on days 1, 4, 7 and 14 respectively. $, ^, @, + signifies statistical 
significance, p<0.05, between scaffolds of the same material groups with 0.05% or 0.5% 
heparin for days 1, 4, 7, and 14 respectively. 
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Released PRGF Effect on Cell Proliferation 
To determine the role that PRGF had in the secretion of macrophage growth 
factors, HPMEC and ADSCs were cultured in media conditioned by macrophages 
exposed to released PRGF. The effect of macrophage conditioned medium on HPMEC 
proliferation is shown in Figure 7.9. HPMEC cultured in preconditioned media from 
macrophages that were cultured on PRGF incorporated scaffolds proliferated as expected, 
increasing over the 7 days. Statistical analysis revealed there to be no significant 
differences between cells cultured in media from different material groups on days 1, 4 
and 7. However, HPMEC cultured in preconditioned media from macrophages cultured 
on PRGF incorporated scaffolds exhibited higher proliferation by day 7 over that from 
PCL control scaffolds, with the highest proliferation occurring in media from PCL:PRGF 
scaffolds. 
 
Figure 7.9. Results of HPMEC proliferation when cultured with macrophage 
preconditioned medium. 
 
 180 
 
 HPMEC proliferation when cultured in preconditioned media without 
macrophages is shown in Figure 7.10. At days 1 and 4, with the exception of cells 
cultured in medium from PCL:PRGF scaffolds, there no significant differences in cell 
proliferation. Surprisingly, cells cultured in conditioned medium from PCL:PRGF 
scaffolds had significantly lower numbers than cells cultured in medium from PCL 
scaffolds at days 1 and 4. By day 7, cells cultured in conditioned medium from PCL 
control scaffolds and TCPS had significantly higher proliferation than cells cultured in 
conditioned medium from PRGF incorporated scaffolds and TCPS:PRGF. In comparing 
the results of HPMEC proliferation in conditioned media with macrophages versus 
conditioned media without macrophages, it is very clear that HPMEC proliferation is 
very much affected by macrophage interaction with PRGF scaffolds. When HPMEC are 
cultured in conditioned media without macrophages their proliferation rate is decreased, 
almost 3 times as much. 
 
Figure 7.10. HPMEC MTS assay results when cultured without macrophage 
preconditioned medium. * signifies statistical significance (p<0.05) compared to PCL 
control scaffolds at day 1. # indicates statistical significance, p<0.05, compared to PCL 
control scaffolds at day 4. % denotes significant differences (p<0.05) at day 7. 
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The results of ADSC proliferation, when cultured in macrophage conditioned 
media, demonstrated no significant differences in proliferation at day 1. However, by day 
4 ADSCs cultured in macrophage conditioned media from scaffolds of PCL:PRGF(100) 
had significantly greater proliferation than ADSCs cultured in macrophage conditioned 
media from the PCL and TCPS control, as well as all other scaffolds (Figure 7.11). By 
day 7, there was significantly greater ADSC proliferation in macrophage conditioned 
media from scaffolds of PCL:PRGF(100) and TCPS:PRGF than ADSCs cultured in 
conditioned media from PCL and TCPS control, as well as all other scaffolds. This was 
expected, as it had previously been demonstrated that PRGF, as well as growth factors 
secreted by macrophages, enhanced fibroblast, mesenchymal and stromal stem cell 
proliferation [302, 352, 354-356, 385]. In general, ADSC proliferation in all 
preconditioned media increased from day 1 to day 4, however, by day 7 it appeared that 
proliferation slowed, and in some cases cell number even decreased, potentially due to 
induced contact inhibition as the cells became confluent in the wells, or died off 
following exhaustion of media nutrients. This may also have been due to the fact that the 
conditioned media used for the ADSCs was macrophage serum free media, which is 
unfavorable over the long-term for ADSC growth, or due to harmful factors expressed 
during macrophage apoptosis [386]. From the results in Figure 7.7, it is evident that the 
effect of macrophages on ADSC proliferation was due to macrophage interaction with 
PRGF containing scaffolds, and not merely macrophage number. 
 182 
 
 
Figure 7.11. Results of ADSC MTS assay when cultured with macrophage conditioned 
media. * and # indicate statistically significant differences, p < 0.05, between material 
groups at day 4 and day 7, respectively. 
 
ADSC proliferation when cultured in PRGF conditioned media without 
macrophages is displayed in Figure 7.12. Overall, ADSCs proliferated from day 1 to day 
4 (with a few exceptions), and from day 4 to day 7, as expected. After day 1 and 4, there 
were no significant differences in ADSC proliferation for any scaffold. By day 7, 
compared to ADSCs cultured in media from the TCPS control, cells cultured in media 
from PCL:PRGF scaffolds had significantly greater proliferation. These results suggest 
that the presence of PRGF does impact ADSC proliferation, and corroborates previously 
published work [302, 352, 354-356]. It is clearly evident from these studies that the 
proliferation of ADSCs, cultured in conditioned media, is different depending on the 
presence or absence of macrophages and macrophage secreted factors over the 7 day 
study duration, and will be discussed further in the following section.  
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Figure 7.12. Results of ADSC MTS assay when cultured without macrophage 
conditioned media. # indicates statistically significant differences, p < 0.05, between 
PRGF containing scaffolds and the TCPS control at day 7. 
 
EC Interaction on PRGF scaffolds 
 In order to elucidate the results from the MTS assay for HPMECs, scaffolds were 
fixed, sectioned, and stained for DAPI at the end of the 14 day time period. Figure 7.13 
displays HPMECs cultured on PCL and PRGF containing scaffolds with and without 
heparin. Cells cultured on PCL and PCL:PRGF(10) scaffolds with and without 0.05% 
and 0.5% heparin appear to remain on the surface of the scaffolds after 14 days, with 
minimal to no infiltration occurring. In contrast, scaffolds incorporated with PRGF at 100 
mg/ml and 200 mg/ml exhibit HPMEC infiltration, particularly throughout those 
scaffolds without heparin. This outcome may explain why there was decreased cell 
proliferation, as determined by the MTS assay, in scaffolds incorporated with high 
amounts of PRGF both with and without heparin. 
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Figure 7.13. DAPI staining of HPMECs cultured on PCL and PRGF containing scaffolds 
with and without heparin. Images taken at 20X. 
 
Evaluation of ADSC Interaction 
 The results of the H&E staining are shown in Figure 7.14. H&E staining revealed 
confluent layers of ADSCs on the surfaces of the control scaffolds by day 7, while 
increased PRGF content resulted in increased cellular penetration into the scaffold. 
Surprisingly, after only 7 days ADSCs had migrated through a quarter of the thickness of 
the PCL:PRGF scaffold. By day 21 this trend was even more apparent, with clear cell 
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migration through nearly the entire thickness of the PCL:PRGF scaffold (Figure 7.12). 
The PCL:PRGF(100) scaffold demonstrated a similar result, with the electrospun 
synthetic PCL material traditionally being difficult to cellularize in vitro [297-299], as it 
too exhibited increased cellular penetration when compared to the PCL scaffold 
containing no PRGF. 
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Figure 7.14. H&E staining of PCL scaffolds at day 7 and 21. Images at 20x. High 
magnification (40x) images of PCL:PRGF scaffolds shown in bottom row, demonstrating 
significant cellular penetration. 
 
Effect of PRGF and Heparin on Macrophage Phenotype 
 Figure 7.15(a) below shows the results of IL-10 release from macrophages 
cultured on PCL and PRGF incorporated scaffolds and TCPS with and without 1 mg/ml 
PRGF. With the exception of day 7, in most cases, IL-10 release from macrophages 
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increased throughout the 14 days. At days 1, 4, and 7 there were no significant 
differences between the different scaffold types and control groups. However, by day 14, 
scaffolds with increased amounts of PRGF (PCL:PRGF(10), PCL:PRGF(100), 
PCL:PRGF) elicited higher IL-10 release from macrophages over control groups (PCL 
scaffolds and M2s), and was significantly different for PCL:PRGF(10) scaffolds. Another 
point worth noting is that, in general, IL-10 release was higher from macrophages 
cultured on electrospun scaffold materials than it was for the positive control (M2) at all 
time points. These results indicate PRGF, as well as electrospun structures overall, may 
have the ability to enhance the release of IL-10 from macrophages, possibly driving them 
towards the M2 phenotype. 
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Figure 7.15(a). Macrophage IL-10 release when cultured on PRGF incorporated 
scaffolds, TCPS and media supplemented with 1 mg/ml PRGF (TCPS:PRGF). Results 
are normalized to amount of IL-10 released (ng/ml) per 10,000 cells. % denotes statistical 
significance (p<0.05) over PCL and M2 control at day 14. Minimum level of detection is 
0.002 ng/ml (dashed line). 
 
 The results of IL-10 release from macrophages cultured on PRGF and heparin 
incorporated scaffolds and TCPS with and without 1 mg/ml PRGF and 0.05% and 0.5% 
heparin are shown in Figure 7.15(b). In general, IL-10 release from macrophages cultured 
on PRGF and heparin-containing scaffolds appeared to be highest at early time points 
(days 1 and 4), and decreased thereafter. Overall, the addition of heparin to scaffolds in 
different amounts did not elicit significant differences in IL-10 release from 
macrophages, with the exception of PCL:PRGF(100)+0.05% heparin and 
TCPS:PRGF+0.5% heparin. In both cases, there was a significantly greater release of IL-
10 when compared to PCL:PRGF(100)+0.5% heparin and TCPS:PRGF+0.05% heparin. 
IL-10 release at day 4 was significantly higher from macrophages cultured on 
PCL:PRGF(100) scaffolds with 0.05% heparin compared to PCL control scaffolds with 
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same amounts of heparin, as well as TCPS:PRGF+0.5% heparin compared to TCPS 
control with 0.05% and 0.5% heparin. At day 7, scaffolds with 100 mg/ml PRGF and 
heparin elicited significantly higher IL-10 release compared to PCL control scaffolds and 
at day 14, PCL:PRGF(100) scaffolds with 0.5% heparin had significantly higher IL-10 
release than PCL control scaffolds with the same amount of heparin. In comparing IL-10 
levels from figure 7.15(a), the addition of heparin, in general, appeared to increase the 
release of IL-10 from macrophages over all, with higher levels released at early stages, 
and decreased thereafter. These results may suggest macrophages cultured on heparin 
incorporated scaffolds may begin as M2s, but over time may undergo a change in 
phenotype. 
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Figure 7.15(b). IL-10 release from macrophages cultured on PRGF incorporated 
scaffolds, TCPS, and TCPS with 1 mg/ml PRGF with the addition of 0.05% or 0.5% 
heparin. Results are normalized to amount of IL-10 released (ng/ml) per 10,000 cells. # 
denotes statistical significance (p<0.05) between PRGF incorporated scaffolds and PCL 
control scaffolds with same amounts of heparin, as well as TCPS:PRGF+0.5% heparin 
and TCPS control with 0.05% and 0.5% heparin at day 4. ^ denotes statistical 
significance, p<0.05, between the different amounts of heparin for the same type of 
material substrate for day 4. % indicates statistical significance (p<0.05) at day 7 between 
scaffolds with PRGF and heparin and PCL control scaffolds. & signifies statistical 
significance, p<0.05, for day 14 between PRGF containing scaffolds and PCL control 
scaffolds with the same amount of heparin. Minimum level of detection is 0.04 ng/ml 
(dashed line). 
 
 Figure 7.16(a) shows the results of TNF-α release from macrophages cultured on 
PCL scaffolds with and without PRGF. At days 1 and 4, only the positive M1 control had 
detectable TNF-α release. By days 7 and 14, release on all scaffold types was detectable, 
with statistical significance on PCL:PRGF(10) scaffolds at day 14. Although there was 
no release from the positive M1 control at days 7 and 14 (due to cell apoptosis), the 
amount of TNF-α released on electrospun scaffolds at days 7 and 14 was much lower 
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than that from the positive control at days 1 and 4. Also worth noting is that at day 14, 
TNF-α release from macrophages cultured on all scaffold types was less than that of IL-
10 release at day 14 (except for PCL). These results indicate PRGF and electrospun 
structures overall, did not enhance the release of TNF-α from macrophages over the 
positive control, and may be driving cells towards the M2 phenotype over the M1 
phenotype (as indicated by amount of chemokine released per 10,000 cells). 
 
Figure 7.16(a). Macrophage TNF-α release when cultured on PCL and PRGF containing 
scaffolds, TCPS, and media supplemented with 1 mg/ml PRGF. Results are normalized 
to amount of TNF-α released (ng/ml) per 10,000 cells.  *, #, & indicates significant 
differences, p<0.05, between all other scaffolds at days 1, 4 and 14 respectively. 
Minimum level of detection is 0.0025 ng/ml (red dashed line). 
 
 Figure 7.16(b) shows the results of TNF-α release from macrophages cultured on 
PRGF incorporated scaffolds with heparin. With the exception of PCL:PRGF(100) 
scaffolds with heparin, release of TNF-α from macrophages cultured on scaffolds was 
low at days 1-7, and increased by day 14. Release from cells cultured on TCPS and 
TCPS:PRGF with heparin appeared constant over the 14 days. Similar to IL-10, the 
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addition of heparin in different amounts did not appear to have a significant affect on 
TNF-α release between substrates. In comparing TNF-α levels from figure 7.16(a), the 
addition of heparin, in general, elicited a higher release of TNF-α over the 14 day time 
period. Based on the results shown, because IL-10 release decreased throughout the 14 
days and TNF-α release increased throughout 14 days, heparin may be driving 
macrophages from the M2 phenotype towards the M1 phenotype.  
 
Figure 7.16(b). TNF-α release from macrophages when cultured on PRGF incorporated 
scaffolds, TCPS, and TCPS with 1 mg/ml PRGF with 0.05% or 0.5%  heparin. * 
indicates statistically significant differences, p<0.05, compared to all other material 
groups at day 1. % indicates TNF-α release on scaffolds of PCL:PRGF(100)+0.05% and 
0.5% heparin is significantly different (p<0.05) from that of other scaffolds at day 7 (but 
not each other). & indicates a significant difference, p<0.05, of TNF-α released compared 
to all other materials at day 14 (but not each other). Minimum level of detection is 0.0025 
ng/ml (red dashed line). 
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EC Angiogenesis Bead Assay 
 To determine the ability of PRGF to induce HPMEC sprouting, an in vitro 
angiogenesis assay was performed. Figure 7.17 illustrates the images of HPMEC covered 
beads cultured in media with PRGF at different concentrations, with results of percentage 
of sproutage and sprout length shown in Figures 7.18. At day 1, there was minimal 
sprouting occurring for cells cultured in all PRGF concentrations, with no significant 
differences over media control for percentage of sprouts and length of sprouts. By day 4, 
there were more sprouts visible, as well as an increase in sprout length, however, no 
significant differences were observed for sprout length or percentage of sprouts. At day 6, 
in general, percentage of sprouts did not increase; however, sprout length did increase. 
HPMEC covered beads cultured in 1 mg/ml PRGF elicited a significantly higher 
percentage of sprouts, while HPMEC cultured in 5 mg/ml PRGF revealed a significantly 
higher length of sprouts, compared to that of media control. PRGF dissolved in media at 
high concentrations (10 mg/ml) started clotting over the 6 day time period, making 
sprouts difficult to visualize. This explains why there were no results obtained for 
percentage of sprouts and sprout length for HPMEC cultured in 10 mg/ml PRGF at day 6.  
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Figure 7.17. Sprout formation of HPMEC cultured in media with PRGF (0, 0.1, 1, 5, 10 
mg/ml) at days 1, 4 and 6. Images taken at 20X. 
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Figure 7.18. Results of percentage of HPMEC sprouts (Top) and length of HPMEC 
sprouts (Bottom) when cultured in different concentrations of PRGF in media over 6 
days. % signifies statistically significant differences, p<0.05, at day 6 over media control. 
 
Discussion 
This study provided insight into the potential for PRGF and/or heparin to enhance 
the regenerative capacity of electrospun synthetic scaffolds. Cellular proliferation of 
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HPMEC and ADSC, migration of macrophages, and sprout formation by HPMEC 
confirmed that PRGF did enhance the bioactivity of the electrospun scaffolds. In 
addition, IL-10 release by macrophages, indicative of an M2 phenotype, was enhanced 
over time on PRGF incorporated scaffolds, indicating the potential for the bioresorbable 
vascular graft materials to stimulate a tissue restorative environment.  
PRP has previously been used clinically, and has shown promising results in 
promoting regeneration and angiogenesis in vitro, as well as in vivo, although the 
mechanism behind the success of PRP in this regard has not yet been fully understood. 
Previous studies have shown that PRP can induce proliferation, chemotaxis and tube 
formation in pro-regenerative cell types (mesenchymal stem cells, bone marrow stromal 
stem cells, ECs, SMCs, ADSCs) [354, 387, 388], and enhance the release of pro-
angiogenic growth factors in inflammatory cell types (macrophages). Additionally, 
specific components within PRP (LXA4 and RANTES) have been shown to drive 
macrophages to towards the pro-regenerative phenotype [313]. In a murine model of hind 
limb ischemia, PRP improved perfusion and neovascularization, providing evidence for 
its benefit in vivo [337]. The use of heparin has been previously investigated as a way to 
reduce the thrombogenicity of the graft surface and as a way to regulate EC and SMC 
proliferation. Studies have shown heparin does prevent coagulation build-up from 
occurring on graft surfaces, as well as a reduction of intimal hyperplasia at the 
anastomoses of the graft [343, 389, 390]. In addition, binding of heparin to various 
growth factors has been reported to protect growth factors from inactivation, thereby 
maintaining their biological activity. Conclusions from the literature demonstrate the use 
of PRGF, and/or heparin, may be beneficial for vascular graft applications, as it may lead 
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to graft vascularization in a more timely manner while reducing the risk of thrombosus 
formation or intimal hyperplasia.  
Macrophage and HPMEC chemotaxis was significantly increased when PRGF 
was dissolved in media at certain concentrations; however, electrospun PRGF 
incorporated scaffolds did not elicit a chemotactic response over PCL control scaffolds. 
These results were most likely due to the duration of the experiment, as well as lack of 
nutrients available to the macrophages in the Transwells, and not the effect of the PRGF. 
For HPMECs specifically, chemotaxis may have been hindered because of the TGF-β 
present in the scaffolds. Much like EC proliferation, it has also been previously reported 
that TGF-β1 has an inhibitory effect on EC migration at certain concentrations in assays 
such as the Boyden chamber assay [381]. One way to verify this observation would be to 
add an anti-human TGF-β1 antibody to the EC media, which would specifically block the 
TGF-β1 in the PRGF containing scaffolds. An increase in HPMEC proliferation and 
chemotaxis when cultured on PRGF incorporated scaffolds would prove this theory. The 
results obtained in this study of HPMEC migration towards PRGF in media seem 
questionable, and requires further investigation to determine the true chemotactic effect 
of PRGF on HPMECs.  
Macrophage proliferation was not affected by the addition of PRGF, both 
dissolved in media and incorporated into scaffolds, which is not seen as necessarily a 
negative outcome; during wound healing, macrophages are a critical cell type needed for 
regeneration; however, too many macrophages could result in a pro-inflammatory 
environment and hinder regeneration. Heparin did hinder the migration of macrophages 
at both concentrations (0.05% and 0.5%) over the 72 hours. This same phenomenon has 
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been observed in in vivo settings as well; heparin coated xenografts implanted in rabbits 
elicited less macrophage infiltration and proliferation, and subsequently, a reduction in 
intimal hyperplasia, than the nonheparin-coated grafts up to 3 weeks. This inhibitory 
effect of heparin on macrophage infiltration and proliferation, and succeeding release of 
MCP-1, at early time points was predicted to be one of the main reasons behind the 
decrease in intimal hyperplasia that was observed [390]. 
The present study demonstrated PRGF does enhance the proliferation of HPMEC 
when dissolved in media at certain concentrations, but not when incorporated into 
electrospun scaffolds, most likely due to the activated TGF-β being released from the 
PRGF incorporated scaffolds. The addition of heparin in different amounts to electrospun 
PCL and PRGF incorporated scaffolds did not have a consistent effect on HPMEC 
proliferation overtime. Conclusions stated in the literature vary as well, indicating the 
mechanism by which heparin affects HPMEC proliferation remains to be elucidated. 
Although the hindrance of HPMEC proliferation by PRGF incorporated scaffolds 
may be looked at as a negative, their proliferative response to conditioned media from 
macrophages cultured on PRGF incorporated scaffolds proves these constructs may be 
beneficial in promoting regeneration, and may even serve as a better illustration of what 
would occur in vivo. HPMEC proliferation was not enhanced over the 7 days when 
cultured in conditioned media from scaffolds containing PRGF, however, in the presence 
of macrophages, their proliferation was enhanced. The fact that HPMEC proliferation 
resulted in very different outcomes when cultured in conditioned media with and without 
macrophages makes it clear that HPMEC proliferation was affected the interaction of 
macrophages with PRGF containing scaffolds.  
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In contrast to results seen for HPMEC cultured in conditioned media with and 
without macrophages, ADSC proliferation was enhanced over 7 days when cultured in 
conditioned media from scaffolds containing PRGF versus those not containing PRGF in 
the presence and absence of macrophages. The existence of several growth factors within 
PRGF, and those that were detected from the electrospun constructs, known to induce 
cell proliferation (VEGF, PDGF, IGF, FGF, and EGF, etc.) is most likely the reason for 
enhanced proliferation [302]. Like HPMEC proliferation, ADSC proliferation was 
different throughout the 7 days depending on the inclusion or exclusion of macrophages, 
alluding to the fact that ADSC proliferation was also affected by the interaction of 
macrophages with PRGF containing scaffolds. It is evident from this study that 
macrophage number is not the most critical factor in HPMEC and ADSC proliferation; 
however, the specific mechanism by which macrophage interaction with the scaffolds 
affects HPMEC and ADSC proliferation still remains to be explained. The authors 
hypothesize that the HPMEC and ADSC proliferation seen in this study might be due, in 
part, to the various growth factors and cytokines secreted by the macrophages. It has been 
shown previously that macrophages cultured on electrospun scaffolds have the ability to 
produce high levels of VEGF and FGF [150], and in the presence of PRGF, produce 
additional pro-angiogenic growth factors and cytokines, including those which enhance 
cell proliferation [313]. Additional experiments, whereby specific growth factor and 
cytokine ELISAs are performed on supernatant from macrophages cultured on PRGF 
incorporated scaffolds, would be valuable to validate this explanation. Although ADSC 
proliferation appeared to stop by day 7 when cultured in macrophage conditioned media, 
this was not perceived as a negative effect brought about by the presence of PRGF, rather 
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most likely due to media mismatch and/or harmful factors produced during macrophage 
apoptosis induced by a lack of nutrient supply in the conditioned media [386].   
Cellular migration and penetration was enhanced in scaffolds containing high 
amounts of PRGF by both HPMEC and ADSC. While historically the ability for cells to 
migrate into a synthetic electrospun structure has been viewed as a challenge, and one of 
the major downfalls of standard blood vessel replacements [297-299], the inclusion of 
PRGF yielded structures that were readily infiltrated. The specific reason for this rapid 
infiltration is not yet fully understood, and will need further examination. The presence of 
an array of chemotactic proteins found in large quantities in PRP may be the most logical 
explanation [337, 388]. It may also be an affect of the change in scaffold mechanical 
properties; as shown in Chapter 6, scaffolds with higher PRGF content exhibited 
decreased mechanical properties which may have allowed for cellular migration into the 
scaffold to occur more readily. The presence of PRGF fibers intermingled amongst the 
polymer fibers of the scaffolds, particularly in the case of PCL:PRGF structures, may 
have also provided paths of easy entry into the thicknesses of the structures. These fibers 
of varying diameter had an apparent impact on the porosity of the scaffolds, and as 
verified in Chapter 6, void space within the scaffold increased as PRGF concentration 
increased. 
This enhanced cellular infiltration, regardless of its root cause, may allow for a 
vascular graft to be more rapidly remodeled with native collagen extracellular matrix; the 
production of which would readily supplement the strength of the scaffolds and 
encourage incorporation into surrounding tissues. Although not investigated in this study, 
the many factors found in PRGF have been proven to increase collagen matrix production 
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in a number of cell types [302, 309, 350, 391]. TGF-β, one such well-known matrix 
production-related growth factor, was released by the electrospun scaffolds in detectable 
quantities (shown in Chapter 6), in some cases for up to 21 days. Should the presence of 
TGF-β and the other matrix production enhancing growth factors be actively taken up by 
the cells, it would be possible for accelerated matrix production to occur, and could 
therefore improve the mechanical strength of the weakened PRGF containing scaffolds. 
Specific ECM protein ELISAs, or assays, such as Sircol
TM
 or hydroxyproline, would be 
interesting to complete after culturing matrix-producing cells on PRGF incorporated 
scaffolds, as this may provide insight into matrix production. 
Macrophage phenotype, as analyzed by chemokine release, was found to be 
influenced by PRGF incorporated scaffolds, both with and without heparin. IL-10, a 
chemokine released mainly by M2s, was secreted by macrophages cultured on all 
scaffolds, increasing over time on PCL and PRGF heparin-free scaffolds, and decreasing 
over time on scaffolds containing heparin. Alternatively, TNF-α, a chemokine mainly 
secreted by pro-inflammatory (M1) macrophages, was not detectable in the early stages 
of the experiment, and only increased slightly by day 14. Regardless, TNF-α release by 
macrophages cultured on electrospun scaffolds and TCPS was 2 – 5 times less than that 
of the positive M1 control. Heparin containing scaffolds elicited a TNF-α release that 
increased over time. RANTES, a mediator of inflammatory process, was detected in 
PRGF containing scaffolds, and may play a role in shifting macrophages towards this 
pro-regenerative phenotype. In addition, although LXA4 was not detectable by ELISAs 
from PRGF incorporated scaffolds, this resolving factor has also been shown to drive 
macrophages towards a tissue restorative phenotype [313, 392]. These results provide a 
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positive insight for PRGF incorporated scaffolds to be used in vascular graft applications. 
As macrophages will be one of the first cell types to the scene, their behavior during their 
interaction with these scaffolds is of utmost importance. The fact that these scaffolds do 
not enhance macrophage proliferation, but do promote macrophage chemotaxis and 
secretion of chemokines associated with the pro-regenerative macrophage is extremely 
beneficial in setting the stage to allow other pro-angiogenic cells to arrive to the graft site. 
Using specific phenotypic markers would allow for a more definitive analysis on 
quantifying macrophage phenotype when cultured on PRGF incorporated scaffolds. This 
can be done by immunohistochemically staining samples with a pan macrophage marker 
(CD68), an M1 phenotype marker (CCR7), or an M2 phenotype marker (CD163) and 
counting the number of immunopositive cells in each sample.  
PRGF dissolved in media at specific concentrations also enhanced sprout 
development and sprout length by HPMEC within 4 days. This rapid sprout formation in 
the presence of PRGF is in agreement with results obtained in previously published 
studies, and may be due to the pro-angiogenic chemokines and growth factors that were 
detected in PRGF in this study, as well as others [393]. Although PRGF induced 
increased sprout formation by HPMECs over media control, the ability of these cells to 
form sprouts in control media could be due to the FBS and ECGS supplemented to the 
media. It would be interesting to replicate this experiment with ECs cultured in media 
without FBS or ECGS, as this would give a better depiction of the effect of PRGF alone. 
In addition, an experiment that would give a better representation of what may occur in 
vivo would be to analyze HPMEC sprout and lumen formation in the presence of other 
cells, such as fibroblasts and SMCs. Regardless, as the regeneration, and thus, success, of 
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an implanted bioresorbable vascular graft relies substantially on the ability of the graft to 
become vascularized by cells, the fact that PRGF induces sprout formation by HPMEC 
sheds a positive light on the potential for these scaffolds to be regenerated when used in 
vascular graft applications.   
In looking at the release kinetics of growth factors from scaffolds reported in 
Chapter 6 and their effect on cell proliferation and sprout formation, it can be concluded 
that growth factor release may have a delayed effect on cell proliferation/sprout 
formation. There was a burst release of growth factors at day 1, and a tapering of this 
release thereafter, while cell proliferation, migration and sprout formation was not 
induced from PRGF and PRGF incorporated scaffolds until day 4. It appears there may 
be a delay in activity by cells in response to the growth factors being released. 
Another important point to note is that electrospinning may alter the molecular 
structures of the different components in PRP, thereby effecting growth factor 
bioactivity. As it was briefly mentioned previously, TGF-β was only detectable in PRGF 
and PRP after performing an acid activation technique, while TGF-β was detectable in 
electrospun constructs without the activation. While this TGF-β ELISA was the only one 
to specifically detect a change in molecular structure after electrospinning, there are most 
likely other growth factors that undergo a change during the electrospinning process that 
may not have been detected by the ELISAs. This observation may also explain the 
differences seen in cell behavior when cultured with PRGF versus electrospun constructs. 
Further analysis of the components contained with electrospun PRGF incorporated 
scaffolds, PRP and PRGF, may confirm this explanation. By performing gel 
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electrophoresis, similar to what was done in Chapter 5, or a similar technique, this task 
could be accomplished.  
 In conclusion, the hypothesis stated at the beginning of this chapter for this study 
was proven. PRGF does positively influence the proliferation and sprout formation of 
HPMEC, as well as chemotaxis of macrophages at specific concentrations in vitro. 
HPMEC and ADSC migration into the electrospun constructs was enhanced, and 
although the addition of PRGF into the constructs may have been one reason for this 
outcome, PRGF cannot take full credit. As mentioned previously, increased pore area and 
decreased mechanical strength most likely lead to an increase in cell infiltration as well. 
The PRGF incorporated scaffolds promoted the release of regenerative chemokines from 
macrophages, illustrating their potential to encourage a pro-regenerative environment. As 
one of the major advantages of PRP, when used clinically, is its ability to deliver a milieu 
of growth factors and cytokines at the patients‟ bedside, the creation of an off-the-shelf 
electrospun vascular graft incorporating PRGF from pooled allogenic blood may have the 
same benefits. While the use of pooled blood is typically frowned upon in the United 
States, the use of allogenic PRP has been gaining popularity in a number of European 
studies with no mention of adverse immune reactions [394-396]. These studies illustrate 
PRGF incorporated scaffolds do have the potential to be used in vascular graft 
applications, however, future studies are needed to determine their ability to promote 
angiogenesis and become regenerated in situ. 
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Chapter 8: Conclusions and Future Research 
 
 
 The creation of an ideal bioresorbable vascular graft has been sought after for 
over 50 years, however, the original Dacron and e-PTFE vascular grafts that were first 
used clinically are still the clinical standard. In small-diameter applications, this graft 
fails to perform optimally, illustrating the critical need for an improved vascular graft 
design. The ability for a tissue engineering scaffold to become completely regenerated is 
a daunting task, as it requires constructive interaction between the implant and host tissue 
in a timely manner. The graft material needs to be able to provide the complex and 
interrelated chemical, physical, and biological cues that are needed to affect remodeling. 
Electrospinning is a popular fabrication method that has been used to create 
vascular graft conduits, as it has the ability to consistently produce nanofibrous constructs 
that mimic the native ECM. Furthermore, electrospinning is very versatile, and gives the 
tissue engineer the ability to alter a wide variety of scaffold properties, including the 
material make-up (natural versus synthetic polymers), mechanical strength, fiber 
diameter, pore area, material biocompatibility, etc. Although electrospinning has been 
used extensively in the design of vascular grafts, one of the main criticisms is the 
scaffold‟s inability to allow for cellular penetration, and hence, graft regeneration, while 
maintaining structural integrity throughout the remodeling phase. In this study we 
investigated different ways to alter the mechanical, biological, and regenerative 
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characteristics of an electrospun scaffold with the intention of creating an acellular 
bioresorbable vascular graft that would have the ability to become completely remodeled 
and develop into a fully functioning artery. 
 The first approach was to design a new copolymer whose mechanical and thermal 
properties could be altered to achieve those characteristics desireable for a vascular graft 
implant. DX and DL-3-MeDX were synthesized and copolymerized in different ratios 
and electrospun for the first time, forming nanofibrous scaffolds of different fiber 
diameters. Characterization of scaffold mechanical and thermal properties determined 
that fiber diameter and mechanical performance increased with increasing polymer 
concentration, polymer masses, and crystallinity. More specifically, increasing DL-3-
MeDX content resulted in decreased peak stress, strain at break, and toughness, as well as 
melting and crystallization temperatures. Nevertheless, the mechanical properties of 
many of the electrospun scaffolds of DX:DL-3-MeDX at different ratios did fall within 
the range of mechanical properties of the native femoral artery. While this comparison 
does not necessarily predict whether these materials would have mechanical properties 
conducive for a small diameter vascular graft, it does give some insight into the strength 
and elasticity of the materials compared to native tissue. Further mechanical testing, such 
as burst strength and compliance would need to be done and compared to that of a small 
diameter coronary artery to really determine if the mechanical properties are sufficient. 
Additionally, because DX is comprised of PDO, these scaffolds exhibit rebound and kink 
resistance, another benefit in vascular graft design. The crystallinity of the copolymers 
was shown to change with different MeDX content as well, which would allow for 
controlled biodegradability and would be useful in growth factor delivery applications. 
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The creation of these novel electrospun copolymer scaffolds proved to have mechanical 
and thermal properties that could be conducive for vascular graft applications; however, 
the bioactivity and biocompatibility of these materials were not investigated in this study, 
and would need to be in the future before using these materials in vascular graft 
applications. 
Following this, scaffolds were created from natural and synthetic polymers 
electrospun individually, or blended, and their potential to be used as vascular graft 
materials without an enhanced risk of failure from an acute thrombotic occlusion was 
investigated. Tissue factor expression by monocytes cultured on PDO, PCL, and PCL:silk 
scaffolds was quantified and compared to that of e-PTFE. Silk scaffolds resulted in the 
lowest amount of TF expression by monocytes, while PDO elicited the highest amount of 
TF expression. Expression of TF on electrospun scaffolds was lower, or as much as TF 
expression from monocytes cultured on e-PTFE. This study provided a positive insight 
for the ability of electrospun grafts of PDO, PCL, silk, or PCL:silk to be successfully 
used in tissue engineering applications without an increased risk of failure due to an acute 
thrombotic occlusion when compared to that of the standard e-PTFE graft. While this is a 
very important aspect to investigate for vascular graft implants, the experiments 
performed in this study do not clearly answer whether these electrospun scaffolds would 
or would not elicit the formation of an acute thrombosus, and therefore, future testing 
would need to be completed to confirm this.   
Electrospun scaffolds were also created out of aPRP, a naturally occurring blood 
component, as a way to provide a sustained release of physiological proteins known to 
improve healing and regeneration and enhance overall scaffold bioactivity. Human PRP 
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was activated, lyophilized to form PRGF and electrospun for the first time to produce 
scaffolds which consisted of nano- to micron sized fibers. These scaffolds were stable for 
an extended period of time in vitro, which was found to be mainly because of the 
fibrinogen backbone, and exhibited a sustained release of proteins for up to 35 days. 
Additionally, these electrospun PRGF scaffolds promoted cellular infiltration within just 
3 days. The presence of a variety of growth factors and chemokines inherent to PRP 
proved to enhance the bioactivity of the scaffolds, even after being dissolved in a harsh 
organic solvent and exposed to high voltages during the electrospinning process. These 
scaffolds could be beneficial if used in vascular graft applications, as the release of 
growth factors in PRP would most likely encourage wound healing and regeneration, 
however, to achieve the mechanical strength needed for a vascular graft they would need 
to be blended with synthetic polymers. Mechanical testing was not performed on pure 
PRGF constructs due to the fragility of the scaffolds after electrospinning.   
Finally, incorporating PRP at different concentrations into electrospun scaffolds 
comprised of PCL was investigated as a way to enhance scaffold bioactivity while 
providing sufficient mechanical stability required of a blood vessel replacement. Heparin 
was also added to the scaffolds as a dual purpose: to reduce the thrombogenicity of the 
graft surface and to modulate the release of growth factors in PRP. Mechanical testing of 
these scaffolds proved that even with the addition of PRGF and heparin, with the 
exception of 100 mg/ml, these scaffolds have mechanical properties that are conducive to 
those needed for a vascular graft. A variety of growth factors known to be in PRP, 
including RANTES, PDGF-BB, TGF-β, were successfully detected to be released from 
the electrospun constructs, however, their molecular composition may undergo a change 
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during the electrospinning process. Additionally, VEGF, SDF-1α, and LXA4 were 
detected when PRGF was dissolved in PBS. The release of these growth factors was 
shown to have an impact on cellular infiltration into the scaffolds by HPMEC and ADSC 
in as little as 7 to 14 days. Conditioned media from macrophages after being cultured on 
these scaffolds also proved to enhance HPMEC and ADSC proliferation. PRGF was also 
chemotactic towards macrophages at certain concentrations, and stimulated sprout 
formation by HPMEC, promoting an increase in number and length of sprouts over media 
controls in just 6 days. Evaluation of macrophage phenotype showed scaffolds without 
heparin drove macrophages towards a pro-regenerative type, while scaffolds with heparin 
elicited a change in macrophage phenotype, from pro-regenerative to pro-inflammatory 
over time. All in all, these scaffolds, specifically those of PCL:PRGF, have proven they 
could be used as a bioresorbable vascular graft, and would allow for cellular infiltration, 
sprout formation, and remodeling, while retaining mechanical strength over time.  
 The results of this study highlight some of the ways that electrospinning can be 
used to tailor the properties of scaffolds for vascular graft applications. Through simple 
solutions, like electrospinning natural and synthetic polymers with different mechanical 
and thermal characteristics, to adding bioactive factors, the requirements needed for the 
design of a successful vascular graft can be achieved. In considering one specific scaffold 
for use as a vascular graft, the PCL:PRGF scaffold may be the most successful. 
Mechanical properties were conducive to that of a vascular graft, endotoxin levels were 
not elevated above standard limits, release of regenerative and pro-angiogenic growth 
factors were detectable, cell infiltration was promoted, and macrophages exhibited 
enhanced release of regenerative chemokines. While these results do shed a positive light 
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on PCL:PRGF scaffolds and their use as a vascular graft, numerous other factors that 
were not addressed in this study may prove otherwise and should be considered. First, 
these grafts will be fabricated for use predominantly in elderly people. While mechanical 
properties were tested in this study, and were shown to be comparable to that of a femoral 
artery, the mechanical properties of the coronary arteries of the elderly is not only going 
to be different from that of a femoral artery, but is also going to vastly differ from one 
elderly person to the next. Some may be extremely fragile, while others may be hardened. 
Therefore, it is almost impossible to say what the ideal mechanical properties should be 
for a vascular graft, and if the properties observed in this study would suffice. This may 
possibly be one of the greatest roadblocks in the design of a vascular graft, and one 
limitation of the current vascular grafts used. How do we design an off-the-shelf product 
with mechanical properties that are adequate for each individual person? Although it may 
seem feasible to fabricate an electrospun vascular graft bedside, while a patient is 
undergoing surgery, to suit an individual‟s mechanical needs, this thought is not very 
realistic. Furthermore, cellular behavior in elderly patients is much different from that of 
the cells used in these in vitro experiments, and also from that of the young animal 
models frequently used in in vivo experiments. Another limitation of the current 
treatments is the lack of bioactivity and inability for cells to infiltrate the materials. While 
PCL:PRGF scaffolds do show enhanced bioactivity and cell infiltration, it may be more 
beneficial to conduct these cell experiments in harsh conditions for the cells (i.e. without 
FBS and ECGS), or with aged cells and/or animals. Overall, the addition of PRGF to an 
electrospun PCL scaffold does appear promising for use as a bioresorbable vascular graft, 
however, additional considerations and testing still remains to be done. 
 212 
 
Future Research 
 
 Future work in this study will involve further investigation of the angiogenic 
potential of incorporated PRP and heparin scaffolds. The results obtained this study 
regarding HPMEC proliferation and macrophage chemokine release on heparin 
incorporated PRGF scaffolds did not provide definitive answers as to the effect of these 
scaffolds on promoting proliferation and driving macrophages towards a specific 
phenotype. Therefore, additional studies are needed to clarify these results. In regards to 
HPMEC proliferation, the addition of an anti-human TGF-β1 antibody to the EC media 
would specifically block the TGF-β1 in the PRGF containing scaffolds, and would 
provide an answer behind why PRGF incorporated scaffolds decrease HPMEC 
proliferation. Using specific phenotypic markers would allow for a more definitive 
analysis on quantifying macrophage phenotype when cultured on PRGF incorporated 
scaffolds. This could be done by immunohistochemically staining samples with a pan 
macrophage marker (CD68), an M1 phenotype marker (CCR7), or an M2 phenotype 
marker (CD163) and counting the number of immunopositive cells in each sample. 
Furthermore, as mentioned in the discussion section of Chapter 7, performing specific 
growth factor and cytokine ELISAs on supernatant from macrophages cultured on PRGF 
incorporated scaffolds would give insight into the growth factors secreted by 
macrophages during their interaction with PRGF containing scaffolds and may verify the 
results observed for HPMEC and ADSC proliferation. 
 Additionally, a more in depth look into these scaffolds‟ mechanical properties is 
needed. In addition to uniaxial tensile testing, burst strength and compliance testing 
should be performed, as these tests would provide insight in the ability of these grafts to 
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withstand physiological pressures. Also, mechanical properties of the grafts after being 
seeded with different cell types would be interesting to observe; macrophages may 
degrade the scaffold over time, and decrease the mechanical integrity of the constructs, 
while ECs and FBs may produce their own matrix, thereby enhancing the mechanical 
strength of the scaffolds. Quantification of matrix production by specific cell types 
cultured on PRGF incorporated scaffolds would also be of interest. As mentioned 
previously, specific ECM protein ELISAs, or assays, such as SircolTM or 
hydroxyproline, could be performed to determine matrix production. 
 Furthermore, while the preliminary work contained within demonstrated PRGF 
and heparin containing materials have the potential to promote sprout formation in vitro, 
the ability for PRGF to induce angiogenesis and regeneration in vitro is important. As 
mentioned previously, it would be interesting to replicate this experiment with ECs 
cultured in media without FBS or ECGS, as this would give a better depiction of the 
effect of PRGF alone. In addition, analyzation of HPMEC sprout and lumen formation in 
the presence of other cells, such as fibroblasts and SMCs would give a better depiction of 
what may occur in vivo.  
 The potential for these grafts to induce angiogenesis and regeneration needs to be 
evaluated in vivo. Implanting these materials subcutaneously into mice would help to 
examine the inflammatory responses and degradation behavior these scaffolds may elicit, 
as well as the ability for these constructs to promote vascularization in vivo. In addition, 
in vivo experiments, for example implanting the graft in the abdominal aorta of a rat, 
would be able to determine the scaffolds‟ true ability to be regenerated, as there would be 
multiple cell types working together, along with a variety of other molecules, growth 
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factors, and chemokines in the microenvironment that would play a role. Finally, the 
potential for these scaffolds to promote angiogenesis and regeneration in situ in a canine 
model needs to be investigated, as this would provide the most accurate results of what 
would happen if these graft materials were to be implanted in humans as blood vessel 
replacements. 
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Abstract 
Platelet-rich plasma (PRP) therapy has seen a recent spike in clinical interest due 
to the potential that the highly concentrated platelet solutions hold for stimulating tissue 
repair and regeneration. The purpose of this study was to incorporate PRP into a number 
of electrospun materials to determine how growth factors are eluted from the structures, 
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and what affect the presence of these factors have on enhancing electrospun scaffold 
bioactivity. PRP underwent a freeze-thaw-freeze process to lyse platelets, followed by 
lyophilization to create a powdered preparation rich in growth factors (PRGF), which was 
subsequently added to the electrospinning process. Release of protein from scaffolds over 
time was quantified, along with the quantification of human macrophage and adipose 
derived stem cell (ADSC) chemotaxis and proliferation. Protein assays demonstrated a 
sustained release of protein from PRGF containing scaffolds at up to 35 days in culture. 
Scaffold bioactivity was enhanced as ADSCs demonstrated increased proliferation in the 
presence of PRGF, while macrophages demonstrated increased chemotaxis to PRGF. The 
incorporation of PRGF into electrospun structures has a significant positive influence on 
the bioactivity of the scaffolds, and may prove beneficial in a number of tissue 
engineering applications. 
Introduction 
Platelet-rich plasma (PRP) therapy is a method of collecting and concentrating 
autologous platelets, through centrifugation and isolation, for the purpose of activating 
and releasing their growth factor-rich - and dense granules. The discharge of these 
concentrated granules releases a number of growth factors and cytokines in 
physiologically relevant ratios, albeit in concentrations several times higher than that of 
normal blood, that are critical to tissue regeneration and cellular recruitment. Some of the 
more highly concentrated factors found within PRP include platelet derived growth factor 
(PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF) [302, 304, 
305, 309, 312-314]. In addition, PRP has also been shown to contain a number of 
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macrophage and monocyte mediators such as RANTES (Regulated upon Activation, 
Normal T-cell Expressed, and Secreted), lipoxin, and an array of interleukins [313]. 
Clinically, PRP therapy has been used to stimulate tissue growth and regeneration 
in a number of different tissues; effectively accelerating the healing response in patients 
suffering from osteochondral defects [302-304], tendon/ligament injuries [302-308], and 
chronic skin wounds (diabetic and pressure ulcers) [303, 304, 309, 310]. Typically, these 
procedures involve a blood draw and centrifugation to concentrate the platelet portion, 
followed by a platelet activation step and the delivery of the activated PRP to the site of 
injury. There have been several methods reported in the literature on successfully 
activating and delivering PRP to an injury site, with most involving the creation of a 
platelet gel using thrombin [302-304, 311] or CaCl2 [302-304, 312]. These PRP gels can 
be easily applied to wound sites through injection or topical application.   
However, studies have shown that the use of thrombin as a clotting agent can 
result in a rapid activation of platelets and a bolus release of growth factors, with 70% of 
growth factors released within 10 minutes of clotting, and nearly 100% released within 1 
hour [302]. This “dumping” method fails to maximize the cell stimulating potential of the 
PRP growth factors as most are cleared before they can take effect [336]. Growth factor 
release from PRP gels can be slowed when the gel is formed with CaCl2 rather than 
thrombin. The addition of CaCl2 to PRP results in the formation of autogenous thrombin 
from prothrombin and the eventual formation of a loose fibrin matrix that will secrete 
growth factors over 7 days [302]. 
Other techniques have been evaluated for further sustaining the release of growth 
factors from PRP and include the use of gelatin gel microspheres [337], lyophilized PRP 
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[338-341], and alginate beads [336]. The injection of PRP gelatin gel microspheres in a 
mouse ischemic hind limb model demonstrated sustained release of the PRP potent 
angiogenic components as illustrated by an increase in perfusion, capillary density, and 
mature blood vessel density [337]. Alginate beads were shown to be successful in 
delivering (based on cell proliferation) PRP-derived growth factors and cytokines over 
the course of 14 days [336]. The use of freeze-dried PRP in a dermal wound has been 
shown to significantly increase cellular proliferation (up to 21 days), tissue regeneration 
and angiogenesis in a mouse dermal wound [338-341]. Collectively, these studies 
demonstrate the importance of keeping PRP-derived growth factors and cytokines in the 
wound site and slowly releasing them as the wound site becomes infiltrated with 
reparative cells. 
While a number of individual growth factors and/or cytokines have been used 
previously in an array of sustained release tissue engineering and regenerative medicine 
applications with positive results, the use of either single or multiple isolated growth 
factors/cytokines is often prohibitively expensive, and it can be difficult to replicate 
physiologically relevant quantities [302]. The purpose of this study was to attempt to 
harness the reparative potential found in PRP, namely the growth factor and cytokine 
milieu contained within, and apply it to tissue engineering through the creation of a PRP 
eluting electrospun scaffold. It was hypothesized that the inclusion of lysed and 
lyophilized PRP would create an effective preparation rich in growth factors (PRGF) 
capable of being introduced into the electrospinning process to create a scaffold with 
enhanced bioactivity capable of a sustained release of growth factors. 
Materials and Methods 
 244 
 
Creation of PRP and PRGF 
 Fresh human whole blood from 3 donors was purchased (Biological Specialty 
Corp.), pooled, and used in a SmartPReP
®
 2 (Harvest Technologies Corp.) centrifugation 
system to create PRP per manufacturers protocol. A small aliquot of both pooled whole 
blood and PRP were sent to the Harvard Immune Disease Institute‟s Blood Research 
laboratory to determine their respective platelet concentrations. PRP was then subjected 
to a freeze-thaw-freeze (FTF) cycle in a -70° C freezer for cell lysis and activation. 
Centrifuge tubes containing PRP were placed in a -70  C freezer for 24 hrs followed by a 
37  C waterbath for 1 hr, and then returned to the -70  C freezer for 24 hrs. The degree of 
activation of the FTF lysed PRP, and thrombin (Recothrom, ZymoGenetics Inc.) and 
10% CaCl2 (American Regent) activated PRPs was quantified through an enzyme-linked 
immunosorbent assay (ELISA) analysis of VEGF and bFGF (Antigenix America Inc.).  
Frozen PRP was then lyophilized for 24 hrs to create a dry PRGF powder which was 
finely ground in a mortar and pestle prior to use.   
Chemotactic Effect of PRGF on Macrophages 
 To determine the role that powdered PRGF had on human macrophage 
chemotaxis, and to demonstrate that lyophilized PRGF retained viable chemotactic 
proteins, PRGF was dissolved in macrophage serum-free media (MSFM, Invitrogen) in a 
range of concentrations (0, 0.01, 0.1, 1, 5, and 10 mg/ml). Using a 24-well Transwell 
plate with 8 µm diameter pores (Corning, Inc.), 600 µl of PRGF containing media was 
placed in the bottom wells, while the top insert was seeded with 100,000 human 
peripheral blood macrophages (ATCC, CRL9855) in 150 µl of control media for 18 
hours (n=3). Following the 18 hour duration, the bottom wells were aspirated and the 
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average cell number was determined through the use an automated cell counter 
(Invitrogen Countess). 
Creation of PRGF Eluting Electrospun Scaffolds 
 Scaffolds used in this study consisted of SF (extracted from bombyx morii 
silkworm cocoons[299, 397]), PGA (Alkermes), and PCL (Lakeshore Biomaterials, 125 
kDa). Each of these materials was dissolved in HFIP (TCI America Inc.) at a 
concentration of 100 mg/ml to create the solutions used in the electrospinning process. 
These materials were chosen as they are three commonly used biomaterials that have 
been well characterized, and have well known degradation characteristics.   
To each of these electrospinning solutions PRGF was added in concentrations of 
10 or 100 mg of PRGF per ml of electrospinning solution (SF:PRGF(10), 
PGA:PRGF(10), and PCL:PRGF(10) and SF:PRGF(100), PGA:PRGF(100), and 
PCL:PRGF(100), respectively) and allowed to dissolve completely into solution. As 
PRGF can be successfully electrospun by itself from HFP at a concentration of 200 
mg/ml[344], PRGF fibers were also integrated into PCL scaffolds using two additional 
electrospinning techniques: 1) a 2 input-1output nozzle that mixed separate PCL and 
PRGF solutions only at the outlet tip as electrospinning occurred (PCL:PRGF(2-1)) and 
2) using two separate syringes of PCL and PRGF electrospinning solutions at 90° from 
each other targeting the same collection mandrel (PCL:PRGF). Both the PCL:PRGF(2-1) 
and PCL:PRGF scaffolds consisted of a 1:1 volume ratio of PCL:PRGF solution. Control 
scaffolds contained no PRGF.   
Processing parameters varied with the polymer, while all solutions were 
electrospun onto a grounded rectangular stainless steel mandrel (1.9 cm wide x 7.5 cm 
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long x 0.5 cm thick) rotating at 400 RPM and translating at 6 cm/s over a distance of 12 
cm, using a Becton Dickinson syringe fitted with a blunt tip 18 gauge needle and a KD 
Scientific syringe pump. SF solutions were electrospun using a charging voltage of +25 
kV, an air gap distance of 15 cm, and a flowrate of 4 ml/hr. PGA and PCL solutions were 
electrospun using a charging voltage of +22 kV, an air gap distance of 15 cm, and a 
flowrate of 6 ml/hr. PCL:PRGF(2-1) used a charging voltage of +30 kV placed on the 
end of the output nozzle, an air gap distance of 15 cm, and a flowrate of 2.5 ml/hr.  
PCL:PRGF used charging voltages of +25 and +27 kV for the PCL and PRGF solutions, 
respectively, an air gap distance of 15 cm from each syringe to the collecting mandrel, 
and a flowrate of 2.5 ml/hr for each solution. 
Characterization of Electrospun Structures 
 Dry, representative samples from each of the electrospun scaffolds was 
characterized through scanning electron microscopy (SEM, Zeiss EV050) to ensure the 
fibrous nature of the structures. Average fiber diameters and pore areas were calculated 
by taking 60 random fiber measurements/pore measurements from across the SEM image 
using ImageTool 3.0 software (Shareware provided by UTHSCSA). 
 Uniaxial tensile testing was performed on a set of representative dog-bone shaped 
samples (overall length of 20 mm, 2.67 mm at its narrowest point, gage length of 7.5 mm, 
n=5) punched from each of the materials electrospun. All specimens were soaked for 4 
hours in DI water prior to testing, with all SF samples first being soaked in ethanol for 30 
minutes to promote beta sheet formation. Samples were then uniaxially tested to failure at 
a rate of 10 mm/min (1.33 min
-1
 strain rate) using an MTS Bionix 200 testing system 
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with a 100 N load cell (MTS Systems Corp.). Peak stress, modulus, and strain at break 
were calculated using TestWorks version 4. 
Evaluation of Cell Interaction 
 To determine the response of human cells on the PRGF containing scaffolds, 10 
mm diameter disks from each electrospun scaffold were punched, disinfected (30 minute 
soak in ethanol followed by three 10 minute rinses in PBS), and placed in a 48-well plate. 
Each scaffold had a sterile Pyrex cloning ring (10 mm outer diameter, 8 mm inner 
diameter) placed on top to keep the scaffolds from floating, and to ensure that all cells 
stayed on the surface of the scaffold during culture. Each scaffold was then seeded with 
50,000 human adipose derived stem cells (ADSC) in 500 µl of culture media (DMEM 
low glucose, 10% FBS, 1% penicillin/streptomycin, Invitrogen). Media was changed 
every third day, and samples were removed from culture and fixed in buffered formalin 
on days 7 and 21 for Hematoxylin and Eosin (H&E) staining.  
Quantification of Protein Release Kinetics 
 From each electrospun material 10 mm diameter disks were punched (n=3), 
disinfected (30 minute soak in ethanol followed by three 10 minute rinses in PBS), and 
placed in a 48-well plate with 500 µl of PBS. The PBS was changed and retained for 
evaluation on days 1, 4, 7, 10, 14, 21, 28, and 35. Samples at each time point were 
subjected to a generic protein assay (BCA Protein Assay, Thermo Scientific Pierce) to 
quantify the concentration of total protein released. Based upon these results, specific 
ELISAs were run on the retained samples (days 1, 4, 7, 10, 14, and 21) to detect proteins 
found in high concentrations in PRP, RANTES, PDGF-BB (Antigenix America Inc.), and 
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TGF-β (Promega Corp.), to demonstrate that it was in fact PRGF being eluted from the 
scaffolds. 
Released PRGF Effect on Cell Proliferation 
To determine the mitogenic potential of the PRGF released from the electrospun 
scaffolds on both ADSCs and macrophages, 10 mm diameter disks of each electrospun 
material were punched, disinfected (30 minute soak in ethanol followed by three 10 
minute rinses in PBS), and placed in a 48-well plate (n=3). Each well was then seeded 
with 300,000 human peripheral blood macrophages (ATCC, CRL9855) in 500 µl MSFM, 
as well as in a control tissue culture polystyrene (TCPS) well containing MSFM with 1 
mg/ml PRGF added (TCPS:PRGF). The macrophage conditioned media was removed 
daily and used as a supplement to feed ADSCs (200 µl MSFM with 300 µl ADSC media) 
cultured on TCPS (25,000 cells/well) in a separate 48-well plate. On days 1, 4, and 7 
media was removed from the wells containing macrophages and replaced with 300 µl 
trypsin to remove macrophages for counting. After 5 minutes trypsin was deactivated 
with 300 µl MSFM, pipetted up and down gently several times, and the suspended 
macrophages were counted using an automated cell counter (Invitrogen Countess). 
ADSC proliferation was analyzed using an MTS Assay (Promega) at days 1, 4, and 7. 
This study was then replicated without the use of macrophage conditioned media 
to isolate the impact of the released PRGF on ADSC proliferation. That is, disinfected 10 
mm diameter disks of each electrospun material were placed in a 48-well plate with 500 
µl ADSC culture media. Media was removed daily and used as a supplement to feed 
ADSCs cultured at 25,000 cells/well in a separate 48-well plate. ADSC proliferation was 
determined with an MTS Assay (Promega) at days 1, 4, and 7.  
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Statistical Analysis 
 All statistical analysis was based on a Kruskal–Wallis one-way ANOVA on ranks 
and a Tukey–Kramer pairwise multiple comparison procedure (α = 0.05) performed with 
the JMP IN 8.0 statistical software package (SAS Institute, Inc.). Graphical depictions of 
mean data were constructed with Microsoft Excel 2007, with error bars representing 
standard deviations. 
 
Results 
Creation of PRP and PRGF 
 Based upon the platelet counts performed at the Harvard Immune Disease 
Institute‟s Blood Research laboratory, it was determined that the pooled whole blood 
used for this study contained 175 x 10
3
 platelets/µl, while the PRP created with the 
SmarPReP
2
 system yielded 955 x 10
3
 platelets/µl. This 5.5 fold increase in platelets is 
consistent with published data[324], and should result in a similar fold increase in growth 
factor concentration based upon the linear relationship between platelet and growth factor 
concentration [315].   
The results of the bFGF and VEGF ELISAs (Figure 1) reveal the FTF method of 
activation, essentially lysing platelets to release their α and dense granule contents, to be 
as effective, if not more so, than the traditional PRP activation techniques of thrombin 
and CaCl2 for releasing growth factors. The FTF activation method resulted in average 
growth factor concentrations of 0.4 ng/ml for bFGF, and 1.6 ng/ml for VEGF. Using the 
traditional CaCl2 and thrombin activation methods bFGF values were 0.8 and 0 ng/ml, 
respectively, while the VEGF values were 0.3 and 0.7 ng/ml, respectively. While there 
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were few statistical differences between the different methods in the bFGF ELISA, with 
only the CaCl2 activated different from the thrombin activated, the VEGF ELISA results 
demonstrated clearly that the FTF method was significantly greater than the other 
activation methods. It should be noted that the thrombin activation method resulted in an 
instantaneous gel, making it difficult to obtain liquid samples for ELISA analysis. The 
CaCl2 activated PRP contained visible floating thrombi, but was mostly liquidous, while 
the FTF activated PRP was completely liquid with no evidence of thrombus formation. 
 
Figure 1. Results of PRP activation method on bFGF and VEGF concentration. * 
indicates significant differences between activation methods, p < 0.05. Minimum levels 
of detection for bFGF and VEGF were 0.11ng/ml and 0.059 ng/ml.. 
 
Chemotactic Effect of PRGF on Macrophages 
 The results of macrophage chemotaxis in response to a dose of PRGF dissolved in 
MSFM are shown in Figure 2. Macrophage chemotaxis increased with the amount of 
PRGF until the concentration of 1 mg/ml, above which it became significantly reduced. 
While a nice trend is apparent, the only value that was significantly different from the 
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group was the 1 mg/ml PRGF concentration, potentially indicating an ideal concentration 
for stimulating macrophage chemotaxis. It should be noted that the addition of powdered 
PRGF to MSFM resulted in a complete gel at 10 mg/ml, and a partial gel at 5 mg/ml. 
This resulting gelation may have had a negative impact on macrophage chemotaxis; 
however, it does indicate a reserve of active fibrinogen contained within the powdered 
PRGF capable of forming a clot in the presence of the Ca
2+
 found in the MSFM. 
 
Figure 2. Results of macrophage chemotaxis in response to PRGF dose.  * indicates 
statistically significant differences, p < 0.05, between the 1 mg/ml concentration and all 
other groups.  # indicates statistically significant differences, p < 0.05, between 0.1 
mg/ml and lower concentrations. 
 
Characterization of Electrospun Structures 
 The results of the electrospun scaffold SEM characterization are shown in Figure 
3. These SEMs demonstrate the fibrous nature of each of the electrospun scaffolds, both 
with and without PRGF. Mean fiber diameters for these scaffolds ranged from 0.5 µm for 
PGA:PRGF(10) to 5.8 µm for SF:PRGF(100). With the exception of the SF:PRGF(100), 
there were no significant differences in mean fiber diameter between the control scaffolds 
and the PRGF containing scaffolds. Somewhat surprisingly, the inclusion of PRGF had 
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no real impact on the average size of the electrospun fibers, although it does appear that 
with the inclusion of high concentrations of PRGF and in the PCL:PRGF(2-1) and 
PCL:PRGF scaffolds there are a number of extremely small diameter fibers. Disregarding 
the SF scaffolds, this potential divergent population of PRGF fibers and synthetic 
polymer fibers may be evident through the rather large standards of deviation determined 
for those structures. Additionally, those same scaffolds appeared to exhibit an increase in 
void space visible in the SEMs as PRGF content was increased. Average pore areas (Fig. 
3) were found to correlate to average fiber diameters: as fiber diameter increased, pore 
area increased. This phenomenon has been well documented in previous electrospinning 
studies (25-27). The addition of 100 mg/ml PRGF to SF and PGA resulted in 
significantly increased pore areas over the control and 10 mg/ml PRGF-containing 
samples, whereas the only difference seen in the PCL structures was between the 
PCL:PRGF(2-1) and the PCL:PRGF(100), PCL:PRGF(10), and PCL control scaffolds. 
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Figure 3. (Top) SEM micrographs of electrospun SF, PGA, and PCL scaffolds with and 
without PRGF. All images were taken at 3,000x, scale bar is 10 µm. (Bottom Left) Graph 
of mean fiber diameters for SF, PGA, and PCL scaffolds with and without PRGF. 
(Bottom Right) Graph of mean pore areas for SF, PGA, and PCL scaffolds with and 
without PRGF. * indicates significant differences within polymer group, p < 0.05. 
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The results of the scaffold uniaxial tensile testing are shown in Figure 4. Mean 
peak stresses ranged from 0.2 MPa for PGA+100 to 5.2 MPa for PGA control, moduli 
ranged from 0.9 MPa for SF+100 to 21.4 MPa for PGA control, while average strain at 
break values ranged from 25.4% for PGA+100 to 112.8% for PGA control. In general, 
mechanical properties were shown to decrease significantly as PRGF concentration 
increased compared to values achieved for the PRGF-free control scaffolds. With the 
exception of the PCL:PRGF(10), average peak stresses and moduli were significantly 
lower for SF, PGA, and PCL scaffolds containing PRGF. These results were not 
unexpected, as traditionally the combination of biologic proteins in large concentrations 
(collagen, elastin, fibrinogen, etc.) with electrospun polymers regarded for their tensile 
strength typically results in significantly reduced mechanical strength.[148, 345, 398] 
The unique structures of PCL:PRGF(2-1) and PCL:PRGF, where both PRGF and 
PCL fibers were created, resulted in mechanical properties that fell between those of the 
PCL control and the PCL:PRGF(100) structures. This difference in mechanical properties 
would seem to indicate that these blended scaffolds resulted in materials that were 
structurally different from those where PRGF was added directly to the electrospinning 
solution. Additional work will be needed to fully differentiate the differences between the 
two methods of PRGF inclusion, and to understand what role individual PRGF fibers 
may play in providing/reducing mechanical strength of the scaffolds. 
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Figure 4. Results of uniaxial tensile testing of electrospun scaffolds. * indicates 
tatistically significant differences, p < 0.05, between control scaffolds and scaffolds 
containing PRGF. # indicates statistically significant differences, p < 0.05, between 
scaffolds containing 10 mg/ml PRGF and other scaffolds. $ indicates statistically 
significant differences, p < 0.05, between scaffolds containing 100 mg/ml PRGF other 
scaffolds. & indicates statistically significant differences, p < 0.05, between PCL:PRGF 
scaffolds and other scaffolds. 
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Evaluation of Cell Interaction 
 The results of the H&E staining are shown in Figures 5 and 6. H&E staining 
revealed confluent layers of ADSCs on the surfaces of the control scaffolds by day 7, 
while increased PRGF content resulted in increased cellular penetration into the scaffold. 
Surprisingly, after only 7 days ADSCs had migrated through half of the thickness of the 
PCL:PRGF(2-1) scaffold. By day 21 this trend was even more apparent, with clear cell 
migration through nearly the entire thickness of the PCL:PRGF(2-1) and PCL:PRGF 
scaffold (Figure 7). The SF:PRGF(100) scaffold also had nearly complete cellular 
penetration by day 21, compared to the SF scaffold containing no PRGF which exhibited 
only minimal migration into the depth of the structure. The PCL:PRGF(100) 
demonstrated a similar result, with the electrospun synthetic PCL material traditionally 
being difficult to cellularize in vitro[297-299], as it too exhibited increased cellular 
penetration when compared to the PCL scaffold containing no PRGF. 
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Figure 5. H&E staining of PGA and SF scaffolds at day 7 and 21. Images at 20x. Note, 
the PGA:PRGF(10) scaffold was completely degraded by day 21 and was unable to be 
processed for histological evaluation. 
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Figure 6. H&E staining of PCL scaffolds at day 7 and 21. Images at 20x. 
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Figure 7. High magnification (40x) images of select scaffolds demonstrating significant 
cellular penetration. 
 
Quantification of Protein Release Kinetics 
The results of quantified protein release from PRGF containing scaffolds are 
shown in Figure 8. The results of this study demonstrated that scaffolds containing high 
concentrations of PRGF (SF:PRGF(100), PGA:PRGF(100), PCL:PRGF(100), and 
PCL:PRGF(2-1)) released detectable amounts of protein over 35 days in culture. The 
protein release from PRGF containing scaffolds peaked at day 1, decreased by about half 
on days 4 and 7, and reached a plateau that was sustained for the remainder of the 
duration. PCL:PRGF(2-1) scaffolds initially had the highest release of protein (300 
µg/ml), but PCL:PRGF(100) had the highest release of protein at all time points after day 
1 (125 µg/ml – 50 µg/ml). Surprisingly, PCL:PRGF scaffolds released the lowest amount 
of protein over the 35 days, even though the concentration of PRGF incorporated was the 
same as that of PCL:PRGF(2-1) scaffolds.  PGA:PRGF(100) and SF:PRGF(100) 
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scaffolds had similar release kinetics as well, eliciting 240 µg/ml and 275 µg/ml of 
protein at day 1, respectively. Similar to the PCL:PRGF(100) and PCL:PRGF(2-1) 
structures, a plateau was acheived around 50 µg/ml and sustained until day 35. Minimal 
protein release was detected for PGA, SF, and PCL control scaffolds and scaffolds 
containing 10 mg/ml PRGF over the 35 days, indicating that the protein detected was in 
fact due to PRGF release and not simply an artifact of scaffold degradation.   
Statistical analysis revealed protein release at day 1 from scaffolds of 
PGA:PRGF(100), SF:PRGF(100), PCL:PRGF(100) and PCL:PRGF(2-1) to be 
significantly greater than protein release from those respective scaffolds at all other time 
points (day 4-35). Additionally, scaffolds of PCL:PRGF(100) had significantly greater 
release at day 4 than day 35. The initial burst of release from the scaffolds at day 1 was 
expected as PRGF from the surface of the scaffolds was released. Remarkably, after the 
first day there was still a sustained release of protein from scaffolds of PGA:PRGF(100), 
SF:PRGF(100), PCL:PRGF(100) and PCL:PRGF(2-1) that continued throughout the 35 
days, presumably due to the degradation of the polymer scaffolds and subsequent release 
of entrapped proteins.   
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Figure 8. Quantification of generic protein released from PRGF containing scaffolds 
over 35 days (Top). * indicates a significant difference, p < 0.05, for day 1 when 
compared to all other time points for each material. # indicate statistically significant 
differences, p < 0.05, between day 4 and day 35 of PCL:PRGF(100). Y-axis scaled to 
emphasize decreased release from days 4-35 (Bottom). Minimum level of detection was 
14.3 µg/ml (dashed line). 
 
Quantification of RANTES and PDGF-BB, and TGF-β from the PRGF containing 
scaffolds revealed detectable release over 21 days (Figure 9) with kinetics similar to 
those of the protein assay results described previously. Scaffolds of PCL:PRGF(100) had 
the highest release of RANTES at day 1 (3 ng/ml), with a continual decrease in release 
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thereafter. PGA:PRGF(100), SF:PRGF(100), and PCL:PRGF(2-1) exhibited a similar 
trend, with peak values of RANTES at day 1 of 2.5 ng/ml, 1.1 ng/ml, and 1 ng/ml for 
each scaffold, respectively. RANTES release from PCL:PRGF scaffolds had a peak of 
0.5 ng/ml at day 1, but values were not detectable after day 4. Statistical analysis revealed 
RANTES release at day 1 from scaffolds of PGA:PRGF(100), SF:PRGF(100), 
PCL:PRGF(100) and PCL:PRGF(2-1) was significantly higher than release from those 
same scaffolds at all other time points (days 4-21). For PCL:PRGF(100), RANTES 
release at day 4 was significantly higher than that of all other time points for that 
scaffold.  
PDGF-BB release was highest from scaffolds of PCL:PRGF(2-1), peaking at day 
1 (0.3 ng/ml), and decreasing thereafter, with values not detectable after day 7. PDGF-BB 
was also detectable from scaffolds of PGA:PRGF(100), SF:PRGF(100) and 
PCL:PRGF(100), with the highest release occurring at day 1 (0.1 ng/ml, 0.075 ng/ml, and 
0.15 ng/ml, respectively). PCL:PRGF scaffolds elicited PDGF-BB release of 0.03 ng/ml 
at day 1, but was undetectable thereafter. PDGF-BB release at day 1 from scaffolds of 
PGA:PRGF(100), PCL:PRGF(100) and PCL:PRGF(2-1) was significantly higher than 
release from those same scaffolds at all other time points (days 4-21). PDGF-BB release 
from SF:PRGF(100) at day 1 was significantly greater than release from the same 
scaffold at days 7-21. For PCL:PRGF(100) and PCL:PRGF(2-1), PDGF-BB release at 
day 4 was significantly higher than that of days 10-21 and all other time points with 
detectable values, respectively, for those scaffolds.   
Much like the release of PDGF-BB from the scaffolds, TGF-  release was highest 
from scaffolds of PCL:PRGF(2-1). Peak release was seen on day 4 (1.17 ng/ml), although 
 263 
 
not significantly different from the release on day 1 (1.13 ng/ml), and decreased 
thereafter. Unlike RANTES and PDGF-BB, TGF-  release values were quantifiable for 
the PCL:PRGF(2-1), PCL:PRGF(100), and SF:PRGF(100) scaffolds throughout the 21 
days evaluated. TGF-  release from scaffolds of PCL:PRGF(100) and PCL:PRGF(2-1) 
was significantly higher at days 1 and 4 than release from those same scaffolds at all 
other time points (days 7-21). In addition, release of TGF-  from scaffolds of 
PCL:PRGF(2-1) at days 7 and 10 was significantly higher than that at days 14 and 21. 
Surprisingly, PGA:PRGF(100) scaffolds did not exhibit a release above the minimum 
level of detection over the 21 days. 
Similar to the protein assay results, RANTES, PDGF-BB, and TGF-β were 
undetectable from both the PGA, SF, and PCL control scaffolds and the scaffolds 
containing 10 mg/ml PRGF at all time points. The results of the statistical analysis 
illustrated that in general, after the initial release of growth factors from the surface of the 
scaffold at day 1, the release of RANTES and PDGF-BB that occurred at all time points 
thereafter is not significantly different, demonstrating a sustained release of growth 
factors from the scaffolds over the 21 day period as the polymer fibers begin to degrade. 
With regards to TGF- , the PCL:PRGF(2-1) scaffolds exhibited a step-wise significant 
decrease in release until day 14, but still maintained a sustained quantifiable release.  
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Figure 9. Results of RANTES, PDGF-BB, and TGF-  release from PRGF containing 
scaffolds over a duration of 21 days. * indicates statistically significant differences, p < 
0.05, between day 1 and all other time points. # indicates statistically significant 
differences, p < 0.05, between day 4 and all other time points. $ indicates statistically 
significant differences, p < 0.05, between day 4 and days 10 and 21. & indicates 
statistically significant differences, p < 0.05, between day 1 and days 7 and 21. ^ 
indicates statistically significant differences, p < 0.05, between day 7 and all other time 
points. % represents statistical significance, p < 0.05, between day 10 and all other time 
points.  Minimum levels of detection for RANTES, PDGF-BB, and TGF-  were 
0.001ng/ml, 0.003ng/ml, and 0.011 ng/ml, respectively (dashed line). 
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Released PRGF Effect on Cell Proliferation 
 The effect of PRGF release on macrophage proliferation is shown in Figure 10. 
As expected, macrophages proliferated in the presence of all scaffolds from days 1 and 4, 
however, by day 7 proliferation slowed, and in some cases, cell number even decreased.  
This may be due to nutrient levels insufficient to support the large number of cells in each 
well, and hence, resultant cell apoptosis. At day 1, there was no significant difference in 
macrophage number between the different scaffolds and TCPS. At day 4, there were 
significantly less macrophages on scaffolds of PCL:PRGF(2-1) than on scaffolds of SF, 
SF:PRGF(10), TCPS, and TCPS:PRGF, and may indicate a loss of macrophages due to 
cellular penetration into the highly bioactive PCL:PRGF(2-1) scaffolds. By day 7, there 
were no significant differences in macrophage proliferation on any scaffold. While these 
results indicated that in general, PRGF did not have an affect on macrophage 
proliferation, taken with the results from the prior macrophage chemotaxis study, it could 
instead be anticipated that PRGF promotes macrophage chemotaxis rather than 
proliferation. 
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Figure 10. Results of macrophage proliferation when cultured on PRGF containing 
scaffolds. * indicates statistically significant differences between material groups of the 
same day, p < 0.05. 
To determine the role that PRGF had in the secretion of macrophage growth 
factors, ADSCs were cultured in media conditioned by macrophages exposed to released 
PRGF. The results of ADSC proliferation, when cultured in macrophage conditioned 
media, demonstrated no significant differences in proliferation at day 1. However, by day 
4 ADSCs cultured in macrophage conditioned media from scaffolds of PCL:PRGF(100) 
and PCL:PRGF(2-1) had significantly greater proliferation than ADSCs cultured in 
macrophage conditioned media from the PCL and TCPS control, as well as all other 
scaffolds (Figure 11). By day 7, there was significantly greater ADSC proliferation in 
macrophage conditioned media from scaffolds of PCL:PRGF(100), PCL:PRGF(2-1) and 
TCPS:PRGF than ADSCs cultured in conditioned media from PCL and TCPS control, as 
well as all other scaffolds. This was expected, as it had previously been demonstrated that 
PRGF, as well as growth factors secreted by macrophages, enhanced fibroblast, 
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mesenchymal and stromal stem cell proliferation [302, 352, 354-356, 385]. In general, 
ADSC proliferation in all preconditioned media increased from day 1 to day 4, however, 
by day 7 it appeared that proliferation slowed, and in some cases cell number even 
decreased, potentially due to induced contact inhibition as the cells became confluent in 
the wells, or died off following exhaustion of media nutrients. This may also have been 
due to the fact that the conditioned media used for the ADSCs was macrophage serum 
free media, which is unfavorable over the long-term for ADSC growth, or due to harmful 
factors expressed during macrophage apoptosis [386]. From the results in Figure 10, it 
was evident that the effect of macrophages on ADSC proliferation was due to 
macrophage interaction with PRGF containing scaffolds, and not the number of 
macrophages. 
 
Figure 11. Results of ADSC MTS assay when cultured with macrophage conditioned 
media. * indicates statistically significant differences, p < 0.05, between material groups 
at day 4. # * indicates statistically significant differences, p < 0.05, between material 
groups at day 7. 
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 ADSC proliferation when cultured in PRGF conditioned media without 
macrophages is displayed in Figure 12. Overall, ADSCs proliferated from day 1 to day 4 
(with a few exceptions), and from day 4 to day 7, as expected. After 1 day, there were no 
significant differences in ADSC proliferation for any scaffold. By day 4, ADSCs cultured 
in media from scaffolds of SF:PRGF(100) had significantly greater proliferation than 
those cultured in media from SF control scaffolds. At day 7, ADSCs cultured in media 
from scaffolds of SF:PRGF(100) and PCL:PRGF(2-1) had significantly greater 
proliferation than cells cultured in media from SF and PCL control scaffolds, 
respectively. Compared to ADSCs cultured in media from the TCPS control, cells 
cultured in media from PCL:PRGF(2-1) and PCL:PRGF scaffolds had significantly 
greater proliferation at day 7. These results suggest that the presence of PRGF does 
impact ADSC proliferation, and corroborates previously published work [302, 352, 354-
356]. It is clearly evident from these studies that the proliferation of ADSCs, cultured in 
conditioned media, is different depending on the presence or absence of macrophages and 
macrophage secreted factors over the 7 day study duration, and will be discussed further 
in the following section. 
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Figure 12. Results of ADSC MTS assay when cultured without macrophage conditioned 
media. * indicates statistically significant differences, p < 0.05, between PRGF 
containing scaffolds and their control scaffolds at day 4.  # indicates statistically 
significant differences, p < 0.05, between PRGF containing scaffolds and their control 
scaffolds at day 7. & indicates statistically significant differences, p < 0.05, between 
PRGF containing scaffolds and the TCPS control at day 7. 
 
Discussion 
 This present study provides a proof-of-principle for the incorporation of a 
powdered PRGF derived from human PRP into electrospun scaffolds of a number of 
materials. Through a number of evaluation methods, we were able to demonstrate that 
PRGF retained its physiologic activity after lyophilization and through the 
electrospinning process, subsequently enhancing the bioactivity of the electrospun 
scaffolds. 
The use of PRP in clinical applications has been gaining in popularity as a means 
to stimulate tissue repair and regeneration with very minimal risk to the patient. 
However, the “black box” approach taken by many of the clinicians utilizing PRP leaves 
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much to be done in the realm of basic science to fully understand and standardize the 
practice. To date, the collection of whole blood and the concentration and isolation of 
platelets to make PRP has been proven effective in vitro for stimulating cellular activity 
in a number of formats, both in liquid[311, 350-356] and in lyophilized PRGF form [338-
341]. 
To the best of the authors‟ knowledge, this manuscript serves as the first instance 
of a powdered PRGF being incorporated into an electrospun tissue engineering scaffold 
to serve as a controlled release vehicle for such a concentrated growth factor and cytokine 
milieu. While electrospun scaffolds have been used as growth factor delivery systems in 
the past[301, 319, 357-360], they have typically been limited to the incorporation of only 
a small number of growth factors due in part to the cost associated with purchasing the 
recombinant or isolated proteins [357]. The incorporation of a cost-effective PRGF 
protein array into an electrospun structure has the potential to deliver a multitude of 
growth factors, cytokines, and chemokines in physiologically relevant ratios. Such a 
platelet-based growth factor cocktail would essentially replicate the necessary factors 
found in a site of normal wound healing and promote the formation of healthy tissue 
through the stimulation of the healing cascade [300]. The results presented in this 
manuscript demonstrated the potential of such a sustained release vehicle through 
enhanced cellular activity consistent with other in vitro studies of PRP/PRGF.  
Cellular migration and penetration into electrospun scaffolds was enhanced, 
regardless of polymer, with the addition of PRGF. While historically the ability for cells 
to migrate into an electrospun structure has been viewed as a challenge, especially with 
synthetic polymers such as PGA and PCL[297-299], the inclusion of PRGF yielded 
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structures that were readily infiltrated. The reason for this rapid infiltration is not yet fully 
understood in this preliminary investigation, and will need further investigation. 
However, the presence of an array of chemotactic proteins found in large quantities in 
PRP may be the most logical explanation. It may also be an affect of the change in 
scaffold mechanical properties; scaffolds with higher PRGF content exhibited decreased 
mechanical properties which may have allowed for cellular migration into the scaffold to 
occur more readily. The presence of PRGF fibers intermingled amongst the polymer 
fibers of the scaffolds, particularly in the case of the PCL:PRGF(2-1) and PCL:PRGF 
structures (Figure 3), may have also provided paths of easy entry into the thicknesses of 
the structures. These fibers of varying diameter had an apparent impact on the porosity of 
the scaffolds. As PRGF content increased, there was an increase in fiber diameter/pore 
area, which may have allowed for more rapid cellular infiltration while decreasing 
mechanical properties.   
While the significant decrease in scaffold mechanical properties observed with the 
addition of large quantities of PRGF makes these scaffolds less than ideal for use in load-
bearing tissue engineering applications, it was not completely surprising to the authors‟, 
nor was it seen as a negative result. As previously mentioned, this decrease in individual 
fiber mechanical properties may have contributed to the rapid cellular infiltration of the 
scaffolds. This enhanced cellular infiltration, regardless of its root cause, would allow for 
a tissue engineered product to be more rapidly remodeled with native collagen 
extracellular matrix; the production of which would readily supplement the strength of 
the scaffolds and encourage incorporation into surrounding tissues. Although not 
investigated in this study, the many factors found in PRGF have been proven to increase 
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collagen matrix production in a number of cell types [302, 309, 350, 391]. TGF- , one 
such well-known matrix production related growth factor, was released by the 
electrospun scaffolds in detectable quantities, in some cases for up to 21 days. Should the 
presence of TGF-  and the other matrix production enhancing growth factors be actively 
taken up by the cells, it would be possible for accelerated matrix production to occur, and 
could therefore improve the mechanical strength of the weakened PRGF containing 
scaffolds. 
With the creation of individual PRGF fibers within the electrospun scaffolds 
containing high concentrations of PRGF (SF:PRGF(100), PGA:PRGF(100), 
PCL:PRGF(100), PCL:PRGF(2-1), and PCL:PRGF), the loss of mechanical strength was 
not surprising. These PRGF fibers, consisting of a fibrinogen backbone mixed with any 
number of blood- and platelet-based proteins, lack inherent mechanical strength [344]. 
Similar in composition to electrospun fibrinogen[321, 345], which performs best 
mechanically when blended with synthetic polymers, and the presence of which can 
significantly decrease scaffold mechanical strength, the PRGF fibers are best utilized in a 
role of enhancing scaffold bioactivity rather than load bearing. 
As demonstrated in the protein release assays conducted herein, detectable levels 
of proteins were released from the electrospun scaffolds for up to 35 days in vitro. While 
it can be assumed that a large percentage of the released proteins were in fact albumin 
and other blood proteins, not growth factors, the fact that RANTES, PDGF-BB, TGF-β 
were detectable in specific materials at up to 21 days attests to the sustained release 
nature of the structures. RANTES, PDGF-BB, and TGF-  release were analyzed as they 
are three of the more highly concentrated proteins contained within PRP/PRGF[313], 
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however from these results it can be interpolated that other factors such as PDGF-ab, 
FGF, and EGF will be released in the same fashion. The nature of the release 
demonstrated from the electrospun scaffolds may prove to be effective in proposed in 
vivo follow-up studies at enhancing migration of cells from surrounding tissues, with a 
large burst of protein creating a substantial chemotactic gradient, followed by a sustained 
release of protein to promote cell proliferation, and scaffold infiltration and remodeling.  
The incorporation and subsequent release of albumin, while seemingly inconsequential, 
may in fact serve as a protectant for the cytokines and chemokines included in the PRGF.  
The hydrophilic albumin molecules have been demonstrated in the literature to have the 
potential to encapsulate smaller proteins, and effectively shield them from potential 
denaturation [362, 363]. 
The retention of PRGF‟s biological activity following the electrospinning process, 
subjected to both high voltages and the organic solvent HFP, is displayed in the ADSC 
response to conditioned media from PRGF containing scaffolds cultured with and 
without macrophages. In both cases, ADSC proliferation was enhanced over 7 days when 
cultured in conditioned media from scaffolds containing PRGF versus those not 
containing PRGF. The presence of several growth factors within PRGF known to induce 
cell proliferation (VEGF, PDGF, IGF, FGF, and EGF, etc.) is most likely the reason for 
enhanced ADSC proliferation[302], however, future ELISA analysis will be needed to 
confirm this. Their proliferation profile over the 7 days was different depending on the 
presence or absence of macrophages, alluding to the fact that ADSC proliferation was 
affected by the interaction of macrophages with PRGF containing scaffolds. It is evident 
from this study that macrophage number is not the most critical factor in ADSC 
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proliferation; however, the specific mechanism by which macrophage interaction with the 
scaffolds affects ADSC proliferation was not specifically explored.   
The authors hypothesize that the ADSC proliferation seen in this study might be 
due, in part, to the various growth factors and cytokines secreted by the macrophages. It 
has been shown previously that macrophages cultured on electrospun scaffolds have the 
ability to produce high levels of VEGF and FGF[150], and in the presence of PRGF, 
produce additional pro-angiogenic growth factors and cytokines, including those which 
enhance cell proliferation [313]. Although ADSC proliferation appeared to stop by day 7 
when cultured in macrophage conditioned media, this was not perceived as a negative 
effect brought about by the presence of PRGF, rather most likely due to media mismatch 
and/or harmful factors produced during macrophage apoptosis induced by a lack of 
nutrient supply in the conditioned media [386]. 
 In conclusion, this study demonstrated the potential for PRP to be subjected to a 
FTF process, lyophilized to create PRGF, and incorporated into electrospun scaffolds of 
various materials. This PRGF was released from the electrospun scaffolds in a controlled 
fashion over a period of 35 days in culture, and retained its potential to positively 
influence the proliferation of ADSCs and chemotaxis of macrophages at specific 
concentrations in vitro. Additionally, the presence of PRGF in high concentrations 
allowed for the rapid infiltration of ADSCs into electrospun structures of both natural and 
synthetic polymers when cultured in vitro for 21 days. Additional studies are needed to 
determine what effect the presence of PRGF will have in vivo on the recruitment of cells 
from the surrounding tissues, and the cellularization and remodeling of the electrospun 
structures. As one of the major advantages of PRP, when used clinically, is its ability to 
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deliver a milieu of growth factors and cytokines at the patients‟ bedside, the creation of 
an off-the-shelf electrospun scaffold incorporating PRGF from pooled allogenic blood 
may have the same benefits. While the use of pooled blood is typically frowned upon in 
the United States, the use of allogenic PRP has been gaining popularity in a number of 
European studies with no mention of adverse immune reactions [394-396, 399]. 
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